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Background: Although glucocorticoids are the most effective treatment for
asthma, some patients show a poor response. In such patients with steroid
resistant asthma, this has been ascribed to altered glucocorticoid receptor
(GR) ligand-binding affinity induced by IL-2 combined with IL-4 or IL-13
alone- all of which can also modulate glucocorticoid function in vitro.
Objective: We sought to assess the ligand-binding affinity in a distinct group
of oral steroid-dependent asthmatic subjects and examine the mechanisms by
which IL-2 and IL-4 (or IL-13) modify the ligand-binding affinity of the GR.
Methods: Using dexamethasone-binding assays, we examined PBMCs ex
vivo from healthy subjects, subjects with controlled asthma, and oral steroid-
dependent subjects with severe asthma. In addition, IL-2 and IL-4 were used
to alter GR affinity in vitro. We used mediators or inhibitors of signal
transduction to investigate the mechanisms of resistance. We also determined
cytokine production of PBMC's by means of ELISA.
Results: GR ligand-binding affinity was significantly reduced in the nucleus
but not in the cytoplasm of oral steroid-dependent asthmatic subjects
compared with that seen in steroid-sensitive and healthy subjects (dissociation
constant, 41.37 ± 17.83 vs. 25.36 ± 2.63 nmol/L vs. 9.40 ± 4.01 nmol/L,
respectively [p<.05 for both in comparison to normals] ).
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This difference in ligand-binding affinity could be mimicked by IL-2 and
IL-4 co-treatment and was blocked by the p38 mitogen-activated protein
kinase (MAPK) inhibitor SB203580. PBMC's rendered resistant in vitro
demonstrated lower IL-10 and increased GM-CSF production following LPS
or PMA & PHA stimulation compared to cells with normal GR affinity.
Resistant cells also showed reduced dexamethasone repression of LPS-
stimulated IL-10 release. These effects were also reversed by SB203580.
Inhibition of the ERK MAPK pathway by PD098059 (10 umol/L),
phosphoinositol 3 kinase by wortmannin (5 nmol/L) or treatment with IL-10
(10 ng/mL) failed to modulate the effect of IL-2 and IL-4 on receptor affinity.
Ro318220 (10 nmol/L), a specific protein kinase C inhibitor and theophylline,
similarly, had no effect on affinity.
Conclusion: GR ligand binding affinity is tiered; compared to normal
subjects; steroid responsive asthmatics have a mild reduction in ligand
binding whereas oral steroid dependent asthmatics have greater reductions.
When mononuclear cells are rendered resistant in vitro, cytokine production
(low IL-10 and high GM-CSF) favours a pro-inflammatory state. Our data do
not support the ERK MAPK, phosphoinositol 3 kinase, protein kinase C
pathways in steroid resistance. Treatment with IL-10 and theophylline also
failed to modulate the effect of IL-2 and IL-4 on receptor affinity. However,
P38 MAPK inhibitors may have potential in reversing glucocorticoid
insensitivity and re-establishing the beneficial effects of glucocorticoids in
patients with severe asthma.
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CHAPTER 1: LITERATURE REVIEW
1.1 ASTHMA-THE DISEASE
Asthma is a chronic inflammatory disease of the airways characterised by
bronchial hyper-responsiveness and reversible airways obstruction. Over the
last 25 years, the prevalence has doubled for reasons that are not well
understood. An analysis of this epidemiologic observation suggests that this
represents a real increase and is not just due to heightened awareness or
better diagnostic capabilities 1 . In this same period, the theories of asthma
aetiology have moved through different paradigms. Initially an intrinsic
airway smooth muscle abnormality was felt to be the primary problem;
however, studies with cultured airway myocytes disproved this theory 1 .
This was followed by the hypothesis that asthma was an autonomic
dysfunction syndrome with excess activity in the cholinergic and tachykinin
pathways- this was neither proven nor disproven 1 . Immunoglobulin E
mediated responses then rose to prominence and when the abundant airway
inflammatory cell infiltrate was detected, the inflammatory nature of the
disease was accepted.
It has generally been presumed that asthmatics have episodic symptoms and
attacks and that lung function is normal in between. This is not true; the
inflammatory nature leads to ongoing structural damage with decreased
reversibility and can lead to loss of lung capacity over time 2 ' 3 .
The rapid growth of molecular medicine has led to major developments in
the understanding of mechanisms of the allergic diathesis that underpin the
disease4 . Asthma is now considered a disease of gene — environment
interaction with an intricate immunobiolo 5gy.
An understanding of the various cells and mediators that orchestrate the
process is essential to appreciate this complexity.
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A. The Immunologic Basis of Allergic Inflammation. 
IgE and Allergen Sensitisation
A large body of early research in asthma supported the notion that
genetically susceptible individuals developed IgE responses that paralleled
the clinical manifestations of asthma. A linear correlation was reported
between the prevalence of asthma, bronchial hyper-responsiveness and IgE
levels 6 ' 7 .
Allergen sensitisation to specific inhalants in asthma can be demonstrated by
skin tests, serum allergen specific IgE antibodies and bronchial challenge
testing. The cross-linking of antigen and IgE bound to high affinity IgE
receptors (FcER1) on mast cells results in intracellular signalling cascades
and a unique biphasic response 8 . The first- an immediate bronchospastic
response is the consequence of the exocytosis and release of preformed
mediators such as histamine, eicasanoids, free radicals, tryptase, chymase
and cytokines 9 . In addition to tryptase potentiated histamine
bronchoconstriction, these toxic products lead to loss of microvascular
integrity with resulting exudative oedema I° . Within a few hours this phase
subsides and the original mediators induce a late phase response —
associated with the influx of eosinophils, neutrophils and mononuclear cells
into the inflamed bronchi 10 .
Cell-Mediated Responses
Mast cells
Increased mast cells in the airways of atopic asthmatics have been
documented by bronchoalveolar lavage 11 . Their preformed and newly




The late asthmatic response and sustained chronic inflammation is due to T
lymphocytes, eosinophils and monocytes 12 . Increased numbers of activated
T lymphocytes are found in peripheral blood and the airways of asthmatics
13 . These cells dictate the composition of the inflammatory response by
secreting mediators-cytokines and chemokines- that stimulate proliferation
and activate eosinophils and monocytes 14, 15 T lymphocytes can further be
divided into two subsets: Th 1 and Th2. There has been particular interest in
the latter as primary cytokines secreted by this type of cell are increased in
bronchoalveolar lavage fluid of atopic asthmatics and production is also
augmented following exposure to allergen 16 -18 .
Eosinophils
Eosinophils are also increased in the peripheral blood and airways in both
allergic and non-allergic asthma and correlate with severity of disease 19 .
Their granules can cause tissue damage, smooth muscle contraction and
increase vascular permeability leading to further mononuclear cell
recruitment. Eosinophil derived proteins include major basic protein (MBP)
and eosinophil cationic protein (ECP) that are toxic to respiratory epithelium
20 . Not all eosinophilic products are toxic; leukotrienes, kallikreins and
neuropeptides promote mucus secretion and increase the contractile tone
that may contribute to BHR 20, 21 .
Macrophages
Macrophages are the most abundant resident cells in the bronchi and
constitute more than 90% of cells detected in BALF in both normal and
stable asthmatic subjects. As the surveillance cells of the airways, they are
pivotal in host defence through phagocytosis and production of enzymes and
reactive oxygen species. They are capable of up-regulating the inflammatory
response by generating cytokines, leukotrienes, prostaglandins and
thromboxane A2 22, 23 Although alveolar macrophages can function as
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antigen presenting cells, this is the primary responsibility of dendritic cells
in the lung 24, 25
Neutrophils
For many years, the notion of allergen mediated inflammation has resulted
in the focus on the eosinophil with little attention to neutrophils. Of note, in
the antigen challenge asthma model, is that neutrophils are the initial cells
recruited to the airways and predominate for the first 6 hours; it is only later
that other immune cells are preponderant 26 ' 27 . The principal chemotactants
for neutrophils are IL-8, IL-6 and leukotriene B4. Neutrophils may also
contribute to pathogenetic mechanisms in asthma through production of
lipid mediators, reactive oxygen species and proteases- myeloperoxidase
and metalloproteinase 28 . Increased neutrophils in the bronchi have been
detected during both infectious and non-infectious acute asthma
exacerbations 29' 30 . Wenzel et al, 31 evaluated 14 severe high dose oral
corticosteroid dependent asthmatics. Compared to controls and milder
asthmatics, the severe group had a 2-fold higher concentration of neutrophils
in BALF with similar results in endobronchial and transbronchial samples.
The highest elevations of the eicosanoid mediators; thromboxane and
leukotriene B4, were also noted in steroid dependent asthmatics. A massive
influx of neutrophils has also been noted in status asthmaticus and also
documented in an autopsy study of fatal asthma 32' 33 . Thus neutrophilic
inflammation appears to be particularly important in very severe asthma.
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B. Mediators: Cytokines, Chemokines and their Relevance to Asthma. 
The Cytokine Network
The proliferation, differentiation and effector functions of immune cells are
regulated by a complex network of interactions involving cell- cell contact
but, to a greater extent, by proteins secreted by activated cells- cytokines.
Cytokines are pleiotropic- exhibiting multiple activities likely dependent on
the inflammatory milieu and disease process.
INTERLEU KIN -1
There are 2 subtypes of IL-1 (oc and13) and although they only share a
sequence homology of 20%, they attach to the same receptor and have almost
identical properties 34 .
IL-1 is produced by most immune and airway cells but the most abundant
source is the monocyte-macrophage 
22
. PGE2 and CS can inhibit IL-1 at the
transcriptional level 35 .
Two IL-1R have been characterized that are widely distributed (IL-1RI & IL-
1 RII). Only IL-1R appears to be involved in signal transduction of IL-1
suggesting that IL-1 R II may be a decoy receptor preventing IL-1 binding to
IL- IR 36, 37 . Further signal transduction occurs via TNF receptor associated
adapter proteins (TRAF) 38 . IL-1 also increases cAMP- the consequent
activation of protein kinase A and PKC could result in phosphorylation of
many substrates and transcription of cellular genes e.g. NF-KB 39 ' 40 .
IL-1 is an important growth factor for T and B cells and induces many
cytokines: IL-1 to IL-6, IL-8, RANTES, GM-CSF, IFN-y and TNF 41 . It also
co-promotes the expression of ICAM -1 and VCAM-1 on endothelial cells
that could lead to increased eosinophil adhesion 42 .
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IL-1 expression is increased, particularly in symptomatic asthma (in both
BAL cells and airway epithelium) and is reduced with CS treatment 43 ' 44 .
INTERLEUKIN 2
The main source of IL-2 is activated T cells, especially Th0 and Th 1 T cells
45 ; although it can also be produced by eosinophils and airway epithelial cells
46, 47 . This is followed by the upregulation of IL-2 receptors (IL-2R) of T cells
themselves; binding of IL-2 to IL -2R stimulates T cell proliferation, cytokine
secretion and growth factor receptor expression following which
internalization of the IL-2R complex occurs. The IL-2R comprises a, p, and
chains and belongs to the haemotopoeitic cytokine receptor group 48 .The a
and 13 chains bind the IL-2 with low affinity whilst the heterotrimer of a/ (3/ 7
constitutes a high affinity complex and any, and 13/7 heterodimers have
intermediate affinity. The constitutively expressed 13 chain is essential for
signal transduction 49 . IL-2 increases the production of GM-CSF in PBMC'S
of asthmatics 50 .
In ovalbumin sensitized Brown-Norway rats, allergen exposure and IL-2
caused a three fold increase in the late asthmatic response compared to those
exposed to saline only 51 ' 52 .
BAL cells from asthmatics express increased IL-2 mRNA and titres of IL-2
16.
 Cyclosporin A inhibits IL-2 gene expression in T lymphocytes through
interference with transcription factors AP-1 and NF-AT causing decreased
allergic airway eosinophilia and may explain the mechanism of benefit in oral
steroid dependant asthma 53 .
INTERLEUKIN -3
Activated Th cells and mast cells are the major source of IL-3 54 ' 55 . The IL-
3R comprises an a subunit (IL-3Ra) and a 13 unit shared with IL-5 and GM-
CSF 56 . After IL-3 binding, there is rapid tyrosine and serine / threonine
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phosphorylation of a host of cellular proteins 57' 58 . A monoclonal antibody to
IL-3Ra was able to abolish its function 59 . IL-3 is a pluripotential
haematopoietic growth factor. Increased IL-3 mRNA has been reported in
bronchial mucosal biopsies and in BALF in asthma 16' 60 .
INTERLEUKIN -4
Cross linking of the CD40 ligand on CD 4 + T cells generates a co-
stimulatory signal that increases IL-4 synthesis 61 ; a similar effect is seen with
cross linking of the IgE Fc receptor on mast cells and basophils and
stimulation of T cells 62 .
The IL-4R consists of an a chain (that transduces growth promotion and
activates transcription) and the IL-2Ry chain that amplifies the signalling of
IL -4R (denoted as the common y chain: yc) 63 .
Airway epithelial and immune cells express IL-4R and do so to a greater
extent in asthma 64 . Upon stimulation, IL-4 induces phosphorylation of the
IL-4 induced phosphotyrosine substrate associated with the p85 subunit of
phosphotidylinositol 3- kinase and with Stat 6 and Janus protein kinase
(JAK) 65 to effect signal transduction.
The RS67 allele of the IL-4Ra subunit has been associated with atopy 
66.
IL-4 is important in B lymphocyte activation through increased expression of
class II MHC molecules and also enhancing the expression of CD 23, the low
affinity ( Fc ERII) receptor, CD 40 and the a chain of the IL-2 receptor. It
plays a pivotal role in immuglobulin class switching of activated B
lymphocytes to the synthesis of Ig G4 and Ig E and also promotes the




IL — 10 was originally discovered as a product of murine Th 2 clones that
inhibited the antigen stimulated cytokine production of Th 1 clones 85 . In
humans, Th 0, Th 1, Th 2, CD 8 + T cells and most cells are all capable of
producing IL — 10 86 '87 . Monocytes in circulation however, produce more IL-
10 than alveolar macrophages 
88
.
The IL-10 Receptor (IL-10 R) is a member of the IFN — receptor family 89 .
Although the precise signalling cascade of IL-10 R has not been identified,
the inhibitory effect on monocytes is dependent on NF-KB 90 .
As regards its effects, although IL-10 can have an immunostimulatory effect,
it is generally considered an immunosuppressive cytokine as it is a potent
inhibitor of monocyte/macrophage function. IL-10 suppresses the production
of most pro-inflammatory cytokines including TNFa, IL-I(3, IL- 6, MIP- 1 a
and IL 8 91-93 . Indirectly, the expression of IL- lra, another anti-inflammatory
cytokine, is upregulated in monocytes by IL-10 94 . IL 10 also inhibits
monocyte MHC class II, B7.1/ B7.2, CD 23 expression and the synthesis of
superoxide anions and NO by activated monocytes 95 ' 96. The production of
RANTES, IL-8 97 ' 98 , IFN -7 and IL-2,-4,-5 can also be inhibited by IL-10
99,100 . IL-10 also promotes B cell viability, proliferation and immunoglobulin
secretion.
Bronchial asthma appears to be characterized by diminished IL10 production;
this may in part be because of genetic defects in IL-10 production or a feature
of asthmatic inflammation 101-1°3(discussed in detail later).
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INTERLEUKIN 12
IL-12 stimulates T cells to produce IFN-y and regulates the differentiation of
T cells such that the balance between Th 1 and Th2 is maintained 104 . In an
animal model, IL-12 reduced allergen sensitisation and airway
inflammation 105 .
The PBMC's of atopic asthmatics also appear to have impaired IL-12
production 1°6 .
INTERLEUKIN 13
IL-13 is produced by activated CD4+, CD8+T cells and all Th cell lines 1°7 .
IL-13R shares the IL-4R a chain 108, demonstrating some economy in
complexity and yet similarity of effects. It is a potent modulator of monocytes
and B cell function. IL-13 upregulates the expression of p i intergrin,
VCAM1, IL-6 and MCP-1 from lung fibroblasts 109 . In monocytes and
macrophages however, IL -113, IL-6, IL-8, IL-10, IL-12, 1FN- y, GM-CSF,
MIP- V, IL- I and TNF- a are inhibited 109-110 .
IL -13 further inhibits the release of IL-8 and RANTES from airway smooth
muscle 110' 111 . IL-13 promotes the expression of CD23 on B cells and, like
IL-4, causes isotype switching to Ig E synthesis 112 Asthmatic patients
exhibit an increased expression of IL-13 in RNA in airway mucosa 113 ' 114 .
INTERLEUKIN 15
IL-15 is also produced by activated CD4 + and CD8+T and can induce IL-18
and MCP- 1 production in monocytes 115 ' 116 .
INTERLEUKIN 16
IL-16 is produced by activated CD8 + T cells, epithelial cells and mast
cells 117 . Following allergen challenge in asthmatics, BALF contains high
concentrations of IL-16 118 .
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INTERLEUKIN 17
IL -17 is produced by CD4 +T cells and stimulates NF-KB, IL-6, IL-8, GM-
CSF and PGE2 in lung tissue 119 .
INTERLEUKIN 18
IL-18 is a powerful inducer of IFN-7 and has an important role in Thl
responses 
120
. It also induces IL-8, MIP- 1 a and MCP-1 in PBMC's. The
synthesis of TNF-a from CD3+/ CD4+ T cells and NK cells is regulated by
IL-18 121 . NF- KB and MAPK can also be activated by IL-18 122 .
INTERLEUKIN 23
IL-23 is structurally related to and has similar biological properties to IL-12
123
INTERLEUKIN 25
IL-25 is released from mast cells via an IgE dependent transduction (thus is
likely to have a role in allergy) and causes the release of Th2 type cytokines:
IL-4,-5 and IL-13 124 ' 125 .
TUMOUR NECROSIS FACTOR a
TNF exists in 2 principal forms: TNF-a and TNF-(3 and binds to similar
receptors. Although primarily produced by macrophages, it can be also be
secreted by T cells, mast cells and epithelial cells and is stimulated by IL-1,
GM-CSF and IFN - 7 126 .
TNF receptors- TNF —R55 and TNF —R75 are found on most cells and further
signalling is mediated via TNF receptor associated factor (TRAF). TNF
effects are similar to IL-113 127 .
TNF is widely expressed in the lung, increases airway hyper-responsiveness
and probably amplifies inflammation 128-130
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GRANULOCYTE — MACROPHAGE COLONY STIMULATING FACTOR
(GM-CSF)
GM- C SF regulates the growth, differentiation and activation of
haematopoietic cells 131 . In the context of asthma it is produced by most
airway cells that include macrophages, eosinophils, T cells, fibroblasts,
endothelial, airway smooth muscle and epithelial cells 132 .
GM-CSF RECEPTOR (GM- CSFR)
The GM-CSF receptor consists of an a chain and a f3 chain — the latter being
shared by the IL-3 & IL-5 receptors 133 all of which signal via JAK, MAPK
and IP-3K pathways 134 . These receptors are found on granulocytes,
monocytes, endothelial cells and fibroblasts. Interestingly, airway biopsies
have shown upregulation of the expression of the GM- CSFR a chain in non-
atopic asthma but not in atopic subjects 135 .
GM-CSF IN ASTHMA
GM-CSF may be involved in priming neutrophils and eosinophils, and can
also enhance the release of superoxide anions and cys —LTs from eosinophils
136
. GM-CSF induces the synthesis and release of many cytokines including
IL-1 and TNF a from monocytes. The expression of GM-CSF is increased in
the bronchial epithelium of asthmatics and in T lymphocytes and eosinophils
after allergen challenge 137-139 .
In acute severe asthma, increased circulating GM-CSF has been noted 140 and
PBMC from stable asthmatics also secrete increased quantities 
141
 The
transient expression of the GM-CSF gene in the epithelium of rats via an
adenoviral vector caused an accumulation of eosinophils and macrophages
and irreversible fibrosis suggesting that GM-CSF could be a factor implicated




Interferon y is produced by Th l cells, has multiple immunoregulatory effects
and is inhibitory to Th2 cells 143 . It is an immune modulator having both anti-
and pro-inflammatory effects. Exogenous administration of IFN-y inhibits
allergic eosinophilia and airway hyper responsiveness 144 and IFN-y levels
also increase during allergen immunotherapy 145 . Corticosteroid therapy is
also associated with an increased expression of IFN-y in asthmatic airways
146 .
IFN-y can also amplify the immune response: following endotoxin exposure,
TNF-oc is released from alveolar macrophages 147 and it can also activate
epithelial cells to release cytokines and express adhesion molecules 148 .
Chemokines
Chemokines are small chemotactic compounds associated with inflammation.
They are designated CC chemokines (when two cysteine residues lie adjacent
to each) or CXC (when the residues flank another amino acid). There is much
interest in CC chemokines as they are involved in eosinophil, monocyte and T
lymphocyte chemoattraction.
CC Chemokines
Macrophage inflammatory protein 1 a (MIP-1 a) is inducible in human
monocytes and attracts inflammatory cells to the site of inflammation 149
Monocyte chemoattactant protein 1 (MCP-1) —as these name suggests,
attracts monocytes and is an activating factor as well 150 .
RANTES- Regulated on Activation, normal T cell Expressed and Selected, is
expressed in IL-2 dependent cell lines 151 .
EOTAXIN- is selective for eosinophil chemoattraction 152 .
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Chemokine Receptors- Although there may be some degree of specificity 153
it appears that most chemokines can bind to the same receptor 154 .
There has been interest in blocking receptors to modify inflammation e.g. a
monoclonal antibody directed to CCR3 (the eotaxin receptor) inhibited
eosinophilia 155 .
The chemokines are pluripotent; most can stimulate and attract eosinophils.
MCP-1 can promote exocytosis of basophils with release of large quantities of
histamine 156 . Intracellular calcium release, respiratory burst and expression of
P2 integrins also occur 
157 .
Not surprisingly, increased chemokine messenger RNA and protein have been
detected in all activated cells, tissues and BALF in asthma.
Growth Factors
Platelet —Derived Growth Factor (PDGF)
Although originally derived from platelets, it is in fact released by many
airway cells. It is a principal mitogen, may activate fibroblasts to secrete
collagen and stimulate airway smooth muscle proliferation and could play a
role in airway remodelling 158 .
Transforming growth factor I (TGF- (3)
Immune and constitutive cells in the lung can produce TGF-fl and this is
increased in asthma. Its role in the turnover of matrix proteins, epithelial
repair and fibroblast stimulation may also contribute to remodelling 159 .
Fibroblast and Epidermal growth factors
(FGF & EGF) are proliferative agents and thought to play a role in
angiogenesis 16° .
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Insulin-like growth factor (IGF)
IGF is a potent mitogen, activates MAP Kinases and mediates LTD4 induced
smooth muscle proliferation 161 .
C. Confluence of Genes, the Environment and Adaptive Immunity in the
Pathogenesis of Asthma.
The Thl/Th2 Paradigm
As regards the biology of asthma, the introduction of allergen to the airways
in childhood probably initiates allergic asthma. Antigen presenting cells,
including dendritic cells, process these antigens and express them on the cell
surface in the binding groove of the MHC II. These cells then migrate to the
regional lymphoid tissue where they activate T cell receptors.
The consequent immune activation — in particular — cytokine expression —
profoundly affects a process referred to as immune deviation. In the presence
of IL -12, the cells have an IFN - y expressing or Th 1 — type phenotype 162 .
The inability to express this phenotype is thought to promote the development
of asthma. The influence of IL - 4 and IL-13 leads to the expression of the Th2
phenotype that appears to be required for the development of asthma 163 . Since
this hypothesis has been proposed, it has become clear that it is an
oversimplification. Th 1 responses exclusively, can cause reversible airway
inflammation and airway hyper responsiveness 164 . Asthma may also develop
through non allergic mechanisms-with genetics, infections and environmental
exposure contributing.
Genetics
Familial clustering clearly demonstrates the indisputable fact that there is a
genetic component to asthma. Segregation analyses using multiple asthma
traits (IgE, airway hyperesponsiveness, atopy, wheeze and asthma) have
revealed that inheritance is probably polygenic 165 .
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To date, major susceptibility genes have not been identified 166. Candidate
gene/ loci studies have reported linkages to many chromosomes and novel
regions of interest. Many of the relationships probably act as disease modifiers
e.g. polymorphisms of 02 adrenoceptor agonists in asthma:
• Gly 16: enhances down-regulation and is over-represented in nocturnal
asthma
• Ile 164: decreased coupling, binding & sequestration
• Glu 27: resists 132 adrenoceptor down- regulation 
167
However, doubts have been raised of the exclusive allergic aetiology of
asthma because although polymorphisms of TNF - a are seen in asthma, there
appears to be no relationship to atopy or IgE 168 .
Also, genes thought to be important in asthma (IL-4, IL-13, T-bet and GATA
3- the latter a transcription factor necessary for IL-5 synthesis) did not actually
correlate with the disease 5 .
Genes have recently been identified that have hitherto been unknown in
asthma pathogenesis. Some of these include a multifunctional gene- a
distintegrin and metalloprotease (ADAM 33) 169 and dipeptidyl preptidase 10
(DPP 10) 170 . ADAM genes are important for cell adhesion, signaling and the
activation and release of cytokines. The DPP 10 encodes a family of proteins
that limit the activity of other proteins by cleaving terminal dipeptides from
cytokines, chemokines and leukotrienes and has been associated with asthma
and steroid- dependent asthma in children.
The mapping of the human genome and technological advances have allowed
the identification of the expression of numerous individual genes using
expression arrays. Following the application of clinically relevant
standardized allergen solutions to airway epithelium, expression genomics
revealed 141 sequences with increased expression and 8 with decreased
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expression 5 . Amongst the 141 sequences were genes known to be associated
with allergen exposure such as lipocortin, NF-KB, and the receptor subunits
for IL-3, IL-4 and IL-5. However, the largest group of genes identified was
those that are involved in growth, differentiation and proliferation. Therefore,
over and above airway inflammation, asthma is a disease involving changes in
growth and tissue responses; this adds credence to the concept of airway
remodeling.
The Hygiene Hypothesis
The hygiene hypothesis of Strachan proposed that the immune system is
skewed to a Th-2 cell construct at birth 171 . As children encounter infections
and other environmental allergens, the immune system repositions in a Th-1 /
Th-2 balance likely through the regulatory effects of IL-10 and TGF-0. Failure
of exposure to these antigens by vaccination, frequent antibiotics, increased
indoor activity and less antigenic food may prevent the re-channeling and
back to a progressive Th-2 state and atopy. Evidence for this comes from the
observation in the Tuscon Children's Respiratory Study; the earlier children
attended daycare and the presence of one or more siblings in the household,
the lower the risk of developing asthma 172 .
D. Asthma Pathogenesis: The Future.
Previous models of asthma have focused on airway smooth muscle
dysfunction and inflammatory pathways. New models will also encompass the
regulatory systems that affect the expression of mediators — subtypes,
polymorphisms etc. including the allergen driven changes in airway resident
cell growth and differentiation that allow us to understand asthma better in
individuals. The confluence of the environment, genes and adaptive immunity
will have been met.
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1.2 THE GLUCOCORTICOID RECEPTOR IN THE PATHOGENESIS
OF STEROID RESISTANT ASTHMA.
Glucocorticosteroids (GC) have a profound influence on human homeostasis
and are used extensively in clinical medicine. GC mediate their effects via the
glucocorticoid receptor (GR) —a member of the superfamily of ligand
regulated nuclear receptors.
Since the cloning of GR in 1985 173 there have been important developments
of the molecular biology of GR that are crucial for improved understanding of
asthma pathophysiology and therapeutics. Although glucocorticoids are
effective in controlling asthma in the majority of patients, there is a minority
of patients who respond less well, needing high doses of inhaled and or oral
glucocorticoids, with a small proportion demonstrating extensive resistance
174
. These patients account for a large proportion of the high costs involved in
treating asthma 175 . Impaired glucocorticoid responsiveness has been most
extensively studied in asthma but has also been reported in other
inflammatory diseases, including rheumatoid arthritis, inflammatory bowel
disease, and transplantation rejection 176 .
An appreciation therefore, of the factors that regulate GR expression, activity
and responsiveness is the subject of intense research currently.
Steroid Resistant Asthma- the beginning
The concept of "steroid resistant asthma" was first proposed by Schwartz et al
in 1968 177 . They studied a group of six asthmatics who had responded
inadequately to systemic steroids and noted a suboptimal eosinopaenic
response to hydrocortisone. The administration of 40mg of intravenous
hydrocortisone to the index cases resulted in a blunted eosinopaenic response
in peripheral blood compared to a control group of asthmatics 177 .
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It was several years later-1981- that Carmichael formally extended these
observations and the term "steroid resistant (SR) asthma," became entrenched
178
. They studied 58 chronic asthmatic patients characterized by a baseline
FEV 1 of < 60% of predicted and a bronchodilator response of 30% or greater.
However, the critical finding was the inability to increase the FEV I by more
than 15% following a 7 day course of prednisolone 20 mg daily. By contrast,
asthmatics who could respond to this steroid course with a FEVI increase of
more than 30% were termed steroid sensitive, "SS".
It must be immediately appreciated that the term SR asthma is a misnomer.
Firstly, endogenous steroids and the GR are essential for normal homeostasis
and true steroid resistance would be incompatible with life. Secondly,
Carmichael assessed the bronchodilator response by nebulisation with 132
agonists- a practice which is not followed contemporarily as metered dose
inhalers are employed. Thirdly, the dose and duration of CS are completely
arbitrary; most clinicians (and patients) do not use higher doses or longer
periods of administration because of the danger of systemic effects. The
American Thoracic Society now defines a significant bronchodilator response
as an increase in FEV i of 12% and 200m1 of the pre-bronchodilator value 179 .
A European Task team was set up by the European Respiratory Society and
asked to look into the issue of SRA and noted that a variety of terms to
describe this category were used: difficult acute, difficult chronic, chronic
severe, acute severe, therapy resistant, difficult to control, corticosteroid
resistant or corticosteroid dependent, symptomatic, life threatening and fatal.
It must be remembered that each of these entities is specific with probable
different pathogenetic mechanisms. The task team decided that the term





There follows a number of caveats before this label would strictly apply;
a) has the diagnosis of asthma been definitively established?
b) have asthmatic variants e.g. allergic bronchopulmonary aspergillosis and
Churg Strauss Syndrome been excluded?
c) that other factors contributing to loss of control are excluded-
"i) poor compliance/adherence to therapy
ii) psychosocial and emotional factors
iii) inadequate medical facilities
iv) poor access to medical facilities
v) inadequate treatment
vi) exposure to allergens
vii) viral respiratory tract infections
vii) gastro-oesophageal reflux
vii) sinusitis
vii) genetic factors 181 "
The importance of the above cannot be adequately emphasized but will not be
discussed further; instead I will concentrate on the disease process of asthma
itself and where alternative terms for difficult asthma are used, they are
referred to in precisely the same way as defined in the original reports.
Steroid Resistant asthma- the story continues
Could there be other reasons for an inadequate therapeutic response to CS?
One aspect could be an enhanced clearance of CS. However, in studies of SR
asthmatics as categorised by Alvarez 182 and Corrigan 183, pharmacokinetic
abnormalities were examined and discounted as an explanation for steroid
resistance. In the report by Alvarez, SR was defined as an FEV1 below 60%
of predicted following a 2 week course of prednisone (mean dose: 45mg/d).
Six of these subjects underwent a steroid pharmacokinetic evaluation where
the rate and extent of absorption and metabolism of prednisone and its active
metabolite, prednisolone, were measured; no abnormality could be detected.
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PBMC's extracted from these patients were stimulated with PHA. The methyl
prednisone dose response showed a significant increase in DNA synthesis
consistent with DNA proliferation compared to steroid sensitive subjects. In
vitro, this abnormality was reversed with 10µg/ml of troleandomycin, a
macrolide with possible immunomodulatory properties, suggesting that this
was an acquired reversible defect.
To further illustrate the lack of consensus on the definition of SRA, Corrigan
used a definition of failure to increase the FEVI by 15% after oral
prednisolone-20mg daily for 1 week followed by 40 mg daily for the second
week in his cohort..
Peripheral Blood Mononuclear Cell studies
SR asthmatic subjects defined in many studies exhibited a number of cellular
abnormalities:
- Kay et al reported that after GC therapy, PBMC's failed to reduce
complement receptor expression as opposed to SS subjects 184
- After exposure of PBMC to methylprednisolone, T lymphocyte proliferation
was insignificantly inhibited whilst this was decreased by more than 60% in
SS 185
- No suppression of leukotriene B4 production following hydrocortisone
treatment 186
- Unchanged TNF production compared to a significant reduction in SS 187
- Increased expression of IL-2R, IFN-y and HLA-DR activation antigens on
circulating T cells 
183,
 188
Lane and colleagues used the tuberculin test to investigate the in vivo
responsiveness to oral prednisolone in SR and SS in a double-blind, placebo
crossover fashion. The SS but not the SR subjects showed suppression in
delayed type hypersensitivity and a decrease in the infiltration of
macrophages, eosinophils and T cells 
189
. Thus differential steroid sensitivity
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can express itself at different sites in addition to the site of inflammation-the
lung.
Structure and Activity of the Glucocorticoid Receptor
The GR is encoded for by a gene on a single locus on chromosome 5q31-32.
Differential expression of the gene results in variation in GR signalling 190
The 3 components of the first exon of the genomic structure exhibit the
potential for functional sequelae as dexamethasone upregulates all 3
transcripts in acute lymphoblastic leukaemia T cells but depresses them
variably in a B-cell line 191 . This and the expression of GR-I3 (see later) have
crucial implications for the understanding of GR expression in disease. The
GR consists of 3 domains (Fig 1) - the amino N-terminal or immunogenic
domain and the carboxy C-terminal or ligand binding domain flanking a DNA
binding domain (DBD) 192 . The inactive GR is located in the cytoplasm as a
hetero-oligomeric complex containing heat shock proteins 50, 70 and 90 and
probably other proteins as well (Fig 2). After binding to GC, the GR
undergoes conformational changes, dissociating from the chaperone proteins
and the homodimerized complex is actively transported through the nuclear
pore into the nucleus where the action of GC is mediated in at least 3 ways
193
The first, a direct genomic mechanism occurs when the binding unravels two
nuclear localisation sequences (NL 1 & 2) that enable translocation to the
nucleus. Here transactivation by GR dimers requires specific palindromic
sequences in the cis-regulatory regions of target genes called the GC response
element-GRE. These are e.g. the mechanisms whereby 13 adrenoceptor
regulation and the inhibitor-I- icBoc of NF- KB, is controlled 194 . Gene




GRa, 777 amino acids
GR J, 742 amino acids
Immunogenic domain DBD LBD
Fig 1. Genomic and complementary DNA and protein structure of the human
Glucocorticoid Receptor. The human GR gene consists of 10 exons. Exonl is
an untranslated region whilst exon 2 codes for the immunogenic domain.
Exon 3 and 4 code for the DNA-binding domain (DBD) and exons 5 to 9
code for the hinge region and the ligand-binding domain (LBD) respectively.
The 2 terminal exons 9 (exon9a and 9(3) are alternatively spliced to produce
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TF
GRE TFRE
Fig 2. Traditional View of Corticosteroid Action
The Glucocorticoid Receptor (GR) is located in the cytoplasm in association
with heat shock and other proteins. Upon binding to the glucocorticoid (GC),
these proteins dissociate and the complex translocates to the nucleus. Here
they interact with transcription factors and positive and negative
glucocorticoid response elements (GRE's) to effect GC action.
TF: transcription factors
TFRE: transcription factor response element
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However, many of the major pro-inflammatory genes do not possess GRE's
suggesting that other mechanisms of inhibition exist 195 . Transrepression
occurs when GR (probably in its monomeric form) engages in protein —
protein interactions without DNA binding: examples include AP-1 and NF-
KB binding- the latter probably related to a mechanism that involves
deacetylation of acetylated core histones 193 ' 196. Histone acetyl- transferases
(HAT) and deacetylases (HDAC) are families of enzymes that regulate
chromatin structure- a key pre-requisite for inflammatory gene expression.
Acetylation of histones by coactivator proteins e.g. CBP- Creb binding
protein, possess intrinsic HAT activity lead to unwinding of the DNA to
allow transcription factors and RNA polymerase II to switch on gene
transcription. In contra-distinction, deacetylation is associated with
transcriptional repression. These represent the direct genomic effects of GC.
In addition, glucocorticoids may also play a role in repressing the action of
proinflammatory kinase cascade systems, such as the extracellular regulated
kinase (ERK) and the Jun N-terminal kinase (JNK) mitogen-activated protein
kinases (MAPKs) 197200. This occurs via non-genomic mechanisms. Thus
directly or indirectly, the GR, functioning as a hormone activated
transcription factor, is estimated to influence glucocorticoid target genes on











AF2 526 556 753 768
Interaction with:
NF-KB 428 777
P160 77 262 526 556 753 768
P300/CBP 526 556 753 768
DRIP/TRAP 77 262 526 556 753 768
Complex DRIP150 DRIP205/TRAP220
Fig 3: Functional domains and sub-domains of the GRa are indicated. DBD:
DNA binding domain; HR, Hinge region; NL 1 and NL2, nuclear
translocation signals 1 and 2. Two transactivation domains, activation
functions (AF) 1 & 2 located in the immunogenic domain and the LBD
(ligand binding domain) respectively co-operate for full transcriptional
activity of GR; deletion of either of them dramatically reduces the
transactivational activity of GR.
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Table 1. Factors that might change the sensitivity of tissues to glucocorticoids
Cellular factors
Ligand export system
Ligand activation-inactivation -HSD and 5a -reductase)
Chaperones-cochaperones
Transcription factors (e.g. NF- KB, AP-1, CREB, STATs,





Viral coactivators (HIV-1 Vpr, Tat)
Chromatin modifiers (SWI/SNF)








11 B —HSD, IIBHydroxysteroid dehydrogenase; AP-1, activator protein 1;
CREB, cyclic AMP-responsive element-binding protein; STATs, signal
tranducers and activators of transcription; C/EBPB, CAAT/enhancer binding
Protein B; DRIP150; vitamin D receptor-interacting protein150;
TRAP220, thyroid hormone receptor - associated protein 220; UDCA,
ursodeoxycholic acid.
Adapted from Reference 202.
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The Glucocorticosteroid receptor splice variant: GR-13
One of the major discoveries in the last few years, particularly for asthma, has
been the recognition of GR-13 203 . Alternative splicing of GR pre-mRNA gives
rise to 2 variants of GR: GRa, the 777 amino acid moiety and active form of
the GR and GR-13- which differs only in the carboxy terminal end by being
deficient in 35 amino acids. However, being the crucial ligand- binding
domain, this isoform is unable to bind CS. Interestingly GR-(3 is synthesized
in tissues of normal individuals; but its production is increased in PBMC's
and BALF cells in asthma and the highest levels are found in severe and near
fatal asthma 
204,205
 In severe steroid dependent and resistant asthmatics, GR-
13 expression is increased as well 206-208
Clearly, this is one mechanism why these patients are poorly responsive to
CS treatment — they have a receptor that cannot bind CS and therefore cannot
mediate the anti-inflammatory effects! Worse still- GR-13 inhibits the GR-a
DNA binding capacity— further diminishing the possibility of a good
therapeutic outcome 209 .
Some of the mechanisms whereby this occurs include GR-13 competitive
binding to GRE- DNA and the formation of transcriptionally impaired GR-a
GR-I3 heterodimers instead of the active homodimer 203 . An important line of
investigation has opened up regarding the control of GR-13 expression and
whether this can be influenced beneficially. We do not know what these
factors are presently but what has been demonstrated is that inflammation
increases GR-13 expression- thus far TNF-a and IL-1 have been shown to
upregulate GR-13 levels 210 . This over-expression can also exert effects on
pro-inflammatory transcription factors e.g. AP-1 and NF-KB and thus
contribute to the regulation of inflammatory responses 211 .
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GR-13 is also increased at night providing yet another mechanism and
explanation for the characteristic diurnal symptomatology of asthma 212 .
Fortunately GR.-13 has a negligible effect on the binding of other steroid
hormones.
Influence of signal transduction on GR.
Cell stimulation by a variety of mediators e.g.cytokines and hormones result
in the activation of intracellular enzyme systems and the generation of a
number of signal transduction proteins. These have the capacity to interact
with GR and enhance / inhibit its function (table 1).
Glucocorticosteroid Receptor Numbers and Affinity.
The effectiveness of a ligand in stimulating GC actions is dependent on its
ability to bind to the receptor and the number of receptors present. The
inability of some patients to respond to GC has been proposed to be due to
altered affinity for GR & or number 
213'214
 One would expect that if there is a
sub-optimal response to GC, that a reduction in the number of corticosteroid
numbers may be an explanation. Contrary to this expectation, several groups
that have studied SRA for some time have actually described an increase in
the number of receptors 183,215, 216 GR numbers can be acutely downregulated
following high dose corticosteroids 183 because of unique intragenic
regulatory sequences in GR itself. These were confirmed by transfection
studies by Burnstein et al, who were able to show downregulation of human
GR via decreased mRNA and protein 217 . Following experiments using RT-
PCR for the a and isoforms in respiratory epithelial cells, Pujols et al were
able to conclude that transcriptional, post-transcriptional and post-
translational mechanisms were involved in the regulation of GR expression
218 .
To test whether a poor glucocorticoid response could be due to altered
affinity, Sher et al 216, studied a group of asthmatics designated SR by failure
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to increase FEV1 by 15% after a 7 day course of prednisolone- 20mg twice
daily. PBMC's from these patients were subjected to [ 3H] dexamethasone
ligand binding assay and Scatchard analysis; the SR patients had a significant
increase in their GR Kd ( implying decreased binding affinity for CS) and an
increased receptor number only in the nuclear fraction compared to SS
patients. This poor affinity was also observed by Corrigan et al 183 , using a
similar methodology and corroborated by Spahn 219 who also demonstrated a
decreased binding affinity in poorly controlled asthmatics. Although Lane 215
also detected a higher Kd in corticosteroid-resistant subjects compared to
cortico-steroid sensitive subjects, this was not statistically significant
(possibly due to small numbers of patients)
In an attempt to further elucidate the reason for diminished affinity for GR,
Leung et al, performed bronchoalveolar lavage in these subjects and detected
an increased number of cells expressing positive hybridisation signals for IL-
2, IL-4, IL-5 220 and (later) IL-13 mRNA 221 . Subsequent in vitro studies
revealed that altered GR affinity could be induced in peripheral blood
mononuclear cells (PBMC) from normal subjects with a combination of IL-2
and IL-4 or IL-13 alone 222 ! Incubation of cells with IL-1, IL-5 and IFN-y
could not alter GR affinity 
222
 Diminished affinity has also been documented
in PBMC's co-incubated with allergens 223 .
Using these data, we developed an in vitro model for steroid resistance to
study the mechanisms underlying this altered affinity and the functional
consequences thereof.
One must appreciate that GR affinity is not static but is altered by disease
states and inflammation. This binding affinity changes diurnally (the decrease
at night being yet another reason for more nocturnal symptoms) and over time
224
. The fact that the alteration in Kd is due to inflammation was well
demonstrated in a study where GR affinity decreased with the onset of the
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allergen season and importantly, before the onset of symptoms 223, 226! In fact,
GC are capable of normalising affinity as inflammation is brought under
control 225 ; the more severe the asthma the more potent the CS needed to
normalise affinity to control symptoms.
A spectrum of glucocorticoid responsiveness in airway inflammatory diseases
may exist, reflecting several mechanisms caused by either disease activity
itself or by the effects of therapy, with the glucocorticoid-resistant asthmatic
subjects at one extreme of this spectrum. At a molecular level, resistance to
the anti-inflammatory effects of glucocorticoids can be induced by several
mechanisms 227 . The reduction in glucocorticoid responsiveness observed in
cells from these subjects has been ascribed to a reduced number of GRs,
altered affinity of the ligand for GRs, reduced ability of the GR to bind to
DNA, or increased expression of inflammatory transcription factors, such as
activator protein 1, that compete for DNA binding.

















1.3 SELECTIVE MEDIATORS AND CYTOKINES IN SIGNAL
TRANSDUCTION.
Phosphoinositide Hydrolysis
Phosphoinositide hydrolysis is one of several important mechanisms of signal
transduction 
228.
 The activation of airway cell surface receptors e.g.,
muscarinic or cysteinyl — leukotriene results in the further activation of the
enzyme phospholipase C (PLC). This in turn converts phosphoinositide 4, 5 —
biphosphate (PIP2) to two second messengers: myoinositol 1, 4, 5-
triphosphate (IP3) and 1,2- diacylglycerol (DAG). These products are
intimately linked to intracellular Ca 2+ and airway smooth muscle contraction
but additionally, to pathways of inflammation in these and other immune cells.
DNA""qillIl-rtCIZVIIC
Fig 4. The IP-3 kinase and Diacylglycerol pathways showing the inhibitors
Wortmannin for IP-3 Kinase and Ro318220 for Protein Kinase 3.
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a) PHOSPHOINOSITIDE 3- KINASE (PI-3K)
Phosphoinositide 3 kinases are lipid kinases (phosphorylating membrane
lipids of the phosphoinositide family) that recruit and activate downstream
targets involved in mitogenesis, apoptosis, differentiation and activation,
cytoskeletal remodelling and vesicular trafficking.
Structure, substrate specificity and regulation have resulted in 3 classes of PI-
3K being recognized 229 . Class II consist of monomers of uncertain
significance (as yet) in mammals. Class III appear unregulated and are thought
to be involved in intracellular "housekeeping" e.g. protein and vesicular
trafficking. Class I are heterodimers of catalytic and regulatory subunits that
subserve principal intracellular functions.
Airway smooth muscle proliferation has been linked to PI-3K. A characteristic
feature of remodelled airway is the increase in airway smooth muscle bulk and
number. In two animal models, a three fold increase in ASM DNA has been
demonstrated 230 '231 . The availability of a PI-3K inhibitor —Wortmannin- was
subsequently shown to decrease ASM DNA synthesis by more than 90% 232
and PI-3K may be important in the remodelling process.
PI-3K are also key regulators of neutrophil recruitment and activation 233
(cells important in severe and fatal asthma)
Eosinophils are also not normally resident in the lung. Their presence in
asthma together with their toxic products ECP & MBP damages airway
epithelium and contributes to BHR. Wortmannin was shown to inhibit IL-5
induced eosinophil release by the bone marrow 234 and blocked eosinophil
migration in response to chemoattractants 
235,
 236.
The induction of cytokine gene expression in monocytes is also sensitive to
PI-3K inhibition 237 .
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b) Protein Kinase C
DAG, the other product of PI hydrolysis is the endogenous activator of
another important regulatory enzyme- protein kinase C (PKC).
The Protein kinase C (PKC) is an increasingly diverse family of
serine/threonine kinases that are involved in multiple cellular processes as
well 238 . Presently, the PKCs comprise twelve different isoforms that are
grouped into three subfamilies based on their unique structure:
- classical PKCs (a, 131, (32 and y) — activated by (DAG) and calcium,
- novel PKCs (6, e, and 0) — activated by DAG, and the
- atypical PKCs and ?JO that do not respond to either DAG or calcium.
PKC isozymes appear to play distinct, and in some cases opposing roles in the
transduction of intracellular signals and are often over expressed in disease
states.
Evans et al demonstrated an increased expression and activation of the PKC4
isoform in sputum eosinophils that occurred in the late phase following
allergen challenge in asthmatics 239 .
However, Vachier et al, reported abnormal regulation of PKC activity in
alveolar macrophages and PBMC's of asthmatic patients and suggested that
this was one mechanism for the functional hyperreactivity of inflammatory
cells in asthma 240 .
Furthermore, activation of PKC in an airway epithelial cell line enhanced
IL-8 expression via an effect on NF-KB suggesting that PKC plays a key role
in the regulation of NF-KB-dependent gene expression in these cells 241 .
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Endothelin is a small peptide that is probably involved in the pathogenesis of
asthma. It is a potent bronchoconstrictor, a mitogen factor for airway smooth
muscle and a powerful stimulator of the extracellular regulated kinase 2
(ERK2) subgroup of MAP kinases. It was established that the endothelin
signal transduction pathway that culminates in ERK2 activation was
dependent on PKC 242
Histamine —another mediator of inflammation- induces the release of many
cytokines including IL-8 and GM-CSF. This action was found to dependent








The Mitogen Activated Protein Kinases in Intracellular Signal
Transduction.
The bronchial epithelial and immune cells are exposed to numerous inhaled
environmental stimuli that could influence intracellular signalling pathways
and a variety of cellular responses. Of these, the mitogen-activated protein
kinases are felt to play a major role in these responses as they regulate
intracellular signal transduction by many agonists, growth factors, hormones,
cytokines, oxidants and environmental stress factors 244 . The MAPK system is
highly conserved in all organisms 245 .
Mitogen Activated Protein Kinase
Fig.5. The Mitogen Activated Protein Kinase Cascades. IL-2 signals via
p38MAPK —the latter being inhibited by SB 203580; PD098059 is a specific
inhibitor of ERK.
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The three best characterised cascades are:
i) the extracellular regulated kinases (ERK)
ii) the p38 MAPK
iii) the c-Jun NH2 —terminal kinases (JNK) (the stress activated protein
kinases)
MAPK are activated by phosphorylation and in turn phosphorylate
cytoplasmic signalling proteins, cytoskeletal proteins or modulate
transcription factors and kinases 245 .
The MAPK / ERK cascade is activated following mitogen exposure and
downstream gene induction leads to the appropriate mitogenic or
differentiation response 244 .
The JNK / SAPK and p38 MAPK are the two most important systems and are
activated by stress, LPS, UV radiation, pro-inflammatory cytokines (1L1 -(3,
TNF-a) but respond weakly to growth factors 245-247 . Inflammatory cytokines
activate the cascade via the Rho family of small GTPases (Rho, Rac and Cdc
42) and p21 Ras- activated kinase (PAK) 248.
Although there is some degree of upstream specificity of the MAPK at the
level of the MKK's, there is a lot of cross - talk 249 . The MAPK stress
pathways are closely related to NF-KB — dependant gene expression 249 .
The study of MAPK modules has been enhanced by the availability of 2 cell
permeable MAPK inhibitors — PD 098059 (a flavone) 25° and SB 203580.
PD 098059 binds to the inactive form of MKK1 with ERK being its specific
downstream effector 259 .
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Experiments with PD 098059 of Relevance to Asthma.
Vanadium pentoxide causes occupational asthma and chronic bronchitis
through unknown molecular mechanisms. A study utilizing rat pulmonary
myofibroblasts demonstrated activation of the extracellular signal-regulated
kinases 1 and 2 (ERK-1/2) with Vanadium but not by the inert metal titanium
dioxide. Vanadium induced ERK-1/2 activation was abolished by
pretreatment with PD98059, indicating a dependence on the mitogen-
activated protein (MAP) kinase kinase pathway 251 .
Endothelin, a small peptide, is a potent bronchoconstrictor and mitogen for
airway smooth muscle and is likely involved in the pathogenesis of asthma.
Endothelin is also a potent stimulator of the extracellular regulated kinase 2
(ERK2) subgroup of MAP kinases and ERK2 activation is closely linked to
smooth muscle cell proliferation. Whelchel reported that PD98059 was found
to significantly inhibit the ability of endothelin to activate ERK in cultured
airway smooth muscle cells 242,252 .
IL-13 dysregulation plays a pathogenetic role in inflammatory and
remodelling diseases with STAT 6 probably mediating its tissue effects.
Because signalling cascades involving MAPKs have been linked to
inflammation and remodelling, Lee et al, administered PD98059 to mice and
studied the consequences. They found that IL-13-induced inflammation and
alveolar remodelling was inhibited with an associated decrease in IL-13-
induced chemokines (MIP- I alpha, MIP-lbeta, MIP-2, RANTES, MMP-2, -9,
-12, and -14, and cathepsin B and increased levels of alphal-antitrypsin 253 .
Respirable particulate matter (PM) is responsible for lung problems and
airway epithelium exposed to PM secretes pro-inflammatory cytokines.
Blanchet et al 254 demonstrated that human bronchial epithelial cells exposed
to PM with an aerodynamic diameter < 2.5 micron (PM2.5) or diesel exhaust
particles, upregulated the expression of amphiregulin (AR), a ligand of the
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epidermal growth factor receptor (EGFR) that is capable of inducing GM-
CSF. They further reported that amphiregulin was inhibited by PD098959
during these studies 254
Finally PD098059 may block tissue eosinophilia as MAPK are responsible for
eotaxin 2 mediated expression of VCAM; when blocked by the inhibitor, cells
shift their adhesion molecule usage away from VCAM dominated pathways to
ICAM pathways 255 .
SB203580 — the Specific p38 MAPK Inhibitor.
SB203580 belongs to a class of pyridinylimidazole compounds initially
investigated for their ability to inhibit inflammatory cytokine synthesis 256
SB203580 is a specific inhibitor of p38a, p3813 and p38-2MAP kinases that
prevent activation of its downstream effector MAPK-activating protein kinase
2 257 . P38MAPK (p38 /Mpk2/ CSBP/ RK) is part of the ras pathway and
responds primarily to stressful and inflammatory stimuli e.g. tumour necrosis
factor- alpha, IL-1 and lipopolysaccharide. Potential cellular targets of MAPK
include PLA2 and p90 s6 kinase 
258
.
Role of P38 MAPK in Pro-inflammatory Cytokine Expression.
p38 MAPK activation leads to the production and activation of inflammatory
mediators that play a role in leucocyte recruitment and activation 259 .
Additionally, p38 MAPK regulates the expression of a number of genes
involved in inflammation e.g. those coding for TNF-a , IL1-I3, IL-6, IL-8
cyclooxygenase 2 and collagenase-1, - 3 260 .
SB 203580 inhibits p38 activation and
- IL- 6 and GM-CSF transcription in TNFa stimulated fibroblasts 261 ,
- IL- 8 transcription in IL -1 stimulated monocytes 261
- translation of IL -1 and TNF-a in LPS stimulated monocytes and inhibits
NFKB — dependant gene transcription (indirectly) 
262
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- decreases RANTES and GM — CSF production of TNF-a or IL-1(3 treated
bronchial epithelial cells (although high concentrations were used in this
report that could have inhibited other MAPKs) 263 .
- causes a reduction in TNF-a mRNA in human macrophages 264
p38 MAPK is also involved in iNOS expression and the inflammatory
response in macrophages 265 .
The therapeutic potential of p38 MAP kinase inhibition has also been
investigated in animal studies. Antisense pharmacodynamic activity was
demonstrated by Duan et al who characterized a potent and selective p38
MAP kinase antisense oligonucleotide, aerosolized, and then administered it
by inhalation in a mouse model of asthma 266 . BALF from the mice showed
significant reductions of ovalbumin-induced increases in total cells,
eosinophils, and IL-4, IL-5 and IL-13 levels. This correlated further with a
dose-dependent inhibition of airway hyper responsiveness in allergen-
challenged mice. The p38alpha-ASO significantly reduced p38alpha MAPK
mRNA expression in mononuclear cells from BALF and peri-bronchial lymph
node tissue. A control 6- base mismatched oligonucleotide did not exhibit any
of these effects.
Thus in the context of asthma pathogenesis, the synthesis of many
inflammatory mediators such as TNFa, IL-4, IL-5, IL-8, RANTES and
eotaxins, are all regulated through activation of p38 MAPK 259
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A significant report that p38 MAPK was crucial for the mitogenic response of
IL-2 prompted us to test SB203580 in the steroid resistance model 267 .
We were aware that glucocorticosteroid receptor resistance in vitro was
dependent on the co-incubation of IL-2 and IL-4 and was not possible with
either cytokine alone. The availability of antibodies against these
cytokines/receptors would have allowed us the opportunity of performing
experiments to see the effect of blocking these cytokines. The next best was to
attempt to block their signal transduction pathways.
It was known that one of the members of the mitogen-activated protein kinase
(MAPK) family, p42/44MAPK (ERK2/1), is activated by 1L-2. Crawley et al,
investigated the response to IL-2 of two other members of the MAP kinase
family, p54MAP kinase (stress-activated protein kinase (SAPK)/Jun-N-
terminal kinase (JNK)) and p38MAP kinase, in a T cell line 267 . They showed
that IL-2, and another T cell growth factor, IL-7, activated both SAPK/JNK
and p38MAP kinase. Importantly, inhibition of p38MAP kinase activity with
SB203580 prevented activation of its downstream effector, MAPK-activating




Theophylline has been used for decades in asthma. However, its narrow
therapeutic range and adverse event profile saw its use decline as the safety
and superior efficacy of LABA+ ICS emerged to become first line therapy in
symptomatic asthma.
Its exact mechanism of action has been debated for decades. The current
views are the inhibition of cAMP and cGMP phosphodiesterases and
adenosine receptor antagonism 268, 269 . c •cAMP is an important second
messenger, inhibition of which will decrease inflammatory responses in many
cells 270 . The predominant PDE isoenzyme is PDE4 in human eosinophils and
although at high theophylline concentrations (IC50 300-661 mM) this enzyme
can be inhibited, at therapeutic concentrations of 27-80 mM there is almost no
inhibition 271 . However, the highly specific PDE4 inhibitor-Rolipram-failed to
inhibit eosinophil degranulation, suggesting that PDE inhibition alone is not
the only prerequisite 272 .
Apart from Al and A2 receptors, adenosine exerts its effect via A3 receptors;
these are abundant on eosinophils 
273
 and when stimulated, inhibit
degranulation and chemotaxis 
274,
 275
Ezeamuzie showed that theophylline at therapeutic concentrations was able to
suppress C5a induced eosinophil degranulation via an A3 agonist effect 276 .
Other effects of theophylline at therapeutic doses include the inhibition of the
late asthmatic response by decreasing the inflammatory response to allergen
and concomitant airway hyper-responsiveness 277-279, the latter effect however,
was not noted by other investigators 280 .
The suggestion that it has anti-inflammatory activity at lower doses 
281, 282 and
two studies where clinical efficacy was noted at this lower dose with ICS
rather than doubling doses of ICS saw a renewed interest in the drug 
283, 284.
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Additionally, the following anti-inflammatory effects have been noted in
experimental and in vitro studies:
- prevention of expression and release of TNF-a and IL-113 by monocytes and
alveolar macrophages 285,286
- non-specific suppression of lymphocyte activity 287
- blocks IL-2 dependent T cell proliferation and IL-2 production by T cells 288
- inhibition of eosinophilic degranulation and release of mediators (high dose)
and low dose causing a decrease in eosinophilic inflammation but no change
in NO 279 ' 2" .
Finally, in the setting of GR related transcription, was the finding that
theophylline at therapeutic levels also inhibited NF-KB in human mast cells
stimulated with TNF 299 .
Since the precise mechanism of action of theophylline was uncertain and the
description of experimental evidence of anti-inflammatory effects that may be




As cytokines were investigated and their functions elucidated, it became
apparent that although most were pro-inflammatory, a few regulated immune
cells and were anti-inflammatory 291 . In this latter category, interleukin-10 is
one of the most important. Prior to full characterization, it was quite clearly an
inhibitor of cytokine synthesis 85 . It is a late release cytokine produced by
lymphocytes, monocytes and macrophages. It inhibits production of iNOS, the
cytokines IL-1, IL-6/-8, TNF-a, GM-CSF, G-CSF, IFN-y and chemokines at
the transcriptional level and also induces humoral responses 91-100, 292, 293
When studying its applicability to asthma it appeared that there was a defect in
the expression of IL-10 which may represent an endogenous reason why
inflammation persists 294 . Production of IL-10 is decreased in alveolar
macrophages and PBMC's in asthma 295 .
One of the other factors contributing to this may be due to genetic
polymorphisms. IL-10 is transcriptionally regulated and there are 3 single base
pair substitutions between - 1117 and -627 at the 5' flanking region that
produce three different haplotypes: ATA, GCC and ACC 296 . These
polymorphisms are in proximity to several transcription factors that might
interfere with transcription 297 . Using sequence-specific oligonucleotide
probes with a dot blot technique, Lim et al looked for the six possible alleles.
They found that significantly fewer severe asthmatics than controls had the
putative high IL 10- producing haplotype GCC and more had the putative low
IL10-producing haplotype, ATA 102 .
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Defective IL-10 expression
Tomitka et al utilised the technique ofLPS stimulation of whole blood cultures
and analysis by flow cytometry 298 . Unlike mild asthmatics and controls, there
was a significant reduction in intracellular staining for IL-10 (and IL-12) in
severe persistent asthma.
Beneficial effect of IL-10
In animal models, IL-10 can effectively suppress the immune response to
inhaled allergen 299 and in another novel report; CD4+ cells engineered to
increase IL-10 secretion also controlled airway reactivity and inflammation30° .
During specific immunotherapy, Th cells secrete more IL-10, offering a
possible explanation for the success of this modality 301 .
Recombinant human IL-10 has been utilized successfully in Crohn's disease
and psoriasis (although haematological side-effects raised safety issues)
ICS therapy is associated with increased IL-10 production by alveolar
macrophages whilst pro-inflammatory cytokine production decreases 302 .
These data on IL-10 prompted us to study its effect in the steroid resistance
model both as a modulator of altered GR binding and its secretion after
resistance was induced in vitro.
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Granulocyte Monocyte - Colony Stimulating Factor.
There is increased expression of GM-CSF in the airways and peripheral blood
in asthma. It enhances the production of a host of cytokines and is chemotactic
for immune cells especially eosinophils.
Deleterious Effect of Elevated GM-CSF
La Grutta et al, 303 from an analysis of GM-CSF and other inflammatory/signal
transduction molecules, have postulated that biological heterogeneity may
exist in children with asthma that has clinical consequences. They studied
steroid —naïve and moderate asthmatics and found that the moderate group had
2 phenotypes of GM-CSF production: low and high producers. This latter
group experienced more exacerbations than the low producers. Moreover, the
p65 nuclear factor-kappaB subunit and phosphorylated IkB alpha expression
by PBMC's was also higher in the moderate asthmatics suggesting greater
inflammatory activation.
The adhesion molecules ICAM-1 and VCAM-1 are members of the
immunoglobulin superfamily adhesion molecules on vascular endothelium
and play a key role in eosinophil accumulation in allergic inflammation.
Although VCAM- 1 has been reported to cause spontaneous eosinophil
adhesion, 3°4 GM-CSF was required and augmented ICAM-1 eosinophil
adhesion. In this in vitro experiment, GM-CSF also increased eosinophil
superoxide anion (02-) generation and eosinophil —derived neurotoxin release.
Decreased GM-CSF is associated with Asthma Improvement
To establish the role of GM-CSF in asthma, a group of asthmatics were given
beclomethasone dipropionate 800m/day for 1 month and subjected to the
sputum induction technique before and after therapy 
305
 The ICS course was
associated with an increase in the mean peak expiratory flow and with a
decrease in the diurnal variation of PEF accompanied by a significant decrease
in the mean GM-CSF level after treatment.
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Superior clinical asthma outcomes have also been described with LABA+ ICS
combination thera 3py 06, 307 A number of synergistic molecular mechanisms
have been demonstrated in vitro to explain the observation of the potentiation
of the anti-inflammatory effect of ICS by the LABA:
increased inhibition of TNF-a induced eotaxin release, thus limiting
eosinophil accumulation in the lung 308
ligand independent translocation of GR to the nucleus 309
activation by GR by formoterol 310 .
A report by Spoelstra et al described decreased GM-CSF production by lung
fibroblasts as a further explanation of the benefits of combination treatment
311 . The cells were pre-incubated with Budesonide and then stimulated with
(IL)- lbeta in the presence of Formoterol. Supernatants were assayed and the
cells subjected to a cell surface ELISA technique. Formoterol had an additive
effect in decreasing GM-CSF production and inhibiting the expression of
ICAM-1 and VCAM-1 as well.
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CHAPTER 2: AIMS
1. Review the history and experimental procedures in Steroid Resistant
Asthma.
2. a. Define a cohort of oral-steroid resistant asthmatics as a surrogate for
steroid resistant asthmatics to explore Glucocorticosteroid Receptor
(GR) characteristics and compare to steroid sensitive patients and
normal subjects.
b. Test whether decreased GR number and/or affinity are responsible for
diminished corticosteroid effects.
c. Administer a corticosteroid burst and re-examine GR parameters.
3. Confirm cytokine induced altered GR affinity in vitro utilizing IL-2 and
IL-4 primarily- use as "steroid resistance model".
4. Attempt to normalize GR affinity with inhibitors of signal transduction in
vitro.
a. IL-4 induces phosphorylation of the IL-4 induced phosphotyrosine
substrate associated with the p85 subunit of phosphotidylinositol 3-
kinase: block with Wortmannin
b. PKC is associated with phosphorylation and the regulation of NF-KB:
block with Ro318330
c. ERK MAPK : block with PD098059
d. P38 MAPK- transduces inflammatory stimuli and essential for
mitogenic response of IL-2: block with SB203580.
e. Theophylline: mechanism of anti-inflammatory action not fully
understood; interacts with transcription factors- possible interaction
with GR.
f. IL-10 is a major regulatory cytokine and inhibits synthesis of most
pro-inflammatory cytokines; co-incubate with 11-2,-4.
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5. Explore functional consequences of altered GR affinity in terms of
cytokine production by cells- hypothesis: cytokine profile should favour a
pro-inflammatory state. Measure IL-10, anti-inflammatory/ regulatory
cytokine and GM-CSF- a pro-inflammatory cytokine.
6. Attempt to demonstrate steroid resistance in vitro by measuring cytokine
expression and the possible effects of dexamethasone.
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CHAPTER 3: Glucocorticosteroid receptor characteristics in
peripheral blood mononuclear cells in oral-steroid dependent
asthma. 
RATIONALE FOR USING PERIPHERAL BLOOD MONONUCLEAR
CELLS AS A REFLECTION OF THE AIRWAY MILIEU
Peripheral blood mononuclear cells (PBMC's) have been used extensively to
study pathogenetic mechanisms in asthma. One of the reasons is their relative
ease of access; studying the airway milieu is relatively invasive and can be
complicated in difficult asthmatics with labile and pre-existing narrowed
airways. I chose to study PBMC's as it was non-invasive, had already been
thoroughly researched and my data would be comparable to existing data on
the subject.
The intuitive question therefore is: to what extent do circulating mononuclear
cells reflect inflammation in the lung? One must remember that airway cells
are derived from the circulation. Thus inflammatory stimuli attract and
activate cells in the bronchi in asthma. These stimuli, including local airway
mediators, also activate immune cells trafficking through the lung circulation
and they in turn, together with circulating mediators, activate cells in the
systemic circulation. This process extends all the way to the bone marrow 10 .
Once mononuclear cell diapedesis has occurred, they become resident in the
lung. Whilst these cells do change phenotypically, they retain many of the
properties of their circulating counterparts' e.g.




IL-13 inhibits expression of MIP 1-a from lung macrophages and blood
mononuclear cells 110
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altered GRP expression is seen in both BAL cells & PBMC's in acute
severe asthma 204,205
There is thus a large body of evidence to suggest that PBMC's do reflect the
behaviour of cells in the airways 10, 12, 13, 77, 88, 90-92,110, 204, 205 .
RESEARCH QUESTION
The research question in phase 1 was: Is there a difference in corticosteroid
receptor number and or affinity that is responsible for decreased
corticosteroid effectiveness in oral-steroid dependent subjects?
METHODS
Patients and subjects.
The study was approved by the Ethics committee of the Royal Brompton
Hospital, and written informed consent was obtained from all subjects.
Nineteen oral steroid-dependent (OSD) asthmatic subjects (poorly controlled
on inhaled and oral steroids) were carefully selected from a group of difficult
asthmatics attending the asthma clinic at the Royal Brompton. A correct
diagnosis of asthma had been ascertained and known factors contributing to
difficult asthma had been excluded in all subjects. Cessation of oral steroids
had been attempted without success and alternate immunosuppressive therapy
had also been tried in many of them in the past.
By way of comparison, ten asthmatic subjects whose symptoms were
controlled (designated steroid sensitive, SS) with ICSs, and 11 healthy, non-
asthmatic subjects (normal, N) were also studied. Their demographic
characteristics are depicted in Table 2. All subjects were matched in terms of
age and atopic status. No patients were current smokers. Asthmatic subjects
were defined as patients who had shown a 15% increase in FEV1 to 400 i_tg of
inhaled salbutamol administered through a metered-dose inhaler. All patients
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were taking inhaled salbutamol on an as-required basis. The mean daily doses
of salbutamol administered through a metered-dose inhaler were 0.4 + 0.1
mg/d and 1.3 ± 0.6 mg/d for the SS and steroid-dependent groups,
respectively.
The SS group had a mean baseline FEV1 of 2.31 ± 0.3 L (76% + 5% of
predicted value) and were on a mean inhaled fluticasone equivalents steroid
dose of 0.8 g/d [range, 0.2-1.2 g/d].
Steroid-dependent patients, however, had a baseline FEV1 of 1.39 ± 0. 2 L
(52% + 3%) of predicted value and were receiving high-dose ICS therapy
(1200 — 1800 pg of fluticasone or equivalent) together with a mean
maintenance dose of oral prednisolone of 20 (range, 15-30) mg per day for
the control of their asthma.(Table 2). This group had been attending the
asthma clinic at the Royal Brompton for many years, were well categorized
and had been on sustained oral prednisone. The diagnosis of asthma was
established and asthma mimics and other treatable factors for difficult asthma
had been excluded.
Eleven healthy volunteers were selected as control subjects. One would have
preferred age-matched subjects, however, donating 100 mls of blood for
research purposes could lead to reservations and I had to settle for willing
volunteers of as close an age as possible. There is no suggestion in the
literature that GR number or affinity is age related-the primary comparison.
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No. of subjects 19 10 11
Age (y), mean 46 (40 - 52) 48 (38 - 58) 32 (27 - 38)
Sex (M/F) 4/15 5/5 6/5
Baseline FEVI pre BD
(% predicted)
1.39 ± 0. 2 L
52 (± 3) §z,
2.31 10.3 L
76 (± 5) t
3.42 + 0.3L
91.6 (± 9)
FEAT ' response to
Salbutamol (%
predicted)
36 (24 - 48) * 18 (12 - 24)
Duration of asthma 29 (21-37) 36 (25 - 48)
Inhaled steroids (mg/d) 1.5 (1.2 - 1.8) 0.8 (0.2 - 1.2)
Years on systemic
steroids
6.8 (3.9 - 9.7)
Maintenance Prednisone
(mg/d)
20 (15 - 30)
Atopy (positive/negative)
16/3 8/2 2/9
Results are expressed as the mean with range or SD (±) in parenthesis
BD, Bronchodilator
*P <.05 and P <.01 compared with ICS group
t P <.05 and § P <.001 compared with healthy subjects
Ventolin dose of 4001.tg
Expressed as dose equivalent to fluticasone propionate
#Atopy is defined as positive skin prick test response to at least 3 common
allergens
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Falcon and washed with 50m1 HBSS (Hank's Balanced Salt Solution) in a
centrifuge at 1600 rpm, 4°C for 10 minutes. Most of the HBSS was discarded,
topped up with fresh HBSS and 2 further washes were performed. After the
final wash, the cells were resuspended in 3m1 RPMI 1640. (RPMI- Roswell
Park Memorial Institute medium-1640 is a standard medium for mononuclear
cell studies)
Ten ul of this monocyte fluid was added to 90u1 of a Kimura cell stain and
counted in a Neubauer counting chamber. Taking the dilution factor into
account, the total number of mononuclear cells can be calculated. This was
approximately 100-150 million cells per subject.
Ten ul of monocyte fluid was also mixed with Trypan Blue and loaded into
the Neubauer counting chamber; the cytoplasm of dead or damaged cells
turns blue. Cell viability was consistently greater than 97%.
Preparation of Tritiated Dexamethasone
CH] dexamethasone 86.0 Ci/mmol (Amersham, Buckingshamshire) came
preconstituted. The calculation of the required concentration was as follows:
86.0 Ci = lmmol (Ci = Curie)
1 Ci = 1/86 mmol
= 1/86 nmol and because 1111= luCi
250 ul = 250 x 1/86 nmol
= 2.907 nmol
l ml = 2.907 x 4 nmol
= 11.63 nmol and
1000m1 = 11.63 umol
= 11.63 x10 -6 M
= 1.163 x10 -5 M
Thus tritiated dexamethasone was a 1.163 x10 -5 M solution.
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Therefore to bring to a 10-6 M solution, a 10 fold dilution was needed and
therefore the dilution factor was 11.63. Next, to constitute a desired
concentration one divides by the dilution factor; therefore, for 100p1 stock
solution, 8.6 pl [3H] dexamethasone, + 91.4p1 RPMI yielded a 10 -6 M solution
(100/11.63 = 8.6).
Similarly 40p1 [3H] dex 10 -6 M solution + 360u1 RPMI yielded
400111 [3H] dex 10 -7 M = 100 nM and taking 200p1 of this + 200u1
RPMI yielded 400p1 [3H] dex 5x10-8 M = 50 nM and sequentially half
diluting resulted in: 2.5 x 10-8 M = 25 nM
1.25 x 10 -8 M = 12.5 nM
0.625 x 10 -8 M = 6.25nM
0.312 x 10 -8 M = 3.12 nM.
Finally, note that when an equal volume of cells was added, all the above
concentrations were halved. After I mastered this, I could vary the
concentrations by a third or quarter to derive different binding isotherms.
Principle of the dexamethasone binding assay.
Dexamethasone is preferred to cortisol in binding experiments because it
binds more tightly to GR, dissociates more slowly and it is less susceptible to
metabolic inactivation.
Receptor assays have the same kinetics as enzyme assays. The problem with
GR in the assay is that there is a large amount of low affinity non-specific (or
non-saturable) binding that is almost unlimited. This can be overcome by
using in the assay, a series of results that are due to the ligand competing with
itself i.e. non-radioactive labelled competing with radio-active labelled
ligand. The non- labelled agent is put in the system in more than a 100 fold
excess so that the labelling only occurs at the non-saturable sites.
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By subtracting the non-specific binding, the specific binding can be
determined. Also by utilising precise molar concentrations and radioactivity,




Fig 6: Graphical representation of the principle of radioligand binding studies
showing saturable and non-saturable binding isotherms.
DPM = disintegrations per minute.
73
Tritiated dexamethasone binding assay.
GR binding characteristics of PBMCs were performed immediately after
fractionation in an adaptation of the method of Crabtree 312 and exactly as
described by Kam and colleagues 222 . 1.5 x 106 cells in 25 fresh RPMI were
incubated with increasing concentrations of 25 [ 3 H ] dexamethasone 86.0
Ci/mmol (Amersham, Buckingshamshire ) from 0.312 to 100nM in
eppendorfs for 1 hour in a shaking water bath at 37°C. Non-specific binding
was measured by incubating 1.5 x 106 cells with 100nM and 33.3nM [3 H]
dexamethasone with 1000 fold excess unlabelled dexamethasone each. All
experiments were performed in duplicate. After incubation the tubes were
centrifuged and 20 of supernatant aspirated for measurement of free [3 H]
dexamethasone. The rest of the supernatant was discarded.
Nuclear Receptor Radioactivity Measurement:
Hypotonic lysis of cells in 1 set of eppendorfs was performed with 1.2 ml of
10mM Nat Mo 04 and 1.5mM MgC1 2 (designed to stabilize the corticosteroid-
nuclear complex) on ice for 30minutes. All tubes were then centrifuged for 5
minutes at 12000 rpm at 4C. The supernatant was discarded, the nuclear pellet
dried and the tip of the eppendorf cut and placed in ars vial in a spectrometer.
Cytoplasmic Receptor Radioactivity Measurement:
Hypotonic lysis of the other set of PBMC's were recovered by vigorous
mixing with 100 of 1.5 mM MgCl2 containing dextran coated charcoal
(this had been pre-prepared with 10m1 MgC12 plus 0.1g charcoal and 0.01g
dextran m.w. 60 000 to 90 000) and placed on ice for 30 minutes. Thereafter
all eppendorfs were centrifuged for 5 minutes at 12 000 rpm at 4C. 100 R1 of
supernatant was carefully aspirated without disturbing the charcoal pellet
(which can cause major contamination as this adsorbs the free steroid whilst
the cytoplasmic complexes remain in the supernatant) and placed in a 13 vial
with Bioflur for liquid scintillation counting. Specific binding for each
concentration was calculated after correcting for non- specific binding.
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Binding isotherms were analyzed with the PRISM curve-fitting program
(GraphPad Software, San Diego, Calif).
Trial of high dose prednisone.
A random selection of the cohort was chosen to assess the effect, if any, of a
short course of high dose prednisone, on lung function and glucocorticoid
receptors
Seven SS patients had a course of 40 mg of oral prednisone, and 9 steroid-
dependent patients supplemented their daily dose of oral prednisone to a total
of 40 mg/d — both for 7 days. FEVI was measured before and after this trial of
prednisolone, and blood was taken for GR binding experiments as well.
Data Analysis.
Data are expressed as means ± SEM of independent observations. The results
obtained before or after drug treatment were compared by means of ANOVA.
Median effective concentration calculations were performed with the
GraphPad Prism program.
RESULTS
GR ligand binding of PBMCs.
There was no significant difference in the cell profile of the PBMCs isolated
from any subject group.
Tables 3-5 show the distribution of affinity and total GR numbers per
mononuclear cell in the individual patient and normal subjects.
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Table 3: Glucocorticoid Receptor Number per cell and Affinity
Steroid Dependant Groupin the Oral
Name Nuclear Cytosolic TOTAL
Kd Receptors Kd Receptors
AC 76.68 8062 2.09 681 8743
MM 31.00 7030 3.30 824 7854
BB 55.23 9597 6.48 602 10199
AG 32.37 2401 4.70 710 3111
LH 67.92 3098 2.23 306 3404
RB 29.75 1502 3.97 473 1975
SL 30.20 4630 5.57 1132 5762
JR 20.29 2269 4.28 666 2935
TD 68.74 1935 5.42 393 2328
JM 36.78 1515 1.21 516 2031
GA 32.53 3623 4.02 832 4455
JS 62.97 7242 1.01 315 7557
AF 25.81 5242 5.00 362 5604
DH 16.52 4088 7.67 927 5015
TT 23.63 5089 6.25 543 5632
RR 47.98 6005 8.16 510 6676
JIB 48.34 6448 4.95 672 7120
KP 32.63 2702 7.18 778 3480
JW 46.72 4738 4.82 684 5422
MEAN 41.37 4590 4.65 628 5224
SD 17.83 2351 2.05 217 2375
Kd, Nuc & Cyt: p< 0.0001
Receptors, Nuc & Cyt: p<0.001
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Table 4: Glucocorticoid Receptor Number per cell and Affinity in the
Asthmatic GroupSteroid Sensitive
Patient Nuclear Cytosolic TOTAL
Kd(nM) Receptors Kd(nM) Receptors
LW 23.95 2039 4.56 344 2383
TT 22.84 1603 6.23 537 2140
JJ 27.54 2715 2.71 289 3004
AF 25.51 1885 5.26 181 2066
SM 22.16 1798 4.25 363 2161
SS 28.20 2672 4.27 458 3130
JGB 27.22 4250 9.40 759 5009
ST 21.13 4374 6.85 798 5172
UBS 27.20 3640 3.97 484 4124
WH 27.86 5020 2.86 682 5702
MEAN 25.36 3000 5.04 490 3489
SD 2.63 1233 2.01 206 1400
Kd, Nuc & Cyt: p< 0.001
Receptors, Nuc& Cyt: p<0.001
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Table 5: Glucocorticoid Receptor Number per cell and Affinity
Subjectsin Normal
Name Nuclear Cytosolic TOTAL
Kd(nM) Receptors Kd(nM) Receptors
EI 7.74 2248 3.22 1075 3323
OL 4.15 1743 4.25 450 2193
TH 11.62 2379 4.94 745 3124
TW 15.12 4382 2.00 469 4851
YN 13.80 4450 4.92 786 5236
HK 10.69 3390 2.56 464 3854
PP 6.77 4032 1.66 321 4353
HP 5.32 3537 4.28 510 4047
KJS 7.13 2080 2.85 279 2359
LD 9.65 4866 4.06 851 5717
RN 8.81 1965 1.53 293 2258
MEAN 9.40 3270 3.48 603 3873
SD 4.01 1033 1.30 246 983
Kd, Nuc & Cyt: p<0.01
Receptors, Nuc & Cyt: p<0.01
Glucocorticoid Receptor Numbers.
Fig 7a illustrates these parameters in comparative form. Although the OSD
group had a tendency to higher GR numbers, there was no statistically
significant difference in nuclear receptor numbers between subject groups
(steroid-dependent group, 5224 + 2375/cell; ICS group, 3489 ± 1400/cell;
healthy subjects, 3873 ± 983/cell;). The number of receptors was higher in the
nucleus than in the cytoplasm (up to 10 fold higher than and as seen by Spahn
as well 219).
There were no statistically significant differences between the groups for the
number of cytoplasmic receptors.
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Fig 7a: Total Glucocorticosteroid Receptor Numbers in the
Individual Patients in the Different Categories
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The individual ligand binding affinities of all the subjects is illustrated in
Tables 3-5 and compared in Fig 7b and 7c.
The ability of dexamethasone to bind to GR was decreased in the nucleus in
subjects with oral steroid-dependent asthma. Steroid-dependent subjects (Kd,
41.37 ± 17.83 nmol/L-NB: the higher the Kd, the lower the affinity) had a
greater Kd compared with those with ICS controlled asthma symptoms (Kd,
25.36 ± 2.63 nmol/L; P < .05) or healthy subjects (Kd, 9.40 ± 4.01 nmol/L; P
< .001). In addition, there was a significant difference in Kd between the ICS
group and the healthy group (P < .05);
GR affinity in the cytoplasm was high in all three groups and no statistically
significant differences were detected amongst any of the groups.
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Fiq 7c: Mean Ligand Binding Affinities in Cytosolic
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Fig 7c: GR binding parameters of PBMCs isolated from healthy subjects
and patients with asthma. Ligand-binding affinity (Kd) in cytosolic and
nuclear compartments was measured in 11 healthy subjects, 19 oral steroid—
dependent (OSD) asthmatic patients, and 10 asthmatic patients whose
symptoms were controlled with ICSs (SS).
In the nuclear compartment, Steroid-dependent subjects (Kd, 41.37 ± 17.83
nmol/L) had a greater Kd compared with those with ICS controlled asthma
symptoms (Kd, 25.36 ± 2.63 nmol/L;) or healthy subjects (Kd, 9.40 ± 4.01
nmol/L).
* p < 0.01 ** p < 0.001
Statistically, the differences in Kd between the nuclear & cytoplasmic
compartments ranged from p= 0.001 to 0.0001 between the groups.
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Response to Oral Prednisolone.
The response to an oral steroid burst in the asthmatics and changes in the
glucocorticosteroid receptor status is shown in Tables 6 a,b,c and 7a,b and Fig
8.
Table 6a: Glucorticoid receptor affinity and numbers in the nuclear and
cytoplasmic compartments before and after the prednisone burst






BB pre 55.23 9597 6.48 602 10199
post 45.37 4724 9.52 410 5134
JS pre 62.97 7242 1.01 315 7557
post 52.68 6289 5.79 707 6996
JR pre 20.29 2269 4.28 666 2935
post 16.36 1813 5.29 159 1972
LH pre 67.92 3098 2.23 306 3404
post 32.27 2968 1.15 196 3164
GA pre 32.53 3623 4.02 832 4455
post 25.30 2957 3.24 684 3641
MM pre 31.00 7030 3.3 1648 8678
post 46.84 3470 5.41 282 3752
DH pre 16.52 4088 7.67 927 5015
post 15.83 2290 4.56 674 2964
TD pre 68.74 1935 5.42 393 2328
post 49.23 1712 4.13 361 2073
JB pre 48.34 6448 4.95 672 7120
post 40.47 5865 3.33 458 5323
Although most subjects demonstrated a decrease in GR Kd and numbers, this
did not reach statistical significance.
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Table 6b: Glucorticoid receptor affinity and numbers in the nuclear and







SS pre 28.2 2672 4.27 458 3130
post 26.9 2412 3.5 477 2889
TT pre 23.00 1603 6.00 537 2140
post 19.61 1094 4.89 762 1856
LW pre 24.00 2039 5.00 344 2383
post 5.59 1480 1.10 648 2128
ST pre 27.10 4374 6.85 798 5172
post 23.97 3257 1.56 174 3431
JGB pre 27.20 4250 9.40 759 5009
post 15.14 3432 1.80 287 3719
UBS pre 27.20 3640 3.97 484 4124
post 27.6 3740 4.86 478 4218
WH pre 27.90 5020 2.86 682 5702
post 26.49 3482 4.42 323 3805
Again, although most subjects demonstrated a decrease in GR Kd and
numbers, this reached statistical significance in the steroid sensitive group for
receptor number only.
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Table 7: Lung Function, depicted as FEV1% predicted






BB pre 72.5 ST pre 71.3
post 81.5 post 74.2
JS pre 32.5 JGB pre 61.9
post 65.1 post 49.3
JR pre 35.7 JJ pre 65.4
post 45.5 post 60.2
LH pre 76.6 TT pre 72.5
post 101.3 post 60.4
GA pre 60.3 LW pre 75.1
post 62.1 post 90.3
MM pre 45.2 UBS pre 80.2
post 43.3 post 120.2
DH pre 57.1 SS pre 83.4
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Fig 8: The effect of prednisolone (40 mg/d for 7 days) on
percent predicted FEV1, GR affinity and receptor number in
9 oral-steroid-dependent and 7 SS subjects is shown. Data
are expressed as individual data points (*p < .05).
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Seven patients in the SS group had a baseline percent predicted FEV1 of 72 .8
± 7.6 %, and (although increased) this was not significantly changed by a
week of 40 mg of oral prednisolone (76.4 ± 23.7 % of predicted value). Nine
steroid-dependent patients had their oral prednisolone increased to 40 mg for
1 week. These patients demonstrated a mean improvement of 20% ± 0.4% in
FEV1 after a 1-week course of 40 mg of prednisolone (55.6 ± 15.5% of
predicted value improved to 67.8 ± 7.6 %; Fig 7A). Treatment of ICS and
steroid-dependent asthmatic subjects with prednisolone (40 mg/d) for 1 week
did not significantly affect the Kd of ligand binding or receptor number
(although most decreased, Fig 7 B, C). The altered ability of steroid-
dependent and steroid-sensitive asthmatic subjects to respond to steroids may
therefore relate to their reduced nuclear GR affinity for ligand. Because
prednisolone did not normalise this altered affinity, this further suggests that
reduced glucocorticoid responsiveness in steroid-dependent subjects is not
caused by prednisolone-induced downregulation of GR expression.
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CHAPTER 4: Characterisation of an in-vitro "Steroid
Resistance Model" in Mononuclear Cells 
Having established that oral steroid dependent asthmatics had an alteration in
GR affinity, we were keen to explore the functional consequences of this
altered affinity. However, we were aware that mononuclear cells incubated in
medium alone in vitro for 48 hours and longer exhibit a normalisation of GR
affinity. Thus it would be difficult to understand the ramifications of altered
affinity if this was normalising during incubation in vitro. The first step was
to confirm that GR affinity returned to normal in vitro.
4.1: Effect of incubating PBMC's with diminished GR affinity in medium
alone for 48 hours.
METHODS
Mononuclear cells were isolated as described previously. In preparation for
stage 2 of the study, cells were incubated in RPMI alone for 48 hours.
Thereafter cells were harvested and GR affinity and numbers were
determined as described in the preceding chapter and compared to results
immediately prior to incubation.
RESULTS
GR characteristics are depicted in Table 8 and 9 and Fig 9.
There were highly significant changes in Nuclear GR affinity in cells
incubated in medium with GR affinity consistently normalising (from 45.60 ±
14.75 to 11.43 ± 2.06). This was typically associated with a decrease in the
mean number of receptor sites (by approximately two thirds) as a reciprocal
relationship exists between affinity and receptor numbers.
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Fig 9: Normalisation of GR affinity (mean) in the
nuclear compartment after 48 hours incubation









Table 8: Glucocorticoid Receptor Number and Affinity in the Nuclear
in the oral steroid dependent asthmatic subjects
hours incubation in medium alone.
compartment in PBMC's
at baseline and after 48
Name Nuclear: baseline Nuclear: post 48 hr
incubation in medium
Kd (nM) Receptors Kd (nM) Receptors
MM1 31.00 7030 11.50 2374
BB1 55.23 9597 12.87 871
AG1 32.37 2401 10.97 1541
LH1 67.92 3098 10.52 1228
JW1 46.72 4738 7.15 677
KP 32.63 2702 13.23 910
TD1 68.74 1935 13.89 1191
MM2 46.84 3470 11.80 2784
BB2 45.37 4724 13.06 1322
AG2 29.13 2689 9.27 1347
MEAN 45.60 4238 11.43 1425




Cytoplasmic GR affinity (Table 9) also improved, however, receptor numbers
did not change significantly. In view of the major mechanism of action of
corticosteroids being exerted in the nucleus, I concentrated mainly on the
nuclear component of GR characteristics in further experiments.
Table 9: Glucocorticoid Receptor Number and Affinity in the
in PBMC's in the asthmatic subjects at









































4.2: Establishing an in-vitro "Steroid Resistance Model" with
mononuclear cells.
Having documented that PBMC's develop normal GR affinity after
incubation in vitro, we then attempted to decrease GR affinity by co-
incubating cells with IL-2 and IL-4 in combination (and later IL-13). These
were based on the experiments of Sher et al 216 after the prior detection of
exclusively increased mRNA for these cytokines in BAL lymphocytes from
steroid resistant asthmatics.
Methods:
Experiments with Cells Incubated with Cytokines
Cells were fractionated as described previously and then, at a concentration of
1 x 106/mL in RPMI with HEPES (20 mmol/L) supplemented with 10% FCS,
penicillin, streptomycin, and amphotericin B were cultured for 48 hours at
37°C in medium alone and in the presence of IL-2 (50 IU/mL; R&D Systems,
Abingdon, United Kingdom) with or without IL-4 (50 IU/mL, R&D Systems)
and IL-13 (50 IU/mL, R&D Systems) alone. Thereafter, cells were harvested
and washed in fresh RPMI after which binding experiments were performed
as described previously.
RESULTS
IL-2&IL-4 or IL-13 Alone Alter GR Ligand Binding In-vitro.
The results of these experiments are depicted in Table 10 and Fig 9.
Incubation of cells with I1-2,-4 in combination led to a significant increase in
GR Kd compared to that of cells in medium alone; 42.16 ± 7.0 vs 11.06 ±
2.05, p < 0.001. This was accompanied by a significant increase in the
number of receptors; usually doubling in magnitude.
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Table 10: Glucocorticoid Receptor Number and Affinity in the Nuclear
in the asthmatic subjects and normal subjects
in medium alone and with IL-2 and IL-4.
compartment in PBMC's
(N) after 48 hours incubation
Name Nuclear: medium Nuclear: post 48 hr
IL-2,-4 incubation
Kd (nM) Receptors Kd (nM) Receptors
MM1 11.50 2374 34.20 8442
BB1 12.87 871 50.24 4801
AG1 10.97 1541 35.01 1932
LH1 10.52 1228 38.38 2179
JW1 7.15 677 48.30 3293
KP 13.23 910 43.06 2877
TD1 13.89 1191 36.64 2835
MM2 11.80 2784 37.58 3137
BB2 13.06 1322 59.03 4480
AG2 9.27 1347 44.79 4318
Ni 8.04 2422 40.23 7216
N2 9.86 2276 41.43 6860
N3 11.64 2610 39.16 7257
MEAN 11.06 1658 42.16 4587
SD 2.05 731 7.00 2176
Kd: p<0.0001
Receptors: p=0.0001
Treatment of PBMC's from oral steroid dependent asthmatics with IL-2,-4
(who had a high Kd initially), would maintain their high Kd whilst PBMC's
from steroid sensitive asthmatics would also develop a higher Kd of
approximately 40 nmo1/1 (compare Tables 3 and 4 to Table 10).
To summarise - no matter the source of PBMC's (any asthma severity or
normal subjects- GR nuclear affinity would always decrease with co-
incubation of IL-2,-4 and normalize (increase) in medium alone.
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Fig 10: Establishment of the Steroid Resistance
Model: Nuclear GR Affinity is Reduced (High Kd) in




















Fig 10: Confirmation of in-vitro steroid resistance as originally
described by Sher et al 216 . Incubation of PBMC's in medium alone
increases GR affinity (Low Kd) but co-incubation with IL-2 and IL-4
decreases GR affinity (high Kd- values similar to the oral steroid
dependant group; p< 0.0001).
Fig 11: The Steroid Resistance Model - Increase in GR
Number in Cells Incubated with IL-2, -4 Compared to
Medium Alone
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Table 1 1 and Fig 12 illustrate an example of a patient with a poor affinity at
baseline (high Kd- pre-incubation) and following culture in media alone for
48 hours resulted in a reversion of the altered nuclear Kd back to levels seen
in healthy subjects. This effect was prevented by treatment of cells with IL-2
and IL-4 but not by treatment with either cytokine alone.
Table 11:  Example of High Kd in OSD subject (JW) at baseline and
normalisation in medium, IL-2 and IL-4 alone but preservation with this
cytokine combination.
Kd (nM)
BASELINE MEDIUM IL-2 alone IL-4 alone IL2,-4
46.7 7.15 9 8.4 48.3
Fig 12: Example of preservation of high Kd in
steroid dependant subject whose PBMC's were












BASELINE MED IL-2 IL-4 IL-2, -4
Fig 12: High GR Kd in PBMC's at baseline, ex vivo. After 48 hrs
incubation in medium, IL-2, IL-4 alone GR affinity normalised.
High Kd was maintained only with IL-2, -4 in combination.
I
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IL-13 (50 IU/mL) alone also reduced GR ligand-binding affinity at 48 hours
(12.39 ± 2.82 vs 38.91 ± 3.13 nmol/L, p < .05: Fig 13).
Tablel2: Effect on nuclear GR Kd and number in PBMC's

















MEAN 12.39 1154 38.91 4074
SD 2.82 213 3.13 230
Kd, med & IL-13: p=0,006
Receptors, p=0.006
Fig 13:  Confirmation that IL-13 alone also decreases GR affinity (high Kd)
95
4.3: Functional Consquences of Altered GR Affinity.
Having ensured that we could maintain a decreased GR binding capacity in
vitro, we could now determine if there were any functional intracellular
sequelae. We chose to examine the cytokine output following stimulation to
ascertain if mononuclear cells are involved in the perpetuation of a pro-
inflammatory state in asthma. In this regard, we chose interleukin 10 as the
anti-inflammatory cytokine and GM-CSF as the protagonist of inflammation.
We also co-incubated cells with dexamethasone to detect steroid resistance in
vitro: i.e.-was there a difference in the dexamethasone suppressive effects in
cytokine production with induction of altered GR affinity.
Methods:
GM-CSF and IL-10 Release: Experimental procedures.
PBMCs were fractionated as described previously.
Cells, (lx 106/mL) were incubated with medium alone or IL- 2 and IL-4 (50
IU/mL) for 48 hours in the presence of 1% FCS and thereafter stimulated
with LPS (10 ng/mL; Sigma, Poole, United Kingdom) or phorbol 12-
myristate 13-acetate (PMA)& Phytohemagglutinin (PHA) for 20 hours at
37°C. Plates were centrifuged, supernatants were collected, and GM-CSF and
IL-10 were measured with a sandwich ELISA. GM-CSF and IL-10
concentrations in the culture supernatant were measured by using a specific
ELISA calibrated with human recombinant GM-CSF (0-200 pg/mL, R&D
Systems) or IL-10 (0-200 International Units/mL, R&D Systems-see next
page).The concentration-dependent effects of steroids on cytokine release
were also studied by adding 10 -6M and 10 -7M dexamethasone to the non-
control plates for IL-10 measurement. (NB In simultaneous experiments the
alteration in GR affinity was confirmed in cells incubated with IL-2,-4 as
described in section 4:2).
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Enzyme-linked Immunosorbent Assay for IL-10 and GM-CSF.
These cytokines were assayed using a quantitive sandwich enzyme
immunoassay technique. A commercially available kit for IL-10 was used
(Quantikine: R & D systems, Abingdon, Oxon, UK). Monoclonal anti IL-10
was coated onto a microtitre plate, to which standards and samples were
added. An enzyme linked polyclonal antibody specific for IL-10 was added to
the wells to sandwich immobilized IL-10.
Addition of a stabilized chromogen and hydrogen peroxide led to a colour
development proportional to the quantity of IL-10. Samples were assayed by
measurement of optical density using a spectrophotometer set to 450 nm, the
lower limit of detection being 10 IU/ml.
The GM-CSF assay utilised round bottom plates that had been coated
overnight with rat anti-human GM-CSF monoclonal antibody (50 Ilg of 2 tig
/ml) at 4 ° C. After washing with phosphate buffered saline (PBS) / PBS / 10
% fetal call serum (200 tig; 2h). GM-CSF samples and standards were added
to the plate overnight at 4 ° C and washed with PBS/Tween. Thereafter a
biotinylated secondary anti GM-CSF antibody (100g1 of 2 jig /ml in PBS
/10% fetal calf serum) and 1:400 avidin peroxidose solution were sequentially
added. After washing GM-CSF was measured colourmetrically at 405nm and
quantified by interpolation from a standard curve. The lower limit of
detection was 16 pg/ ml.
RESULTS
Effect of IL-211L-4 on GM-CSF and IL-10 Release.
The results are tabulated in Tables 13-15.
The most striking effect was the reduction in IL-10 output in cells rendered
resistant in vitro; IL-10 production as measured in the supernatants was a
mean of only 40% in cells treated with IL-2,-4 compared to cells in medium
alone with presumed normal GR affinity; p=0.08 (Fig 14).
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Table 13: Absolute Interleukin-10 production (IU/ml) by mononuclear
cells at 60 hrs incubation in medium with and without IL-2,-4 following
LPS stimulation.
Patient Medium IL-2,-4 Percentage
production relative
to medium
A 624 289 46
B 468 95 20
C 233 137 59
D 168 43 26
E 183 106 58
F 100 15 15
G 64 11 17
H 110 90 81
Mean 262 99 40
SD 78 36 24
p=0.02
Fig 14: Comparison of IL-10 Production Following LPS Stimulation of PBMC's














Effect of Dexamethasone on IL-10 Release in cells co-incubated with IL-
2,-4 or medium alone.
The suppressive effects of dexamethasone were studied on the stimulated
IL-10 production and are presented in Table 14.
Table 14: Absolute Interleukin-10 production at 60 hrs incubation in medium
with and without IL-2,-4 following LPS stimulation and
the effect of varying concentrations of dexamethasone
Patient Incubation in Medium
Post-
stimulation +Dex 10-6M %inhib Dex 10-7M %inhib
A 624 no dose response measured
B 468 118 75 234 50
C 233 112 52 140 40
D 168 65 61 124 26
E 183 77 58 113 38
F 100 34 66 57 43
G 64 18 72 23 64
H 110 55 50 62 44
MEAN 262 62.00 44
SD 78 9.54 12
Patient Incubation with Interleukin - 2,-4
Post-
stimulation +Dex 10-6M %inhib Dex 10-7M %inhib
A 289 no dose response measured
B 95 49 48 57 40
C 137 93 32 98 28
D 43 28 35 34 20
E 106 67 27 84 21
F 15 below detection
G 11 below detection
H 90 82 9 87 3
MEAN 99 30.2 22.4
SD 36 14.17 13.46
p=0.001 p=0.015
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Fiq 15: Effect of Dexamethasone on LPS Induced
IL-10 Release by PBMC's Incubated in Medium
Alone or IL-2, -4
dex 10 -6M dex 10 -7M dex 10-6M dex 10-7M
Medium . IL-2,-4
Dexamethasone (10 -6M and 10-7M) inhibition of IL-10 production was
approximately double of the amount in medium compared to IL-2,-4 treated
cells where the inhibition was 10-20%; p= 0.001 & p=0.015 respectively, i.e.
steroid resistance to the effects of IL-2,-4 was demonstrated in vitro.
(Fig 15)
Fig 15: Results of experiments to demonstrate steroid resistance in vitro.
The inhibitory effect of dexamethasone 10 -6 M and 10 -7 M on IL-10 release
is minor compared to the dexamethasone effect on the cells incubated in
medium alone, * p<0.015.
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As regards GM-CSF, the absolute values following PMA, PHA co-
stimulation are shown in Table 15 and Fig 16. PMA & PHA were chosen to
give a stronger stimulus as LPS stimulation only gave low level production of
GM-CSF (data not shown).
Table 15: Absolute levels of GM-CSF (pg/ml) following stimulation with
for 48 hours in medium alone or withPMA&PHA after PBMC incubation
IL-2,-4
MED IL-2,-4
EXPERIMENT 1 152 250
EXPERIMENT 2 90 226
EXPERIMENT 3 110 212




Following PMA & PHA stimulation, there was an approximately 2 fold
increase in the amount of GM-CSF protein in the supernatant of combined IL-









Fig 16: Mean GM-CSF Production After PMA,PHA
Stimulation After GR Affinity had Normalised or
Decreased with Co-incubation with IL-2, -4
Fig 16: PBMC's were incubated in medium alone and IL-2, -4 for 48 hrs.
Thereafter they were stimulated with PMA, PHA and GM-CSF measured
by ELISA in the supernatant. Levels in the IL-2, -4 supernatants were
almost twice the amount in media alone, p< 0.01.
These data on cytokine release suggest that when there is altered affinity of
the glucocorticoid receptor, the output of higher GM-CSF and low IL-10
production might amplify inflammation.
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CHAPTER 5: Signal-transduction Mechanisms and
Functional Sequelae of Altered Affinity of the
Glucocorticosteroid Receptor in-vitro. 
Having established a "steroid-resistant model" we were then keen to explore
how IL-2,-4 mediated altered GR affinity. There was absolutely no literature
in this respect. We identified major signal transduction pathways that might
react with the steroid receptor and associated transcription factors that could
induce altered affinity. These were protein kinase C, Inositol 3-P kinase the
Mitogen Activated Protein Kinase system and interleukin-10 and theophylline
associated pathways. Specific inhibitors of the first three pathways existed
and we postulated that by their co-incubation in our model, we could define
possible interactions.
5.1: Experiments with Cells Incubated with Cytokines and Inhibitors of
Signal Transduction.
METHODS:
PBMC's were isolated as described previously.
Cells, at a concentration of 1 x 10 6/mL in RPMI with HEPES (20 mmol/L)
supplemented with 10% FCS, penicillin, streptomycin, and amphotericin B
were cultured for 48 hours at 37°C in medium alone and in the presence of
IL-2 (50 IU/mL; R&D Systems, Abingdon, United Kingdom) and IL-4 (50
IU/mL, R&D Systems) or IL-13 (50 IU/mL, R&D Systems). The effects of
the signal-transduction pathway inhibitors wortmannin (5 nmol/L),
PD098059 (10 !mon), Ro318220 (10 nmol/L), SB203580 (1,3,10 !mon —
the lower concentrations to exclude possible non-specific MAPK inhibition)
and theophylline; all from Calbiochem, Nottingham, United Kingdom, and
IL-10 (3 ng/mL, R&D systems) on IL-2— and IL-4-stimulated modulation of
GR binding characteristics were investigated by co-incubation with IL-2,-4.
(NB- Leung's original description of in vitro steroid resistance was with IL-
2,-4 and these were used in most experiments). Thereafter, cells were
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harvested and washed in fresh RPMI before binding experiments were
performed.
RESULTS:
The results of GR affinity and receptor numbers are shown in Table 16a, b &
17, and Figures 17 & 18.
Inhibition of the ERK MAPK pathway by PD098059 (10 mon) had no
effect on the altered receptor affinity induced by IL-2,-4 Inhibition of
phosphoinositol 3 hydroxy kinase by wortmannin (5 nmol/L) or treatment
with Ro318220 (10 nmol/L), a specific protein kinase C inhibitor and IL-10
(10 ng/mL) also failed to modulate the effect of IL-2 and IL- 4 on receptor
affinity, and theophylline similarly had no effect on affinity.
Receptor numbers were largely unchanged as well.
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Table 16 (a): Results of GR binding experiments of PBMC's incubated in medium
with and without IL-2,-4 and inhibitors of signal transduction:
Wortmannin, IL-10 and Theophylline
Kd (nM) Receptors
Wortmannin
med IL-2,-4 + IL-2,-4
Subjectl 7.15 48.30 43.09
Subject2 10.52 38.38 42.47
Subject3 9.27 44.79 38.12
MEAN 8.98 43.82 41.23
SD 1.70 5.03 2.71
Kd, med & IL-2,-4: p= 0.001
Kd, med & IL-2,-4+W: p= 0.002
Wortmannin






R, med & IL-2,-4: p=0.036
R, med & IL-2,-4+W: p=0.028
IL-10
med IL-2,-4 + IL-2,-4
Subjectl 11.50 43.48 38.79
Subject2 11.40 41.41 37.95
Subject3 10.72 42.19 39.90
MEAN 11.21 42.36 38.88
SD 0.42 1.05 0.98
Kd, med & IL-2, -4: p= 0.0000
Kd, med & IL-2, -4 +IL-10 :p= 0.0000
IL-10






R, med & IL-2,-4: p= 0.017
R, med& IL-2,-4+IL-10:p= 0.05
Theophylline
med IL-2,-4 + IL-2,-4
Subjectl 9.27 45.12 42.38
Subject2 10.82 41.81 44.26
Subject3 10.24 40.10 38.94
MEAN 10.11 42.34 41.86
SD 0.78 2.55 2.70
Kd, med & IL-2, -4: p= 0.0001
Kd, med & IL-2, -4 +T :p= 0.0001
R= Receptors W= Wortmannin T= Theophylline
Theophylline






R, med & IL-2,-4: p= 0.004
R, med & IL-2,-4+T:p= 0.003
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Table 16(b): Results of GR binding experiments of PBMC's incubated in medium




med IL-2,-4 + IL-2,-4 med IL-2,-4 + IL-2,-4
Subjectl 9.47 44.21 41.10 1360 3921 3511
Subject2 9.14 39.27 43.21 1428 4021 4416
Subject3 11.50 34.20 29.87 1255 2038 2014
MEAN 10.04 39.23 38.06 1348 3327 3314
SD 1.28 5.01 7.17 87 1113 1217
Kd, med & IL-2, -4: p= 0.005 R, med & IL-2,-4: p= 0.02
Kd, med & IL-2, -4 +PD: p= 0.005 R, med & IL-2,-4+PD: p= 0.02
Ro318220 Ro318220
med IL-2,-4 + IL-2,-4 med IL-2,-4 + IL-2,-4
Subjectl 10.72 42.19 37.61 2212 6453 2999
Subject2 14.10 37.58 42.24 1790 3137 2784
Subject3 16.15 34.83 39.12 2071 3761 4009
MEAN 13.66 38.20 39.66 2024 4450 3264
SD 2.74 3.72 2.36 215 1762 654
Kd, med & IL-2,-4: p = 0.003 R, med & IL-2,-4: NS
Kd, med & IL-2,-4 +Ro: p = 0.002 R, med & IL-2,-4+Ro: NS
R=Receptors
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Fig 17: Nuclear GR Affinity in Medium With and Without















Fig 17: Effect of 48 hours incubation of PBMC's with medium
alone, IL-2/IL-4 (both at 50 IU/mL combined), IL-2/IL-4 and
Wortmannin (5 nmol/L), IL-10 (3 ng/mL), Ro318220 (10 nmol/L),
PD098059 (10 p.mol/L) or theophylline on GR ligand-binding
affinity (Kd).
GR affinity normalizes in medium but increases significantly with
IL-2, -4 and remains unaltered with these inhibitors of signal
transduction.
There was no statistically significant difference in Kd between cells
incubated with IL-2,-4 and those cells co-incubated with these signal
transduction inhibitors
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p38 MAPK Regulates IL-2/IL-4 Alteration of GR Ligand-binding
Affinity.
In contradistinction, inhibition of the p38 MAPK pathway with SB203580
(10 !Amon) completely prevented the IL-2/IL-4—mediated reduced receptor
affinity in PBMC's; p<0.001 (Table 17, Fig 18a). These experiments were
repeated with SB203580 at 1 and 3 !Amon and similar effects were noted
thus excluding non-specific effects of the higher concentration.
IL-2 and IL-4 co-treatment also restored the reduced levels of receptors per
cell in PBMCs from steroid-dependent subjects seen after 48 hours'
incubation in medium alone (Fig 18b- this did not reach statistical
significance because of the high receptor numbers expressed by the patient in
experiment 1).
Table 17: Results of GR binding experiments of PBMC's incubated in
medium with and without IL-2,-4 and SB 203580
Kd nM) Receptors
med IL-2,-4 IL-2,-4+ med IL-2,-4 IL-2,-4+
SB203580 SB203580
Exptl 6.31 39.16 10.91 6399 11132 8402
Expt2 7.24 49.14 9.58 982 2209 906
Expt3 11.4 41.42 9.63 1598 6860 1265
Expt4 9.23 38.43 11.2 2048 4275 2205
Expt5 8.92 45.22 8.02 2786 4492 2296
Expt6 10.46 42.64 12.17 3275 5421 2996
MEAN 8.93 42.67 10.25 2848 5731 3012
SD 1.911 4.006 1.472 1923 3052 2746
Kd, IL-2,-4 & IL-2,-4 + SB203580: p<0.001
Kd, med & IL-2,-4 + SB203580: NS
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Fig 18a: Nuclear GR Affinity in PBMC's Exposed to Media, IL-
2, -4 With and Without SB203580
IL-2, -4 MEDIA IL-2, -4 + SB 203580
Fig 18a: Nuclear GR affinity (mean) of PBMC's, co-incubated with
IL-2, -4, is reduced but increases during incubation with medium or
IL-2 or IL-4 alone. Cells co-incubated with IL-2, -4 + SB 203580
increase GR affinity (low Kd); * p<0.001.
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Fig 18b: Effect on Glucocorticoid Nuclear Receptor Number
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Fig 18b: When affinity increases, receptor number decreases. Here cells
incubated in medium alone expressed decreased GR numbers. With
co-incubation with IL-2, -4 and poor affinity (high Kd; fig 18a) receptor
number increase. This effect on receptor number is also blocked by SB
203580.
A similar effect was also seen with SB203580 (111 mol/L) on IL-13—induced
changes in ligand-binding affinity (38.9 ± 1.8 vs 11.4 ± 1.58 nmol/L, p < 001,
Table 18 and Fig 19).
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Table18:  Effect on nuclear GR Kd and number in PBMC's incubated in medium
with and without Interleukin 13 and SB203580 for 48 hours
Medium IL-13 IL-13+SB203580
Kd Receptors Kd Receptors Kd Receptors
Subject l 9.47 1172 42.37 4271 11.21 1382
Subj ect2 12.61 1357 36.26 3821 9.93 989
Subj ect3 15.1 933 38.1 4131 13.07 1817
MEAN 12.39 1154 38.91 4074 11.40 1396
SD 212.57 212 3.13 230 1.58 414
For increase in Kd with IL-13 alone: p<0.0001
For increase in receptor expression with IL-13 alone: p<0.001.
Fig 19: Effect of PBMC's incubation in medium and IL-13 with








5                                     
MED IL-13 IL-13 + SB203580
Fig 19:  Confirmation that IL-13 alone also decreases GR affinity (high Kd) and
normalisation with SB 203580 co-incubation, * p<0.0001.
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5.2: Functional sequelae of restoration of GR affinity
Having identified a signal transduction inhibitor that normalised GR affinity,
we proceeded to investigate if functional sequelae could also be reversed by
SB 203580.
METHODs
Cells were isolated as described previously and the incubated in medium, IL-
2,-4 and IL-2,-4 with SB203580. After 48 hours cells were stimulated with
LPS and IL-10 measured by ELISA as described earlier.
RESULTS
IL-10 concentrations in the various experimental situations are depicted in
Table 19 and Fig 20.
Co-treatment of cells with IL-2,-4 +SB203580 restored higher IL-10
production i.e. when induction of GR resistance was blocked, IL-10
production was increased.
Table 19 : Absolute Interleukin-10 production at 60 firs incubation in medium
and SB203580 following LPS stimulationwith and without IL-2,-4








D 168 43 26 142 85
E 183 106 58 194 >100
F 100 15 15 84 84
G 64 11 17 72 >100
MEAN 29 92
SD 20 9
IL-10 production with SB relative to IL-2,-4 alone, p= NS.
Decreased IL-10 production with IL-2,-4 relative to med: p= 0.003.
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Fig 20: Absolute IL-10 Production Expressed as a Percentage of













Fig 20: Results of experiments with cells incubated in medium, IL-2, -4 with
and without SB 203580. Thereafter cells were stimulated with LPS. IL-10
production in medium (with normal GR affinity) was approximately 5 times
more than that of IL-2, -4 cells. This effect was restored with SB 203580,
*p= 0.003
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5.3: Demonstration of decreased activated p38 MAPK protein
To further corroborate the effect of SB203580 on cytokine mediated altered
GR affinity, we attempted to demonstrate that there was decreased
intracellular activated p38 MAPK protein when mononuclear cells were
incubated with IL-2,-4 & SB 203580. We chose the technique of western
blotting to test this hypothesis.
Western Blot for Activated P38 MAPK.
METHODS
Cells, at a concentration of lx 10 6 /ml in RPMI with HEPES (20 mM )
supplemented with 10% FCS , penicillin, streptomycin, and amphotericin B
were cultured for 48 hours in medium alone and IL-2, 50U/m1 and IL-4,
50U/ml with or without SB203580. Thereafter cells were harvested, washed
in fresh RPMI and lysed with 20mM Tris HCl ph7.4, 10mM EDTA
100mMNaC1 2%Tritora-100, PMSF 1mM, 1mM dithiothreitol (DTT) and
the protease inhibitors aprotinin lOug/m1 and leupeptin lOug/ml.
Protein concentration was measured by the Bradford assay and 2Oug aliquots
were used for Western Blotting. Proteins were added to an equal volume of
125 mm Tris-HC1, pH 6.8, 1% w/v SDS, 10% v/v glycerol, 0.1% w/v
bromphenol blue, 2% v/v 2-mercaptoethanol (2x SDS loading buffer) and
boiled for 5 min. Samples were separated by 10% SDS-PAGE (sodium
dodecyl sulfate-10% polyacrylamide gel electrophoresis), and the proteins
were blotted onto a hybond-ECL membrane (Amersham Pharmacia Biotech).
Membranes were blocked with 5% skimmed milk in Tris-buffered saline with
0.05% Tween 20, pH 7.6 overnight at 4°C and probed with Anti-ACTIVE
p38 antibody (Promega) used in 1: 2000 dilutions. After washing, membranes
were incubated with secondary antibody coupled to horseradish peroxidase
(Amersham and Pharmacia Biotech) for 1 h at room temperature. Antibody—
antigen complexes were then detected using ECL chemiluminescent detection
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system according to the manufacturer's instructions (Amersham and
Pharmacia Biotech). Polyvinyl chloride wrap was used to cover the blot
before exposing it to acetate transparency film (Kodak, Rochester, NY). The
blot was exposed for 60 s before being developed.
RESULTS
A photograph of the blot is presented below.
Fig 21: Western blot of activated p38 Mitogen Activated Protein Kinase
(MAPK). Proteins were extracted from cells incubated in medium alone and
IL-2, -4 with and without SB 203580. They were then subjected to Western blot
analysis.
Molecular weight markers are indicated on the left of the above blot. There is a
dense band of p38 MAPK activation with IL-2, -4 and the band density is
clearly decreased with SB 203580. Non-specific induction also occurred in
medium.
Thus at the final stage of the project, decreased activated p38 MAPK at the
protein level was demonstrated when cells were incubated with IL-2,-4 and
SB203580.
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CHAPTER 6: DISCUSSION 
We have focused on the glucocorticosteroid receptor in the pathogenesis of
treatment resistant/ difficult asthma and used a group of oral steroid
dependent asthmatics and in vitro studies to explore GR characteristics.
The Concept of Steroid Resistant Asthma.
The term steroid resistant asthma (SRA) is attributed to Schwartz and
Carmichael 177 ' 178 . Thereafter a number of investigators, who focused on
, Kay 184 ,SRA for several years, led by Corrigan 183 , 189 and Sher 216 ,
developed the concept further. However, the steroid receptor is crucial for a
host of homeostatic processes in the body and complete steroid resistance
would be incompatible with life. These subjects were in fact "partially
resistant." The first problem with their definition was that it was completely
arbitrary and this was perpetuated by subsequent investigators. The method of
demonstrating and quantifying the bronchodilator response was not
standardised. The doses of 132 agonist varied depending on whether a metered
dose inhaler or nebuliser was used and equally, steroids were given in
variable doses and by different routes (see box). Clearly patients could easily
fall into a category purely arbitrarily if they failed to achieve a pre-specified
bronchodilator response.
Corticosteroid
Schwartz 177 	40 mg cortisol 21- succinate
Carmichael 177 ' 178 	Prednisolone 20mg daily x 7 days only
Corrigan 183 	Prednisolone 20mg mgx 7 days then 40mg x 7 days
Alvarez 182 	Prednisone 45mg daily x 14 days
Lane 184 	Prednisolone 40mg daily x 14 days
Sher 216 	Prednisone 20mg twice daily x 7days
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From a clinical standpoint, the concept of SRA led to much confusion.
Occasionally, patients who did not even have asthma, but an asthma mimic,
would be labeled SRA. This led to much deliberation in the literature and
clear guidelines became available 180, 181. In the first instance, the diagnosis of
asthma must be firmly established. Secondly, the patient must be treated with
an appropriate dose of ICS commensurate with the degree of severity. Finally,
in the third instance, a host of remediable factors should be excluded before
the patient is labeled therapy resistant or a difficult asthmatic.
Many doctors are accustomed to the bronchodilator response of 132 agonists
and do not appreciate the bronchodilator response of ICS. In general, the
more severe the inflammation, the poorer the bronchodilator response to P2
agonist- exemplified most in acute severe asthma. However, in clinical
studies, improvement in airway caliber is measured by serial spirometry
before a P2 agonist is given. I reanalyzed the clinical data of Price 313 and
Ostrom 314 looking at lung function improvement with ICS alone. I arbitrarily
considered an improvement in FEV 1 of 50% as excellent. The results are







MAGNITUDE OF THE FEV i RESPONSE TO ICS
Fig 22. The magnitude of the FEV I response to ICS follows a Gaussian
distribution. This must be differentiated from the bronchodilator response to
/32 agonists which is dependent on the degree of inflammation and can
therefore be equally variable.
Not surprisingly, consistent with most biological variables, the curve
followed a Gaussian distribution 315 . Most had a good increase with ICS,
some excellent and some- a poor response. It is likely that Schwartz and
Carmichael and other investigators of SRA were looking at this left-end of
the spectrum of steroid responders; increased or differences in inflammatory
responses may be responsible for this phenomenon.
It is noteworthy that Malmstrom's analysis of the FEV1 response to the
leukotriene antagonist, Montelukast, 316 compared to beclomethasone in
asthma (although represented as bar graphs) also had a distribution very
similar to my calculations.
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The next issue is that asthma is likely to improve if a sufficient dose of
steroid, whether inhaled or oral is given. In many apparent therapy resistant
cases, both patient and doctor are concerned about corticosteroid side-effects
and the dose chosen is a compromise that both parties are happy with
(primarily from an adverse-effect point of view, although the overall cost of
asthma medication is also a consideration). Even in patients that are
apparently steroid sensitive, the dose may be sub-optimal if a reasonable (but
incomplete) therapeutic outcome; satisfactory symptom control and lung
function, is achieved. This was exemplified in my study population where
although not statistically significant, many subjects in both the oral-steroid
dependent and steroid sensitive groups had better lung function after a course
of prednisone for just 1 week (Fig 2).
This improvement in spirometric parameters was also described by Corrigan,
Lane and Leung in all their SRA cohorts as well.
When Schwartz described SRA, only inhaled beclomethasone- a relatively
weak steroid- was available. Since then, more potent and lung selective
steroids have become available, markedly increasing the number of patients
that can achieve good asthma control 180
The effect of using a more potent ICS was elegantly demonstrated by Nelson
et al 317 . They identified a group of 111 oral steroid dependent asthmatics. In
a placebo controlled manner, they then administered Fluticasone Propionate
at 2 doses; 1000ug and 2000ug/ day, via MDI. The percentage of subjects that
were able to discontinue oral steroids completely was 9%, 75% and 89% for
the placebo, 1000ug and 2000ug doses respectively. The mean corresponding
percentage improvement in FEV1 was 0.5%, 8% and 24% respectively with
improvement in the quality of life questionnaires in the ICS groups. Not
many physicians would use these doses of medication. This study illustrated
that there is persistent inflammation in oral steroid dependent asthmatics and
119
that when one uses an ICS with a greater affinity for the steroid receptor
(fluticasone propionate has approximately twice the relative receptor affinity
of beclomethasone monopropionate or budesonide), a better anti-
inflammatory effect is achieved. This is manifest by significant improvements
in asthma control and the ability to withdraw oral corticosteroids.
The practice of not controlling asthmatics completely is more widespread
than one would expect. In a recent summary of global surveys on asthma
control involving approximately 11 000 patients 318 , Rabe stated that only 5%
of patients sampled had well controlled asthma!
Thus SRA is a misnomer and provided patients with severe asthma are
properly assessed, investigated and treated, there will be very few patients
with true therapy resistant asthma.
What then was the reason for the host of laboratory abnormalities seen in
apparent SRA 
182-189?
 In large measure (one cannot exclude possible genetic
and other acquired abnormalities with certainty), these reflected persistent
inflammation-these were primarily the result of sub-optimal control of the
asthma pathological processes. The principal reason for this assertion is that
in vitro, these abnormalities were almost always reversible. As we've come to
understand pathogenic mechanisms in asthma better so has come the
realization that there is a process of inflammatory activation of resident lung
and circulating immune cells and when these cells are removed from the
body, away from excitatory stimuli that characterize asthma in vivo, they
return to a non-activated state.
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Reasons for Sub-optimal Response to Corticosteroids.
a. Glucocorticosteroid Receptor Number.
One of the reasons that has been proposed for a sub-optimal therapeutic
response in asthma is a decrease in the number of receptors. Although there
are intragenic sequences in the GR capable of down-regulation with ligand
217 183, 184, 186 .
, most studies with SRA have not verified this We also could not
demonstrate a decrease in receptor numbers as a cause of the poor response to
CS. On the contrary, receptor numbers were preserved to high in our OSD
group (although the inability to reach statistical significance might have been
due to a degree of down-regulation caused by oral CS therapy). Equally
compelling, is that due to the decreased affinity that we have confirmed, an
increase in receptor numbers would be anticipated! Therefore, more
important than the expectation of down regulation of binding sites because of
treatment, is knowledge of the affinity of the receptors: a poor affinity will
dictate that more receptors be expressed to compensate for the decreased
binding ability as a reciprocal relationship exists between receptor number
and affinity in pharmacology.
b. Alteration in GR affinity
An important factor that influences CS action is the capacity to bind to the
glucocorticoid receptor. This ability is measured by the affinity/ dissociation
constant-the Kd. We have demonstrated that nuclear GR affinity is altered in
asthmatics and to a greater extent in oral steroid-dependent asthmatics. Thus
the ability of dexamethasone to bind to GR was decreased according to the
degree of asthma severity. GR affinity is therefore tiered; mild asthmatics
have an approximate doubling of the Kd compared to normal, whilst severe
asthmatics have double to triple the Kd value of mild asthmatics. Previous
researchers of SRA did not make this observation because of smaller numbers
of patients (although the trends were there) and would often group all
asthmatics together.
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The mean Kd in OSD asthma is approximately the same numerical value of
the Kd of PBMC's rendered steroid resistant in vitro with co-incubation with
cytokines. This difference was detected only in the nuclear compartment and
not in the cytoplasm, possibly reflecting an effect of a nuclear protein
masking the GR ligand-binding site or in an altered conformation of the
activated GR.
The observation that the GR binding is only decreased in the nucleus reflects
recent insights into GR activity. GR translocation to the nucleus is a highly
complex process, not just DNA binding 
202.
 We are only just beginning to
understand this. The GR-ligand complex has to be actively transported
through the nuclear pore. It is possible that further chaperone molecules and
other compounds — a result of diverse signal transduction activation- link with
the GR to modulate this action. Within the nucleus there is a reassembly
before and after gene interaction before it is actively exported out back into













Fig 23.Contemporary View of Corticosteroid Action
Translocation to the nucleus is an active process of import through the
nuclear pore. A number of signal transduction proteins are likely to
modulate this process. After gene interaction the GR is reassembled
before export out of the nucleus.
This altered affinity of dexamethasone for GR may reflect either an intrinsic
defect in the GR within these patients or may relate to changes in the receptor
induced by the increased level of inflammation in subjects with more severe
asthma. The reversal of the reduced binding affinity by means of incubation
with healthy media suggests that the latter is a more likely possibility. Our
results confirm the differences in Kd between asthmatic and healthy subjects
at baseline originally described by Leung and coworkers 216,220,222 .
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The magnitude of the decreased GR affinity seen in our oral-steroid
dependent subjects was almost identical to that reported by Corrigan and Sher
as well 183, 216 . The normalisation of GR affinity when we incubated cells in
medium alone was the experience of these investigators as well.
GR affinity is dynamic and can change diurnally and over time and appears to
be proportional to the degree of inflammation. Thus when inflammatory
stimuli and pathological features of asthma increase at night 224, GR affinity
decreases, and may account for a decreased therapeutic response of CS at
night i.e. from decreased binding capacity to steroid receptors. This may be
one of the reasons for the characteristic nocturnal symptomatology of asthma.
This has also translated into clinical practice in that, when nocturnal
symptoms are particularly troublesome, an increased dose of CS is
administered in the evening with a better treatment outcome! It is likely that
these higher doses are able to overcome the decreased GR affinity with
improved GR mediated effects.
Another report that illustrates the dynamic nature of GR affinity was serial
studies of GR affinity in patients with allergic asthma. With the onset of the
allergy season, serial GR Kd measurements performed in these patients
demonstrated a sequential decline in affinity 223 . Intriguingly, symptoms only
appeared after the GR affinity had already declined. It is tempting to postulate
that endogenous anti-inflammatory mechanisms fail when this affinity alters
and inflammation escalates, precipitating symptoms.
To illustrate the importance of inflammation influencing GR affinity, the
following study is salutary. Nimmagadda et al studied 13 steroid dependent
asthmatics 226 . GR affinity was studied serially over 1 year whist the patients
received Fluticasone Propionate 1000- 2000 µg/day. The patients gradually
improved, oral steroid requirements dropped substantially and ECP levels
declined. GR Kd which was a mean of 42.5nM at the outset improved to
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19.5nM at 6 weeks and was maintained for the rest of the year. (Interestingly,
the initial Kd is about the same as my oral steroid group and the improved
value similar to my SS group). Thus to a certain extent GR affinity is auto-
regulated. As a more potent CS is used which can bind with greater avidity,
so inflammation is brought under control, and these decreased inflammatory
stimuli improve the affinity of GR!
In another report Spahn et al 219, studied a group of asthmatics with severe
symptoms, decreased FEV1 with marked diurnal variation requiring
prednisone therapy. Median FEV1 improved by 25% following treatment.
The GR binding affinity was a median of 29nM and decreased significantly
after the prednisone course. Serum ECP and sIL-2R (soluble IL-2 receptor
which is only up-regulated with immune activation) that were elevated before
treatment also decreased significantly following clinical improvement. These
observations again support abnormal GR binding during periods of
uncontrolled asthma during which there is heightened inflammation and that
this is reversible with high dose corticosteroid therapy.
Establishing the "Steroid Resistance Model"
One of the difficulties in studying GR characteristics of immune cells ex vivo
is that outside the body and presumably away from inciting/ inflammatory
stimuli the GR affinity rapidly normalizes (as seen consistently in over 200
binding experiments done by me).
It was therefore fortuitous that we were aware of the in vitro experiments of
Leung et al, who after initially demonstrating increased mRNA for IL-2,-4,
and -13 in BALF cells of SRA 
220.221 
used these cytokines to manipulate GR
affinity in vitro 222 . We confirmed that diminished GR affinity could be
induced in vitro by incubating PBMCs with IL-2/IL-4 in combination only or
IL-13 alone i.e. that we could render mononuclear cells "glucocorticoid
resistant".
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Since their first description was with IL-2,-4 we used this as a "Steroid
Resistance model", and could now examine mechanisms of resistance and the
functional consequences thereof.
Functional sequelae of steroid resistance in vitro
There is a paucity of data on the functional sequelae of this steroid resistance
model. Leung's group was able to show that IL-2,-4 resistant cells secreted
more IL-6 and expressed more GR P 222, 204 They also demonstrated that
PBMC's with diminished GR binding affinity were less sensitive to the
suppressive effects of CS on lymphocyte proliferation 222 . These cells were
co-incubated with a mitogen (PMA/ionomycin) and increasing concentrations
of methylprednisolone for a further 72 hrs. Thereafter cells were pulse
labelled with 3H- thymidine and counted. There was a greater proliferative
response in the control cells than GR resistant cells.
They also addressed the issue of the clinical relevance of a two to three fold
decrease in GR binding affinity. They argued that since physiological levels
of cortisol can regulate IgE dependent allergic inflammation, and since
diminished GR binding renders calls less susceptible to the inhibitory effect
of PMA/ionomycin proliferation, that it is possible that the magnitude of
decreased GR affinity seen could impair the ability of endogenous steroids to
suppress ongoing airway inflammation 222 . This same degree of decrease GR
affinity was seen in their subsequent experiments with concomitant
diminished GR mediated effects.
We were able to demonstrate that ccombined treatment of cells with IL-2 and
IL-4 (inducing altered GR affinity of the same magnitude as Leung et al)
resulted in increased expression of the proinflammatory cytokine GM-CSF
and reduced expression of the anti-inflammatory cytokine IL-10. In addition,
we showed that the ability of dexamethasone to inhibit LPS- or PMA/PHA-
stimulated IL-10 production in PBMCs pretreated with IL-2 and IL-4 was
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impaired i.e. steroid resistance in vitro. Utilizing this model as well, Larsson
observed that the inhibitory effect of budesonide on GM-CSF was also
attenuated 319
This suggests that the balance of cytokine production in a situation of
diminished GR affinity favours a pro-inflammatory state that may contribute
to asthma severity.
The Role of GM-CSF in Asthma
Asthma is characterized by up-regulation of GM-CSF. There is an increased
expression in bronchial epithelium and airway T lymphocytes and eosinophils
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Increased circulating levels of GM-CSF are seen in chronic and acute asthma
141, 140 .
It has a permissive effect on eosinophil function and amplifies inflammation
137, 304 A phenotypically high GM-CSF producing asthmatic sub-group was
noted to have more difficult asthma 303 . Our data on elevated GM-CSF as a
function of induced resistance is consistent with this body of literature. Again,
when GR affinity is decreased, this is accompanied by elevated GM-CSF
which exacerbates asthma control. By contrast, when clinical asthma
improves with corticosteroids or concomitant LABA therapy, this is
paralleled by decreased airway elaboration of GM-CSF 305 ' 311 .
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The Role of IL-10 in Asthma
Interleukin-10 is a major regulator of inflammation. The data on defective IL-
10 expression and production in asthma is remarkably consistent. Our finding
of diminished IL-10 production when mononuclear cells are rendered
resistant in vitro is concordant with
the significant reduction of IL-10 m RNA and protein expression in
alveolar macrophages of asthmatics compared to non-asthmatics 298
a similar in vitro study performed by Hawrylowicz et al where T
lymphocytes rendered resistant had diminished IL-10 production 320
Of the many beneficial molecular effect of corticosteroids in ameliorating
inflammation was the restoration of reduced IL-10 release from macrophages
from asthmatics following ICS therapy 295 with a concomitant reduction in
MIP-la, GM-CSF and IFN-y. In vitro, CS drive T cell differentiation towards
a phenotype with greater IL-10 and a less pro-inflammatory cytokine profile
321 .
The delicate balance of inflammatory control was illustrated in a study where
despite similar doses of corticosteroids, an unstable asthma group showed a
decrease in IL-10 producing T cells in peripheral blood compared to stable
subjects 322 .
It is interesting to note that one of the mechanisms whereby theophylline
might exert its beneficial effect is by increasing IL-10 secretion 323 .
Furthermore during specific immunotherapy, Th cells secrete more IL-10,
which may contribute to controlling allergic phenomena.
Although most of the data favour both inflammation and the association with
diminished GR affinity decreasing IL-10 production by immune cells, there
may be IL-10 genetic polymorphisms predisposing to uncontrolled asthma 101 '
102
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Thus in asthma the decrease in IL-10 may favour a pro-inflammatory state
rendering the patient difficult or therapy resistant.
Signal Transduction Pathways that are not Involved in Decreasing GR
Affinity.
Despite the fact that several intracellular signalling pathways related to second
messengers, phosphorylation compounds and transcription factors are
transduced through the ERK MAPK pathway, inhibition by PD098059 had no
effect on the altered receptor affinity induced by IL-2,-4. Similarly, blocking
phosphoinositol 3 hydroxy kinase by wortmannin or treatment with
Ro318220, a specific protein kinase C inhibitor, theophylline and IL-10 all
failed to modulate the effect of IL-2 and IL- 4 on receptor affinity.
Concerns have been raised about the single mediator/receptor antagonism/
enhancement strategy that has been the subject of intense research 324 . Studies
with novel agents such as monoclonal antibodies against IL-5 and
recombinant IL-12- both directed at eosinophils, have essentially failed 
325,
 326.
In the former, eosinophils disappeared from the circulation and the airways
with virtually no change in the asthma phenotype; physiological parameters
such as airway hyper responsiveness, the late asthmatic reaction, lung
function and symptoms remained static. Recombinant IL-12 was associated
with poor clinical outcomes for asthma and significant toxicity 326 .
Antagonising TNF-a is slightly more promising.
Howarth et al, studied the role of TNF alpha in corticosteroid dependent
asthma 327 . Bronchoalveolar lavage was performed in control subjects and
mild and severe asthmatics. The asthmatics were also subjected to
endobronchial biopsies. The severe asthmatics had increased levels of TNF
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alpha in BALF with accompanying increased TNF alpha gene expression and
immunoreactive cells in bronchial tissue. Amongst this severe group, 17
subjects were then given etanercept (Enbrel(R)), the soluble TNF alpha
receptor-IgGlFc fusion protein, for 3 months in an open-label study. Asthma
symptom scores, lung function and BHR all improved.
A definitive placebo-controlled study with etanercept 25mg twice weekly
over lOweeks was then performed 328 . In this study, patients with refractory
asthma had increased expression of membrane-bound TNF-alpha, TNF-alpha
receptor 1, and TNF-alpha-converting enzyme by peripheral-blood
monocytes. A lower level of expression of these markers was noted in mild
asthmatics which was identical to normal controls. A significant improvement
was noted in BHR, quality of life scores and post-bronchodilator (but not pre-
bronchodilator) FEV 1.
However, there were no significant differences between groups in single-flow
nitric oxide concentration, calculated alveolar nitric oxide concentration,
sputum total or differential cell counts, or sputum eosinophilic cationic
protein, interleukin-8, or cysteinyl leukotriene concentrations. These suggest
that TNF-a blockers have modest effects and not a broad range of anti-
inflammatory effects and cannot be used without corticosteroids.
Combined IL-2,-4 or IL-13 Induced Diminished Glucocorticoid Receptor
Affinity Normalises with the p38 MAPK Inhibitor, SB203580, In-vitro.
SB203580, the specific p38 MAPK inhibitor consistently ameliorated both
the diminished affinity and number of receptor sites induced by IL-2 and IL-4
or IL-13 alone in our experiments. Furthermore we were able to demonstrate
decreased activated p38 MAPK protein quantatively by Western Blot in cells
treated with IL-2,-4 and SB203580.
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IL-13 has similar effects to IL-4 and the evidence from cDNA cloning of the
IL-13 receptor suggests that the IL-4R a chain is shared by the IL-13R. We
were able to show that IL-13 could also induce altered GR affinity in vitro
and that this could be reversed with SB203580. As IL-4 is required in the
steroid resistance model, it is therefore conceivable that IL-13 could alter GR
affinity through the IL-4 Receptor through mechanisms that are not
elucidated presently.
SB203580 is a specific pyrinidyl imidazole inhibitor of both a and 13 isoforms
of p38 and p38-2 MAP kinases that prevent activation of its downstream
effector MAPK-activating protein kinase 2. This MAPK signalling cassette is
highly conserved in many species. P38MAPK responds primarily to stressful
and inflammatory stimuli e.g. tumour necrosis factor- alpha, IL-1 and
lipopolysaccharide. Potential cellular targets of MAPK include PLA2 and p90
s6 kinase.
Activation of the MAPK system results in pro-inflammatory cytokine and
chemokine production. These result in cellular recruitment and perpetuation
of the inflammatory process. By way of example, p38 MAPK regulates IL-5
synthesis and SB 203580 was able to inhibit eosinophil recruitment by human
T cells 329 .
Intracellular MAPK cascades modulate signalling and nuclear transcription
via e.g. NF-KB. These processes are known to interact with GR mediated
responses as well. P38MAPK has been shown to be essential for the
mitogenic response of IL-2 267 and its inhibition predictably normalised
affinity as IL-4 needs the co-operation of IL-2 to decrease GR affinity.
However, the precise mechanism whereby GR affinity normalises is not
known. GR is a phosphoprotein that contains consequences for numerous
kinases such as protein kinase A, casein kinasell, protein kinase C, cyclin
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dependent kinases, glycogen synthase kinase3 and MAPK 33° . MAPK are
involved in transcriptional and post -transcriptional regulation of pro-
inflammatory cytokine expression. By way of example, many of the mRNA's
coding for genes involved in inflammation are unstable and are stabilised by
p38MAPK signalling 331 . The latter generates proteins that bind to AU rich
sequences in the 3' untranslated region of inflammatory mediator genes
stabilising the mRNA. The consequence is that mRNA levels can be rapidly
adjusted and the amplitude of the inflammatory response can be magnified.
These effects are precisely opposite to those observed with glucocorticoids.
There are various domains in the GR through which subsequent interaction
may occur with MAPK. These activation pathways can interact with GR,
modifying each others actions and occurring at the level of the transcription
factors themselves 332 . Eevidence suggests that GR can inhibit the activity of
both ERK and JNK enzymes, thus limiting the inflammatory response 333-336 .
Rogatsky et al, have, in turn, shown reciprocal inhibition of rat GR reporter
gene activity by JNKs by means of a direct phosphorylation of serine 246
through the consensus nonpolar-X-Ser/Thr-Pro motif, whereas ERK can
inhibit GR action by means of an indirect effect, possibly through
phosphorylation of a cofactor 337 . Our data cannot determine whether this is a
direct or indirect effect of p38 MAPK or whether GR phosphorylation alters
ligand-binding affinity directly, but our data in Fig 18a &18b clearly show
that SB203580 can modify ligand binding parameters. Previous data have
shown that reversible serine-threonine phosphorylation of GR may influence
the binding of the hormone to the cytoplasmic GR complex, GR nuclear
translocation, GR binding to glucocorticoid response elements, and formation
of an activated transcriptional complex 338 .
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Our data suggest that IL-2/IL-4 may alter the functional activity of GR
through phosphorylation, by means of p38 MAPK within the nucleus. The
resultant effect is to change GR binding characteristics and probably also its
ability to interact with components of the transcription apparatus. This may
result from either a change in GR conformation caused by association of
distinct cofactors or partial blocking of the ligand-binding domain caused by
association of the GR with nuclear transcriptional modulating proteins.
Similar results have been seen after nitric oxide treatment of GR, whereby
nitrosylation of GR at an hsp90 interaction site modified ligand binding 339 .
The GR phosphorylation sites and the sequences immediately surrounding it
are highly conserved, suggesting functional conservation for transcriptional
antagonism between the GR and p38 MAPK. Leucine-rich sequences may be
involved in nuclear export 
340,
 or this region may form a surface that interacts
with factors involved in transcriptional regulation 341 . Interactions between the
rat GR and the transcriptional complex involve several domains within the N-
terminal region of GR, including a leucine-rich domain surrounding the p38
MAPK site 341 , may alter or disrupt the protein-protein interactions regulating
GR action.
It is possible that p38 MAPK induces GR phosphorylation thus providing a
novel mechanism for downregulation of GR activity in T cells in response to
proinflammatory stimuli, leading to relative glucocorticoid resistance or oral-
steroid dependence Enhanced activation of this pathway as a result of
stimulation by inflammatory mediators, such as IL-2 and IL-4, which are
elevated at the site of inflammation in corticosteroid-resistant asthma, may
modify GR directly, leading to recruitment of distinct GR-associated proteins
and resulting in reduced glucocorticoid function.
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Another possibility is altered receptor affinity due to chaperone proteins
during the nuclear importation of GR. An end substrate of p38 MAPK
activation is a different heat shock protein: HSP27 342 . This might complex
with the GR-CS complex after activation.
Targeted treatment with low doses of p38 MAPK inhibitors may reverse
glucocorticoid resistance and improve the anti-inflammatory effects of
glucocorticoids in these glucocorticoid-dependent or partially glucocorticoid
resistant patients with asthma, who are usually unresponsive to other currently
available therapies. Both agents have a broad range of anti-inflammatory
effects that are likely to be synergistic in attenuating inflammation. Caution




Steroid Resistant Asthma —SRA-is a misnomer. The glucocorticoid receptor is
essential for life and true steroid resistance would be fatal. The inflammatory
nature of asthma is extremely complex and thus far the single mediator
amelioration has met with little success; glucocorticoids will remain the
mainstay of treatment for many years to come. There is however, a spectrum
of responses to ICS with therapy resistant asthma at one end of the spectrum.
These patients have often been erroneously labelled as steroid resistant/ oral
steroid dependent; most of them will respond to higher doses of high affinity
ICS such as fluticasone propionate or ciclesonide 317, 343 . It is also possible
that other mechanisms are driving the inflammation and some patients may
well respond to anti-TNF agents or anti IgE therapy 344, by-passing the steroid
un-responsive pathways.
The vast majority of apparently steroid resistant subjects described previously
and our experience has revealed that there is persistent inflammation that can
be detected in the airways and by activation markers of inflammatory cells in
the peripheral blood. Genetic factors may play a part; polymorphisms of
mediators or receptor isoforms that cannot transduce an anti-inflammatory
signal effectively or are antagonised. Examples include the DPP 10 gene
linked to difficult asthma 170 and the high GM-CSF expressors in children 303 .
However, most patients have an altered GR affinity that is acquired due to
inflammation; in vitro GR affinity normalises away from the inciting stimuli
of the disease. It is likely that there is a spectrum of altered GR affinity as
well; with mild asthma exhibiting a slight alteration in GR binding- that is still
capable of effecting most corticosteroid action whilst severe asthma is
accompanied by poor GR binding and consequent limited control of
inflammation.
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Thus GR affinity is an index of asthma control as well. The greater the
inflammation, the poorer the affinity and as inflammation resolves GR affinity
improves 219,226
GR affinity is dynamic- it changes diurnally and over time, dependent on
exogenous aeroallergens 
224, 223
and the degree of inflammation. The data on
GR binding capacity, including ours, suggest that with increasing
inflammatory stimuli, GR affinity decreases, and endogenous and therapeutic
doses of corticosteroids become inadequate to control inflammation. This
explains the clinical observation of increased symptoms and the need for
supplementing ICS.
Inflammation should not be seen as one dimensional; that it is present or not.
Rather there are grades-exemplified by GR-13. GR-(3 expression is a function
of inflammation. Normal subjects have low grade production, it is increased
in mild asthma, even more is produced in severe asthma and the highest levels
occur in fatal asthma 210, 206, 205. Being unable to bind CS, the resultant anti-
inflammatory effect is increasingly inadequate with greater GR-f3 expression-
worse still; it inhibits the functional GR-a.
Perhaps inflammation is different in different categories of asthma; there may
be negligible TNF-a activation in mild asthma but this is a feature of severe
asthma 327 ' 328 .
Apart from GR and its variants and diverse types of cytokine and other
mediators there may also be a discrete cell predominance in distinct types of
asthma e.g. neutrophil dominant asthma 31-33 .
Whatever the reason, genetic or non-genetic inflammatory activation,
inflammation dictates GR affinity and this very affinity dictates GR function
and the ability to bring inflammation under control.
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We have used a steroid resistance model to demonstrate that p38 MAPK is
one pathway for altered GR affinity due to IL-2,-4. The magnitude of that
alteration is the same as the GR Kd in oral steroid dependent subjects. When
cells are rendered resistant in vitro, the output of inflammatory cytokines
favours a pro-inflammatory state: high GM-CSF and low IL-10 production-
by extrapolation, we believe that this is what happens in refractory asthma as
well. p38 MAPK inhibitors have the potential to improve GR affinity and
enhance corticosteroid activity in difficult asthma.
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Epilogue
The Royal Brompton has a proud tradition of respiratory research excellence.
When one looks at the unimpressive façade, it's hard to comprehend;
however, its people that make up an institution.
I was trained by fellow scientists. The research fellows I trained in turn in the
steroid resistance model went on to demonstrate that p38 MAPK indeed
phosphorylates GR. This and the principal findings of my work were
published in The Journal of Allergy and Clinical Immunology 345 prompting
an editorial by Chrousos- one of the foremost researchers into the molecular
activity of the glucocorticoid receptor 2°2.
There are over eight p38 MAPK inhibitors in development currently for a
variety of inflammatory disorders including obstructive airways disease 346 .
My research was awarded a prize by the Allergy and Clinical Immunology
Assembly of the European Respiratory Society at their annual ERS
Conference for innovative research in asthma.
138
REFERENCES.
1. Elias JA, Lee CG, Zheng T, Ma B, Homer RJ, Zhu Z. New insights into
the pathogenesis of asthma. J Clin Invest 2003; 111: 291-297.
2. Lange P, Parner J, Vestbo J. A 15-year follow-up study of ventilatory
function in adults with asthma. N Engl J Med 1998; 339: 1194-1200.
3. Dijkstra A, Vonk JM, Jongepier H, Koppelman GH, Schouten JP, ten
Hacken NHT, Timens W, Postma DS. Lung function decline in asthma:
association with inhaled corticosteroids, smoking and sex. Thorax 2006;
61: 105-110.
4. Barnes PJ, Adcock IA. How do corticosteroids work in asthma? Ann
Intern Med 2003; 139: 359-370
5. Lilly CM. Diversity of asthma: Evolving concepts of pathophysiology
and lessons from genetics. J Allergy Clin Immunol 2005; 1115: S526-
S531.
6. Burrows B, Martinez FD, Halonen M, Barbee RA, Cline MG.
Association of asthma with serum IgE levels and skin-test reactivity to
allergens. N Engl J Med 1989; 320: 271-277.
7. Sears MR, Burrows B, Flannery EM, Herbison GP, Hewitt CJ,
Holdaway MD. Relationship between airway responsiveness and serum
Ig E in children with asthma and in apparently normal children. N Engl
J Med 1991; 325: 1067- 1071.
8. Busse WW, Lemanske RF. Asthma. N Engl J Med 2001; 344: 350- 362.
9. Bousquet J, Jeffery P, Busse WW, Johnson M, Vignola AM. Asthma:
from bronchoconstriction to airway inflammation and remodeling. Am J
Respir Crit Care Med 2000; 161: 1720-1745.
10. Rothenberg ME. Eosinophilia. N Engl J Med 1998; 338: 1592- 1600.
11. Kirby JG, Hargreave RE, Gleich GJ, O'Byrne PM. Bronchoalveolar cell
profiles of asthmatic and non asthmatic subjects. Am Rev Respir Dis
1987; 136: 379-383.
12. Corrigan CJ, Hartnell A, Kay AB. T lymphocyte activation in acute
severe asthma Lancet 1988; 1: 1129-1132.
139
13. Wilson JW, Djukanovic R, Howart PH, Holgate ST. Lymphocyte
activation in bronchoalveolar lavage and peripheral blood in atopic
asthma. Am Rev Respir Dis 1992; 45: 958-960.
14. Rothenberg ME, Owen WF, Silberstein DS, Woods J, Soberman RJ,
Austen KF, Stevens RL. Human eosinophils have prolonged survival,
enhanced functional properties, and become hypodense when exposed
to human interleukin 3. J Clin Invest 1988; 81: 1986- 1992.
15. Lopez AF, Williamson DJ, Gamble R. Recombinant human interleukin
5 is a selective activator of human eosinophil function. J Clin Invest
1986; 78: 1220-1228.
16. Robinson DS, Hamid Q, Ying S, Tsicopoulos A, Barkans J, Bentley
AM, Corrigan C, Durham SR, Kay AB. Predominant TH2-like
bronchoalveolar T-lymphocyte population in atopic asthma. N Engl J
Med 1992; 326: 298-304.
17. Kelly EA, Rodriguez RR, Busse WW, Jarjour NN. The effect of
segmental bronchoprovocation with allergen on airway lymphocyte
function. Am J Respir Crit Care Med 1997; 156: 1421- 1428.
18. Robinson DS, Hamid Q, Bentley A, Ying S, Kay B, Durham SR.
Activation of CD4 + T cells, increased Th2-type cytokine mRNA
expression, and eosinophil recruitment in bronchoalveolar lavage after
allergen inhalation challenge in patients with atopic asthma. J Allergy
Clin. Immunol 1993; 92: 313- 924
19. Bousquet J, Chanez P, Lacoste JY, Barneon G, Ghavanian N, Enander
I, Venge P, Ahlstedt S, Simone-Lafonteine J, Godard P. Eosinophilic
inflammation in asthma. N Engl Med 1990 ; 323 : 1033- 1039.
20. Flavahan NA, Slifman NR, Gleich GJ, Vanouette PM. Human
eosinophil major basic protein causes hyperreactivity of respiratory
smooth muscle: role of the epithelium. Am Rev Respir Dis 1988; 136:
685-688.
21. Leckie MJ, ten Brinke A, Khan J, Diamant Z, O'Connor BJ, Walls CM,
Mathur AK, Cowley KC, Chung KF, Djukanovic R, Hansel TT,
Holgate ST, Sterk PJ, Barnes PJ. Effects of an interleukin-5 blocking
monoclonal antibody on eosinophils, airway hyper-responsiveness, and
the late asthmatic response. Lancet 2000; 356: 2144-2148.
140
22. Gosset P, Tillie-Leblond I, Oudin S, Parmentier 0, Wallaert B, Joseph
M, Tonel AB. Production of chemokines and proinflammatory and anti-
inflammatory cytokines by human alveolar macrophages activated by Ig
E receptors. J Aller Clin Immunol 1999; 103: 289-297.
23. Mautino G, Oliver N, Chanez P, Bousquet J, Capony F. Increased
release of matrix metalloproteinase-9 in bronchoalveolar lavage fluid
and by alveolar macrophages of asthmatics. Am J Respir Cell Mol Biol
1997; 17: 583- 591.
24. Balbo P, Silvestri M, Rossi GA, Crimi E, Burastero SE. Differential
role of CD 80 and CD86 on alveolar macrophages in the presentation of
allergen to T lymphocytes in asthma. Clin Exp Allergy 2001; 31: 625-
636.
25. Lambrecht BN, Salomon B, Klatzmann D, Pauwels RA. Dendritic cells
are required for the development of chronic eosinophilic airway
inflammation in response to inhaled antigen in sensitized mice. J
Immunol 1998; 160: 4090-4097.
26. Nocker RE, Out TA, Weller FR, Mul EP, Jansen HM, van der Zee JS.
Influx of neutrophils into the airway lumen at 4h after segmental
allergen challenge in asthma. Int Arch Allergy Immunol 1999; 119: 45-
53.
27. Teran LM, Carroll MP, Frew AJ, Redington AE, Davies DE, Lindley I,
Howarth PH, Church MK, Holgate ST. Leukocyte recruitment after
local endobronchial allergen challenge in asthma. Relationship to
procedure and to airway interleukin -8 release. Am J Respir Crit Care
Med 1996; 154: 469- 476.
28. Woodruff PG, Fahy JV. A role for neutrophils in asthma? Am J Med
2002; 112: 498-500.
29. Kraft M, Cassell GH, Henson JE, Watson H, Williamson J, Marmion
BP, Gaydos CA, Martin RJ. Detection of Mycoplasma pneumoniae in
the airways of adults with chronic asthma. Am J Respir Crit Care Med
1998; 158: 998- 1001.
30. Sur S, Crotty TB, Kephart GM, Hyma BA, Colby TV, Reed CE, Hunt
LW, Gleich GJ. Sudden-onset fatal asthma: a distinct entity with few
eosinophils and relatively more neutrophils in the airway submucosa?
Am R Resp Dis 1993; 148: 713-719.
141
31. Wenzel SE, Szefler SJ, Leung DYM, Sloan SS, Rex MD, Martin RJ.
Bronchoscopic evaluation of severe asthma: Persistent inflammation
associated with high dose glucocorticoids. Am J Respir Crit Care Med
1997; 156: 737-743.
32. Tonnel AB, Gosset P, Tillie-Leblond I. Characteristics of the
Inflammatory Response in Bronchial Lavage Fluids from Patients with
Status asthmaticus. Int Arch Allergy Immunol 2001; 124: 267-271.
33. Carroll NG, Mutavdzic S, James AL. Increased mast cells and
neutrophils in submucosal mucous glands and mucus plugging in
patients with asthma. Thorax 2002; 57: 677 — 682.
34. March CJ, Mosley B, Larsen A, Cerretti DP, Braedt G, Price V, Gillis
S, Henney CS, Kronheim SR, Grabstein K. Cloning, sequence and
expression of two distinct interleukin-1 complementary DNAs. Nature
1985; 315: 641-7.
35. Kern JA, Lamb RJ, Reed JC, Daniele RP, Nowell PC. Dexamethasone
inhibition of interleukin 1 beta production by human monocytes:
posttranscriptional mechanisms. J Clin Invest 1988; 81: 237-44.
36. McKean DJ, Podzorski RP, Bell MP, Nilson AE, Huntoon CJ, Slack J,
Dower SK, Sims J.Murine T helper cell-2 lymphocytes express type I
and type II IL-1 receptors, but only the type I receptor mediates
costimulatory activity. J Immunol 1993; 151: 3500-3510.
37. Colotta F, Dower SK, Sims JE, Mantovani A. The type II 'decoy'
receptor: a novel regulatory pathway for interleukin 1. Immunol Today
1994; 15: 562-566.
38. Cao Z, Xiong J, Takeuchi M, Kurama T, Goeddel DV .TRAF6 is a
signal transducer for interleukin-1. Nature 1996; 383: 443-446.
39. Yamamoto KK, Gonzalez GA, Biggs WH 3rd, Montminy MR.
Phosphorylation-induced binding and transcriptional efficacy of nuclear
factor CREB. Nature 1988; 334: 494-498.
40. Kaur P, Saklatvala J. Interleukin 1 and tumour necrosis factor increase
phosporylation of fibroblast proteins. FEBS Lett 1988; 241: 6-10.
142
41. Lipsky PE, Thompson PA, Rosenwasser LJ, Dinarello CA. The role of
interleukin 1 in human B cell activation: inhibition of B cell
proliferation and the generation of immunoglobulin-secreting cells by
an antibody against human leukocytic pyrogen. J Immunol 1983; 130:
2708-2714.
42. Godding V, Stark JM, Sedgwick JB, Busse WW. Adhesion of activated
eosinophils to respiratory epithelial cells is enhanced by tumor necrosis
factor-alpha and interleukin-1 beta. Am J Resp Cell Mol Biol 1995; 13:
555- 562.
43. Sousa AR, Lane SJ, Nakhosteen JA, Lee TH, Poston RN. Expression of
interleukin —1 beta (IL- 1 beta) and interleukin —1 receptor antagonist
(IL-1 ra) on asthmatic bronchial epithelium. Am J Respir Crit Care Med
1996; 154: 1061-1066.
44. Sousa AR, Trigg CJ, Lane SJ, Hawksworth R, Nakhosteen JA, Poston
RN, Lee TH. Effect if inhaled glucocorticoids on IL-1 beta and IL-1
receptor antagonist (IL-1 ra) expression in asthmatic bronchial
epithelium. Thorax 1997; 52: 407-410.
45. Morgan DA, Ruscetti FW, Gallo R. Selective in vitro growth of T
lymphocytes from normal human bone marrow. Science 1976; 193:
1007-1008.
46. Levi Schaffer F, Barkans J, Newman TM, Ying S, Wakelin M,
Hohenstein R, Barak V, Lacy P, Kay AB, Moqbel R. Identification of
interleukin -2 in human peripheral blood eosinophils. Immunology
1996; 87: 155-161.
47. Aoki Y, Qiu D, Uyei A, Kao PN. Human airway epithelial cell express
interleukin -2 in vitro. Am J Physiol 1997; 272: L276-L286.
48. Taniguchi T, Minami Y. The IL-2/IL-2 receptor system: a current
overview. Cell 1993; 73: 5-8.
49. Hatakeyama M, Mori H, Doi T, Taniguchi T. A restricted cytoplasmic
region of IL-2 receptor beta chain is essential for growth signal
transduction but not for ligand binding and internalization. Cell 1989;
59: 837-845.
50. Nakamura Y, Ozaki T, Kamei T, Kawaji K, Banno K, Miki S, Fujisawa
K, Yasuoka S, Ogura T. Increased granulocyte/macrophage colony-
stimulating factor production by mononuclear cells from peripheral
blood of patients with bronchial asthma. Am Rev Respir Dis 1993; 147:
87-91.
143
51. Renzi PM, Sapeinza S, Waserman S, Du T, Olivenstein R, Wang NS,
Martin JG. Effect of interleukin-2 on the airway response to antigen in
the rat. Am Rev Respir Dis 1992; 146: 163-169.
52. Elwood W, Lotvall JO, Barnes PJ, Chung KF. Effect of dexamethasone
and cyclosporine A on allergen-induced airway hyper responsiveness
and inflammatory cell response in sensitized Brown —Norway rats. Am
Rev Respir Dis 1992; 145: 1289-1294.
53. Alexander AG, Barnes NC, Kay AB. Cyclosporin A in corticosteroid-
dependent chronic severe asthma. Lancet 1992; 339: 324-327.
54. Fung MC, Hapel AJ, Ymer S, Cohen DR, Johnson RM, Campbell HD,
Young IG. Molecular cloning of cDNA for murine interleukin-3. Nature
1984; 307: 233-237.
55. Arai KI, Lee F, Miyajima A. Cytokines; co-ordinators of immune and
inflammatory responses. Annu Rev Biochem 1990; 59: 783-836.
56. Hayashida K, Kitamura T, Gorman DM, Arai K, Yokota T, Miyajima
A. Molecular cloning of a second subunit of the receptor for human
granulocyte-macrophage colony-stimulating factor (GM-CSF):
reconstitution of a high —affinity GM-CSF receptor. Proc Natl Acad Sci
USA 1990; 87: 9655-9659.
57. Sornsen P, Mui AL, Krystal G. Interleukin-3 stimulates the tyrosine
phosphorylation of the 140-kilodalto interleukin-3 receptor. J Biol
Chem 1989; 264: 19253-19258.
58. Isfort R, Huhn RD, Frackelton AR, Ihle IN. Stimulation factor —
dependent myeloid cell lines with interleukin induces tyrosine
phosphorylation of several cellular substrates. J Biol Chem 1988; 263:
19203-19209.
59. Sun Q, Woodcock JM, Rapoport A, Stomski FC, Korpelainen EI,
Bagley CJ, Goodall GJ, Smith WB, Gamble JR, Vadas MA, Lopez AF.
Monoclonal anti body 7G3 recognizes the N-terminal domain of the
human interleukin-3 (IL-3) receptor alpha- chain and functions a
specific IL-3 receptor antagonist. Blood 1996; 87: 83-92.
60. Robinson DS, Hamid Q, Bentley AM, Durham SR, Kay AB. Activation
of CD4+ T cells and increased IL-4, IL-5 and GM-CSF mRNA positive
cells in bronchoalveolar lavage fluid ( BAL) 24 hours after allergen
inhalation challenge of atopic asthmatic patients. J Allergy Clin
Immunol 1993; 92: 313-324.
144
61. Blotta ME, Marshall ID, DeKruyff RH, Umetsu DT. Cross-linking of
the CD40 ligand on human CD4+ lymphocytes generates a co
stimulatory signal that up-regulates IL-4 synthesis. J Immunol 1996;
156: 133-140.
62. Blotta MH, DeKruyff RH, Umetsu DT. Corticosteroids inhibit IL-12
production in human monocytes and enhance their capacity to induce
IL-4 synthesis in CD4+ lymphocytes. J Immunol 1997; 158: 5589-5595.
63. Idzerda RL, March CJ, Mosley B, Lyman SD, Vanden Bos T, Gimpel
SD, Din WS, Grabstein KH, Widmer MB, Park LS et al. Human
interleukin-4 receptor confers biological responsiveness and defines a
novel receptor superfamily. J Exp Med 1990; 171: 861-873.
64. Kotsimbos TC, Ghaffar 0, Minshall EM, Humbert M, Durham SR,
Pfister R, Menz G, Kay AB, Hamid QA. Expression of the IL-4
receptor alpha — subunit is increased in bronchial biopsy specimens
from atopic and nonatopic asthmatic subjects. J Allergy Clin Immunol
1998; 102: 859-666.
65. Imani F, Rager KJ, Catipovic B, Marsh DG. Interleukin-4 (IL-4)
induces phosphatidylinositol 3-kinase (p85) dephosphorylation.
Implications for the role of SHP-1 in the IL-4 induced signals in human
B cells. J Biol Chem 1997; 272: 7927-7931.
66. Swain SL, Weinberg AD, English M, Huston G. IL-4 directs the
development of Th2 - like helper effectors. J Immunol 1990; 145: 3796-
3806
67. Le Gros G, Ben-Sasson SZ, Seder R, Finkelman FD, Paul WE.
Generation of interleukin 4 (IL-4) producing cells in vivo and in vitro:
IL-2 and IL-4 are required for in vitro generation of IL-4- producing
cells. J Exp Med 1990; 172: 921-929.
68. Brusselle G, Kips J, Joos G, Bluethmann H, Pauwels R. Allergen-
induced airway inflammation and bronchial responsiveness in wild-type
and interleukin-4-deficient mice. Am J Respir Cell Mol Biol 1995; 12:
254-259.
69. Coyle AJ, Gros G, Bertrand C, Tsuyuki S, Heusser CH, Kopf M,
Anderson GP. Interleukin-4 is required for the induction of lung Th2
mucosal immunity. Am J Respir Cell Mol Biol 1995; 13: 54-59.
145
70. Gavett SH, O'Hearn DJ, Karp CL, Patel EA, Schofield BH, Finkelman
FD, Wills-Karp M. Interleukin-4 receptor blockade prevents airway
responses induced by antigen challenge in mice. Am J Physiol 1997;
272: L253-L261.
71. Shi HZ, Deng JM, Xu H, Zong ZX, Xiao CQ, Liu ZM, Qin SM, Jiang
HX, Liu GN, Chen YQ. Effect of inhaled interleukin-4 on airway hyper
reactivity in asthmatics. Am J Respir Crit Care Med 1998; 157: 1818-
1821.
72. Sanderson, CJ, Campbell HD, Young IG. Molecular and cellular
biology of eosinophil differentiation factor (interleukin-5) and its effects
on human and mouse B cells. Immunol Rev 1988; 102: 29-34.
73. Takatsu K, Takaki S, Hitoshi Y. Interleukin-5 and its receptor system:
implication in the immune system and inflammation. Adv Immunol
1994; 57: 145-149.
74. Hamid Q, Azzawi M, Ying S, Moqbel R, Wardlaw AJ, Corrigan CJ,
Bradley B,. Durham SR, Collins JV, Jeffrey PK. Expression of mRNA
for interleukin-5 in mucosal bronchial biopsies from asthma J Clin.
Invest 87: 1991; 1541-1549.
75. Robinson DS, Ying S, Bently AM, Meng Q, North J, Durham SR, Kay
AB, Hamid Q. Relationships among numbers of bronchoalveolar lavage
cells expressing messenger ribonucleic acid for cytokines, asthma
symptoms, and airway methacholine responsiveness in atopic asthma J
Allergy Clin Immunol 1993; 92: 397-405.
76. Humbert M, Corrigan CJ, Kimmitt P, Till SJ, Kay AB, Durham SR.
Relationship between IL-4 and IL-5 mRNA expression and disease
severity in atopic asthma. Am J Respir Crit Care Med 1997; 156: 704-
711.
77. Corrigan CJ, Haczku A, Gemou-Engesaeth V, Doi S, Kikuchi Y,
Takatsu K, Durham SR, Kay AB. CD-4 T-lymphocyte activation in
asthma is accompanied by increased serum concentrations of
interleukin-5: effect of glucocorticoid therapy. Am Rev Respir Dis
1993; 147: 540-547.
78. Gulbenkian AR, Egan RW, Fernandez X, Jones H, Kreutner W, Kung
T, Payvandi F, Sullivan L, Zurcher JA, Watnick AS. Interleukin -5
modulates eosinophil accumulation in allergic guinea pig lung. Am Rev
Respir Dis 1992; 146: 263- 266.
146
79. Mauser PJ, Pitman A, Witt A, Fernandez X, Zurcher J, Kung T, Jones
H, Watnick AS, Egan RW, Kreutner W, Adams GK Inhibitory effect of
the TRFK-5 anti IL-5 antibody in a guinea pig model of asthma. Am
Rev Respir Dis 1993; 148: 1623-1627.
80. Renauld JC, Groethals A, Houssiau F, Merz H, Van Roost E, Van Snick
J. Human P40/IL-9. Expression in activated CD4+ T cells, genomic
organization and comparison with the mouse gene. J Immunol 1990;
144: 4235-4241.
81. Houssiau FA, Renauld JC, Stevens M, Lehmann F, Lethe B, Coulie PG,
Van Snick J. Human T cell lines and clones respond to IL-9. J Immunol
1993; 150: 2634-2640.
82. Dugas B, Renauld JC, Pene J, Bonnefoy JY, Pete-Frere C, Braquet P,
Bousquet J, Van Snick J, Mencia-Huerta JM. Interleukin-9 potentiates
the interleukin-4 induced immoglobulin (IgG, IgM and IgE) production
by normal human B lymphocytes. Eur J Immunol 1993; 23: 1687-1692.
83. Hultner L, Druez C, Moeller J, Uyttenhove C, Schmitt E, Rude E,
Dormer P, Van Snick J. Mast cell growth-enhancing activity (MEA) is
structurally related and functionally identical to the novel mouse T cell
growth factor P40/TCGFIII (interleukin 9). Eur J Immunol 1990; 20:
1413-1416.
84. Temann UA, Geba GP, Rankin JA, et al. Expression of interleukin 9 in
the lungs transgenic mice causes airway inflammation, mast cell
hyperplasia and bronchial hyper responsiveness. J Exp Med 1998; 188:
1307-1320.
85. Fiorentino DF, Bond MW, Mosmann TR. Two types of mouse helper T
cells. IV. Th2 clones secrete a factor that inhibits cytokine production
by Th 1 clones. J Exp Med 1989; 170: 2081-2089.
86. Enk AH, Katz SI. Identification and induction of keratinocyte-derived
IL-10. J Immunol 1992; 149: 92-95.
87. Spits H, de Waal Malefyt R. Functional characterization of human IL-
10. Int Arch Allergy Appl Immunol 1992; 99: 9-15.
88. Berkman N, John M, Roesems G, Jose PJ, Barnes PJ, Chung KF.
Inhibition of macrophage inflammatory protein-1 a by interleukin-10:
differential sensitivities in human blood monocytes and alveolar
macrophage. J Immunol 1995; 155: 4412-4418.
147
89. Liu Y, Wei SH, Ho AS, de Waal Malefyt, Moore KW. Expression
cloning and characterization of a human IL-10 receptor. J Immunol
1994; 152: 1821-1829.
90. Wang P, Wu P, Siegel MI, Egan RW, Billah MM. Interleukin (IL) -10
inhibits nuclear factor kappa B (NF kappa B) activation in human
monocytes. IL-10 and IL-4 suppress cytokine synthesis by different
mechanisms. J Biol Chem 1995; 270: 9558-9563.
91. Fiorentino DF, Zlotnik A, Mossmann TR, Howard M, O'Garra A. IL-
10 inhibits cytokine production by activated macrophages. J Immunol
1991; 147: 3815-3822.
92. de Waal Malefyt R, Abrams J, Bennett B, Figdor CG, de Vries JE.
Interleukin 10 (IL-10) inhibits synthesis by human monocytes: an auto
regulatory role of IL-10 produced by monocytes. J Exp Med 1991; 179:
1209-1220.
93. Seitz M, Loetscher P, Dewald B, Towbin H, Galatti H, Baggiolini M.
Interleukin-10 differentially regulates cytokine inhibitor and chemokine
release from blood mononuclear cells and fibroblasts. Eur J Immunol
1995; 25: 1129-1132.
94. de Waal Malefyt R, Yssel H, Roncarolo MG, Spits H, de Vries JE.
Inteleukin-10. Cun- Opin Immunol 1992; 4: 314-320.
95. de Waal Malefyt M, Haanen J, Spits H Roncarolo MG, to Velde A,
Figdor C, Johnson K, Kastelein R, Tssel H, de Vries JE . Interleukin 10
(IL -10)and viral IL-10 strongly reduce antigen —specific human T cell
proliferation by diminishing the antigen —presenting capacity of
monocytes via down regulation of class II major histocompatibility
complex expression. J Exp Med 1991; 174: 915-924.
96. Cunha FQ, Moncada S, Liew FY. Interleukin-10 (IL-10) inhibits the
induction of nitric oxide synthase by interferon gamma in murine
macrophages. Biochem Biophys Res Commun 1992; 182: 1155-1159.
97. John M, Hirst SJ, Jose PJ, Robichaud A, Berkman N, Witt C, Twort
CH, Barnes PJ, Chung KF. Human airway smooth muscle cells express
and release RANTES in response to Th-1 cytokines: regulation by Th-2
cytokines and corticosteroids. J Immunol 1997; 158: 1841-1847.
98. John M, Au BT, Jose PJ, Lim S, Saunders M, Barnes PJ, Mitchell JA,
Belvisi MG, Chung KF. Expression and release of interleukin-8 by
human airway smooth muscle cells: inhibition by Th-2 cytokines and
corticosteroids. Am J Respir Cell Mol Biol 1998; 18: 84-90.
148
99. Moore KW, O'Garra A, de Waal Malefyt R, Vieira P, Mosmanm TR.
Interleukin -10. Annu Rev Immunol 1993; 11: 165-90.
100. Schandene L, Alonso Vega C Willems F, Gerard C, Delvaux A, Velu T,
Devos R, de Boer M, Goldman M. B7/CD28- dependant IL-5
production by human resting T cells is inhibited by IL-10. J Immunol
1994; 152: 4368-74.
101. Rosenwasser LJ, Borish L. Genetics of atopy and asthma: the rationale
behind promoter -based candidate gene studies (IL-4 and IL-10). Am J
Respir Crit Care Med 1997; 156: S152-155.
102. Lim S, Crawley E, Woo P, Barnes PJ. Haplotype associate with low
interleukin -10 production in patients with severe asthma. Lancet 1998;
352: 113.
103. Chung F. Anti-inflammatory cytokines in asthma and allergy:
interleukin-10, interleukin-12, interferon gamma. Mediators Inflamm
2001; 10: 51-59.
104. Gately MK, Renzetti LM, Magram J, Stern AS, Adorini L, Gubler U.
The interleukin-12/interleukin-12-receptor system: role in normal and
pathologic immune responses. Annu Rev Immunol 1998; 16: 495-521.
105. Gavett SH, O'Hearn DJ, Li X, Huang SK, Finkelman FD, Wills-Karp
M. Interleukin-12 inhibits antigen- induced airway hyper-
responsiveness, inflammation and Th2 cytokine expression in mice. J
Exp Med 1995 ; 182: 1527-1536.
106. van der Pouw Kraan TC, Boeije LC, de Groot ER, Stapel SO, Snijders
A, Kapsenberg ML. Reduced production of 1-12 and IL-12 dependent
IFN- gamma release in patients with allergic asthma. J Immunol 1997;
158 : 5560-5565
107. Minty A, Chalon 0, Derocq J-M, Dumont X, Guillemot JC, Kaghad M,
Labit C, Leplatois P, Liauzun P, Miloux B et al. Interleukin -13 is a new
human lymphokine regulating inflammatory and immune responses.
Nature 1993; 362 : 248-250.
108. Doucet C, Brouty-Boye D, Pottin-Clemenceau C, Jasmin C, Canonica
GW, Azzarone B. IL-4 and IL-13 specifically increase adhesion
molecule and inflammatory cytokine expression in human lung
fibroblasts. Int Immunol 1998; 10: 1421- 1433.
149
109. de Waal Malefyt R, Figdor CG, Huijbens R, Mohan -Peterson S,
Bennett B, Culpepper J, Dang W, Zurawski G, de Vries JE. Effects of
IL-13 on phenotype, cytokine production, and cytotoxic function of
human monocytes. J Immunol 1993; 151: 6370-6381.
110. Berkman N, Roesems G, Jose PJ, Barnes PJ, Chung KF. Interleukin -13
inhibits expression of macrophage-inflammatory protein-1 a from
human blood monocytes and alveolar macrophages. Am J Respir Cell
Mol Biol 1995; 15: 382-389.
111. John M, Hirst SJ, Jose PJ, Barnes PJ, Chung KF. Human airway
smooth muscles express and release RANTES in response to Th-1
cytokines: regulation by Th-2 cytokines and corticosteroids. J
Immunol 1997; 158: 1841-1847.
112. John M, Au BT, Jose PJ, Lim S, Saunders M, Barnes PJ, Mitchell JA,
Belvisi MG, Chung KF. Expression and release of interleukin-8 by
human airway smooth muscle cells• inhibition by Th-2 cytokines and
corticosteroids. Am J Respir Cell Mol Biol 1998; 18: 84-90.
113. Punnonen J, Aversa G, Cocks BG, McKenzie AN, Menon S, Zurawski
G, de Waal Malefyt R, de Vries JE. Interleukin 13 induces interleukin-
4-independent IgG4 and IgE synthesis and CD23 expression by human
B cells. Proc Natl Acad Sci USA 1993; 90: 3730-3734.
114. Naseer T, Minshall EM, Leung DY, Laberge S, Ernst P, Martin RJ,
Hamid Q. Expression of IL-12 and IL-13 mRNA in asthma and their
modulation in response to steroid therapy. Am J Respir Crit Care Med
1997; 155: 845-851.
115. Grabstein KH, Eisenman J, Shanebeck K, Rauch C, Srinivasen S, Fung
V, Beers C, Richardson J, Schoenborn MA, Ahdieh A et al. Cloning of
a T cell growth factor that interacts with the beta chain of the
interleukin-2 receptor. Science 1994; 264: 965-968.
116. Badolato R, Ponzi AN, Millesimo M, Notarangelo LD, Musso T.
Interleukin -15 (IL-15) induces IL-8 and monocyte chemotactic protein
1 production in human monocytes. Blood 1997; 90: 2804-2809.
117. Rumsaeng V, Cruikshank WW, Foster B, Prussin C, Kirshenbaum AS,
Davis TA, Kornfeld H, Center DM, Metcalfe DD. Human mast cells
produce the CD4+ T lymphocyte chemoattractant factor, IL-16. J
Immunol 1997; 159: 2904-2910.
150
118. Cruikshank WW, Long A, Torpy RE, Kornfeld H, Carroll MP, Teran L,
Holgate ST, Center DM. Early identification of IL-16 (lymphocyte
chemoattractant factor) and macrophage inflammatory protein 1 a
(MIP-1 a) in bronchoalveolar lavage fluid of antigen-challenged
asthma. Am J Respir Cell Mol Biol 1995; 13: 738-747.
119. Fossiez F, Djossou 0, Chomarat P, et al. T cell interleukin -17 induces
stromal cells to produce proinflammatory and hematopoietic cytokines
(see comments) J Exp Med 1996; 183: 2593-2603.
120. Ushio S, Namba M, Okura T, Hattori K, Nukada Y, Akita K, Tanabe F,
Konishi K, Micallef M, Fujii M, Torigoe K, Tanimoto T, Fukuda S,
Ikeda M, Okamura H, Kurimoto M. Cloning of the cDNA for human
IFN gamma-inducing factor, expression in Escherichia coli and studies
on the biologic activities of the protein. J Immunol 1996; 156: 4274-
4279.
121. Xu D, Chan WL, Leung BP, Hunter D, Schulz K, Carter RW, McInnes
IB, Robinson JH, Liew FY. Selective expression and functions of
interleukin 18 receptor on T helper (Th) type 1 but not Th2 cells. J Exp
Med 1998; 188: 1485-1492
122. Matsumoto S, Tsuji-Takayama K, Aizawa Y, Koide K, Takeuchi M,
Ohta T, Kurimoto M. Interleukin-18 activates NF-kappaB in murine T
helper type 1 cells. Biochem Boiphys Res Commun 1997; 234: 454-
457.
123. Oppman B, Leswley R, Blom B, Timans JC, Xu Y, Hunte B, Vega F,
Yu N, Wang J, Singh K, Zonin F, Vaisberg E, Churokova T, Liu M,
Gorman D, Wagner J, Zurawski S, Liu Y, Abrams JS, Moore KW,
Rennick D, de Waal-Malefyt R, Hannum C, Bazan JF, Kastelein RA.
Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with
biological activities similar as well as distinct from IL-12 Immunity
2000; 13: 715-725.
124. Hurst SD, Muchamuel T, Gorman DM, Gilbert JM, Clifford T, Kwan S.
New IL-17 family members promote Thl or Th2 responses in the lung:
in vivo function of the novel cytokine IL-25. J Immunol 2002; 169:
443-453.
125. Ikeda K, Nakajima H, Suzuki K, Kagami SI, Hirose K, Suto A, Saito Y,
Iwamoto I. Mast cells produce interleukin-25 upon Fc {epsilon} RI-
mediated activation. Blood 2003; 101: 3594-3596.
151
126. Gearing AJ, Beckett P, Christodoulou M, Churchill M, Clements J,
Davidson AH, Drummond AH, Galloway WA, Gilbert R, Gordon JL et
al. Processing of tumour necrosis factor-alpha precursor by
metallaproteinases. Nature 1994; 370: 555-557.
127. Eder J. Tumor necrosis factor alpha and interleukin 1 signalling: do
MAPKK kinases connect it all? Trends Pharmacol Sci 1997; 18: 319-
22.
128. Ohkawara Y, Yamauchi K, Tanno Y. et al. Human lung mast cells and
pulmonary macrophages produce tumor necrosis factor-a in sensitized
lung tissue after IgE receptor triggering. Am J Respir Cell Mol Biol
1992; 7: 385- 392.
129. Yates DH, Barnes PJ, Thomas PS. Tumor necrosis factor-a alters
human bronchial reactivity and induces inflammatory cell influx. Am
Rev Respir Dis 1993; 147: A1011.
130. Shah A, Church MK, Holgate ST. Tumor necrosis factor alpha: a
potential mediator of asthma. Clin Exp Allergy 1995; 25: 1038-1044.
131. Hayashida K, Kitamura T, Gorman DM, Arai K, Yokota T, Miyajima
A. Molecular cloning of a second subunit of the receptor for human
granulocyte-macrophage colony-stimulating factor (GM-CSF);
reconstitution of a high affinity GM-CSF receptor. Proc Natl Acad Sci
USA 1990; 87: 9655-9699.
132. Bussolino F, Wang JM, Defilippi P. Granulocyte- and granulocyte-
macrophage-colony stimulating factor induce human endothelial cells to
migrate and proliferate. Nature 1989; 337: 471-473.
133. Kitamura T, Sato N, Arai K, Miyajima A. Expression cloning of the
human IL-3 receptor cDNA reveals a shared subunit for the human IL-3
and GM-CSF receptors. Cell 1991; 66: 1165-74.
134. Martinez-Moczygemba M, Huston DP. Biology of common beta
receptor-signalling cytokines: IL-3, IL-5 and GM-CSF. J Allergy Clin
Immunol 2003; 112: 653-655.
135. Kotsimbos AT, Humbert M, Minshall E. Upregulation of alpha GM-
CSF-receptor in non-atopic asthma but not in atopic asthma. J Allergy
Clin Immunol 1997; 99: 666-672.
136. Hallsworth MP, Giembycz MA, Barnes PJ. Cyclic AMP-elevating
agents prolong or inhibit eosinophil survival depending on prior
exposure to GM-CSF. Br J Pharmacol 1996; 117: 79-86.
152
137. Sousa AR, Poston RN, Lane SJ, Nakhosteen JA, Lee TH. Detection of
GM-CSF in asthmatic bronchial epithelium and decrease by inhaled
corticosteroids. Am Rev Respir Dis 1993; 147: 1557-1561
138. Broide DH, Lotz M, Cuomo AJ, Coburn DA, Federman EC,
Wasserman SI. Cytokines in symptomatic asthmatic airways. J Allergy
Clin Immunol 1992; 89: 958-967.
139. Broide DH, Firestein GS. Endobronchial allergen challenge:
demonstration of cellular source of granulocyte macrophage colony-
stimulating factor by in situ hybridization. J Clin Invest 1991; 88: 1048-
53.
140. Brown PA, Crompton GK, Greening AP. Proinflammatory cytokines in
acute asthma. Lancet 1991; 338: 590-593.
141. Nakamura Y, Ozaki T, Kamei T, Kawaji K, Banno K, Miki S, Fujisawa
K, Yasuoka S, Ogura T. Increased granulocyte-macrophage colony-
stimulating factor production by mononuclear cells from peripheral
blood of patients with bronchial asthma. Am Rev Respir Dis 1993; 147:
87-91.
142. Xing Z, Ohkawara Y, Jordana M, Graham. F, Gauldie J. Transfer of
granulocyte-macrophage colony —stimulating factor gene to rat lung
induces eosinophilia, monocytosis, and fibrotic reactions. J Clin Invest
1996; 97: 1102-1110.
143. Romagnini S. Regulation and deregulation of human IgE synthesis.
Immunol today 1990; 11: 316-321.
144. Lack G, Bradley KL, Hamelmann E, Renz H, Loader J, Leung DY,
Larsen G, Gelfand EW. Nebulised IFN-gamma inhibits the
development of secondary allergic responses in mice. J Immunol 1996;
157: 1432-1439.
145. Lack G, Nelson HS, Amran D, Oshiba A, Jung T, Bradlry KL, Giclas
PC, Gelfanf EW. Rush immunotherapy results in antigen-specific
alterations in lymphocyte function and interferon- gamma production in
CD4+ T cells. J Allergy Clin Immunol 1997; 99: 530-538.
146. Bentley AM, Hamid Q, Robinson DS, Shotman E, Meng Q, Assoufi B,
Kay AB, Durham SR. Prednisolone treatment in asthma. Reduction in
the numbers of eosinophils, T cells, tryptase-only positive mast cells,
and modulation of IL-4, IL-5, and interferon-gamma cytokine gene
expression within the bronchial mucosa. Am J Respir Crit Care Med
1996; 153: 551-556.
153
147. Gifford GE, Lohmann-Matthess ML. Gamma interferon priming of
mouse and human macrophages for induction of tumour necrosis factor
production by bacterial lipopolysaccharide. J Natl Cancer Inst 1987; 78:
121-124.
148. Look DC, Rapp R, Keller BT, Holtzman MJ. Selective induction of
intracellular adhesion molecule-1 by interferon-gamma in human
airway epithelial cells. Am J Physiol 1992; 263: L79-L87.
149. Sporn SA, Eierman DF, Johnson CE, Morris J, Martin G, Ladner M,
Haskill S. Monocyte adherence results in selective induction of novel
genes sharing homology with mediators of inflammation and tissue
repair. J Immunol 1990; 144: 4434-4441.
150. Matsushima K, Larsen CG, Du Bois GC. Purification and
characterisation of a novel monocyte chemotactic and activating factor
produced by a human myelomonocytic cell line. J Exp Med 1989; 169:
1485- 1490.
151. Schall TJ, Jongstra J, Dyer BJ, Jorgensen J, Clayberger C, Davis MM,
Krensky AM. A human T cell-specific molecule is a member of a new
gene family. J Immunol 1988; 141: 1018-25.
152. Jose PJ, Griffiths-Johnson DA, Collins PD, Walsh DT, Moqbel R, Totty
NF, Truong 0, Hsuan JJ, Williams TJ. Eotaxin: a potent eosinophil
chemoattractant cytokine detected in a guinea pig model of allergic
airways inflammation. J Exp Med 1994; 179: 881-887.
153. Bonecchi R, Bianchi PP, Bordignon PP, D'Ambrosio D, Lang R,
Borsattti A, Sozzani S, Allavena P, Gray PA, Mantovani A, Sinigaglia
F. Differential expression of chemokine receptors and chemotactic
responsiveness of type 1 T helper cells (This) and Th2s. J Exp Med
1998; 187: 129-134.
154. Neote K, Digregorio D, Mak JY, Koruk R, Scahall TJ. Molecular
cloning, functional expression and signalling characteristics of a C-C
chemokine receptor. Cell 1993; 72: 415-425.
155. Heath H, Qin S, Rao P, Wu L, LaRosa G, Kassam N, Ponath PD,
Mackay CR. Chemokine receptor usage by human eosinophils. The
importance of CCR3 demonstrated using an antagonistic monoclonal
antibody. J Clin Invest 1997; 99: 178-184.
154
156. Kuna P, Reddigari SR, Rucinski D, Oppenheim JJ, Kaplan AP.
Monocyte chemotactic and activating factor is a potent histamine-
releasing factor for human basophils. J Exp Med 1992; 175: 489-493.
157. Rollins BJ, Walz A, Baggiolini M. Recombinant human MCP-1/JE
induces chemotaxis, calcium flux, and the respiratory burst in human
monocytes. Blood 1991; 78: 1112-1116.
158. Bywater M, Rorsman F, Bongcam Rudloff E. Expression of
recombinant platelet-derived growth factor A- and B-chain homodimers
in rat-1 cells and human fibroblasts reveals differences in protein
processing and autocrine effects. Mol Cell Biol 1998; 8: 2753-2762.
159. Raghu G, Masta S, Meyers D, et al. Collagen synthesis by normal and
fibrotic human lung fibroblasts and the effect of transforming growth
factor 13. Am Rev Respir Dis 1989; 140: 95-100.
160. Folkman J, Klagsbrun M. Vascular physiology. A family of angiogenic
peptides. Nature 1987; 329: 671-672.
161. Cohen P, Noveral JP, Bhala A, Nunn SE, Herrick DJ, Grunstein MM.
Leukotriene D4 facilitates airway smooth muscle cell proliferation via
modulation of the IGF axis. Am J Physiol 1995; 269: L151-L157.
162. Mosmann TR, Coffman RL. Thl and Th2 cells: different patterns of
lymphokine secretion lead to different functional properties. Annu Rev
Immunol 1989; 7: 145-173.
163. Castro M, Chaplin D, Walter M, Holtzman M. Could asthma be
worsened by stimulating the T-helper type 1 immune response? Am J
Respir Mol Cell Biol 2000; 22: 143-146.
164. Hansen G, Berry G, DeKruyff RH, Umetsu DT. Allergen-specific Thl
cells fail to counterbalance Th2 cell induced airway hyper reactivity but
cause severe airway inflammation. J Clin Invest 1999; 103: 175-183.
165. Lawrence S, Beasley R, Doull I. Genetic analysis of atopy and asthma
as quantitive traits and ordered polychotomies. Ann Hum Gen 1994; 58:
359-368.
166. Holgate ST. Asthma genetics: waiting to exhale. Nat Genet 1997; 15:
227-229.
167. Liggett S. Polymorphisms of the 132 adrenergic receptor and asthma. Am
J Respir Crit Care Med 1997; 156: S 156-S162.
155
168. Moffat M, Cookson W. Tumour necrosis factor haplotypes and asthma.
Hum Mol Genet 1997; 6: 551-554.
169. Van Eerdewegh P, Little RD, Dupuis J, Del Mastro RG, Falls K, Simon
J, ...Holgate ST. Association of the ADAM 33 gene with asthma and
bronchial hyper responsiveness. Nature 2002; 418: 426-430.
170. Allen M, Heinzmann A, Noguchi E, Abecasis G, Broxholme J, Ponting
CP, et al. Positional cloning of a novel gene influencing asthma from
chromosome 2q14. Nat Genet 2003; 35: 258-263.
171. Strachan DR. Hay fever, hygiene, and household size. BMJ 1989; 299:
1259-1260.
172. Ball T, Castro-Rodriguez J, Griffith K, Hilberg CJ, Martinez FD,
Wright AL. Siblings, day-care attendance and the risk of asthma and
wheezing during childhood. N Engl J Med 2000; 348; 543 -548.
173. Hollenberg SM, Weinberger C, Ong ES, et al. Primary structure and
expression of a functional human glucocorticoid receptor cDNA.
Nature 1985; 318: 635-641.
174. Barnes PJ. Therapeutic strategies for allergic diseases. Nature 1999;
402 (suppl): B31-B38.
175. Karin M. New twists in the gene regulation by glucocorticoid receptor:
Is DNA binding dispensable? Cell 1998; 93: 487-490.
176. Barnes PJ. Inhaled glucocorticoids for asthma. N Engl J Med 1995;
332: 868-875.
177. Schwartz HJ, Lowell FC, Melby JC. Steroid resistance in bronchial
asthma. Ann Intern Med 1968; 69: 493 - 499.
178. Carmichael J, Paterson IC, Diaz P, Crompton GE, Kay AB, Grant IWB.
Corticosteroid resistance in chronic asthma. Br Med J 1981; 282: 1419
- 1422.
179. American Thoracic Society. ATS standardisation of spirometry: 1994
update. Am J Resp Crit Care Med 1994; 152: 1107-1136.
180. Chung KF for the ERS Task Force. Difficult/therapy- resistant asthma.
ERJ 1999; 13: 1198-1208.
181. Woolcock AJ. Steroid resistant asthma: what is the clinical definition?
Eur Respir J 1993; 6: 743-747.
156
182. Alvarez J, Surs W, Leung DYM, Ikle' D, Gelfand EW, Szefler SJ.
Steroid-resistant asthma: Immunologic and pharmacologic features. J
Allergy Clin Immunol 1992; 89: 714-721.
183. Corrigan CJ, Brown PH, Barnes NC, Szefler SJ, Tsai JJ, Frew AJ, Kay
AB. Glucocorticoid resistance in chronic asthma: Glucocorticoid
pharmacokinetics, glucocorticoid receptor characteristics, and inhibition
of peripheral blood T cell proliferation by glucocorticoids in vivo. Am
Rev Respir Dis 1991; 144: 1016-1025.
184. Kay A B, Diaz P, Carmichael J, Grant I W B. Corticosteroid - resistant
chronic asthma and monocyte complement receptors .Clin Exp
Immunology 1981; 44: 576-580.
185. Poznansky M C, Gordan A C H, Douglas J G ,Krajewski A S, Wyllie
A H , Grant I W B . Resistance to methylprednisolone in cultures of
blood mononuclear cells from glucocorticoid - resistant asthmatic
patients. Clin Sci 1984; 67: 639-645.
186. Wilkinson JR, Crea AEG, Clark TJH, Lee TH. Identification and
characterisation of a monocyte- derived neutrophil activating factor in
corticosteroid-resistant bronchial asthma. J Clin Invest 1989; 84: 1930-
1941.
187. Vecchiarelli A , Siracusa A , Ceaci E , Puliti M , Abbriti G . Effect of
corticosteroid treatment on interleukin - 1 and tumour neurosis factor
secretion of monocytes from subject with asthma. Clin Exp Allergy
1992; 22: 365-370.
188. Corrigan CJ, Brown PH, Barnes NC. Glucocorticoid resistance in
chronic asthma. Am Rev Respir Dis 1991; 144: 1026-1032.
189. Lane SJ, Sousa AR, Poston RN, Lee TH. In vivo cutaneous tuberculin
response to prednisolone in corticosteroid resistant bronchial asthma. J
Allergy Clin Immunol 1993; 91: 222A.
190. Cato AC, Nestl A, Mink S. Rapid actions of steroid receptors in cellular
signalling pathways. Sci STKE 2002; 2002(138): RE9.
191. Pederson KB, Vedeckis WV. Quantification and glucocorticoid
regulation of glucocorticoid receptor transcripts in two human
leukaemic cell lines. Biochemistry 2003; 42: 10978-10990.
192. Kino T, Chrousos GP. Glucocorticoid and mineralocorticoid resistance/
hypersensitivity syndromes. J Endocrinol 2001; 169: 437-445.
157
193. Adcock IM. Molecular mechanisms of glucocorticosteroid actions.
Pulm Pharmacol Ther 2000; 13: 115-26.
194. Barnes PJ, Karin M. Nuclear factor-kappaB: a pivotal transcription
factor in chronic inflammatory diseases. N Engl J Med 1997; 336:1066-
71.
195. Barnes PJ. Efficacy of inhaled corticosteroids in asthma. J Allergy Clin
Immunol 1998; 102: 531-8.
196. Cosio BG, Mann B, Ito K, Jazrawi E, Barnes PJ, Chung KF, Adcock
IA. Histone acetylase and deacetylase activity in alveolar macrophages
and blood mononocytes in asthma. Am J Respir Crit Care Med 2004;
170: 141-147.
197. Swantek JL, Cobb MH, Geppert TD. Jun N-terminal kinase/stress-
activated protein kinase (JNK/SAPK) is required for lipopolysaccharide
stimulation of tumor necrosis factor alpha (TNF-alpha) translation:
glucocorticoids inhibit TNF-alpha translation by blocking JNK/SAPK.
Mol Cell Biol 1997; 17: 6274-6282.
198. Caelles C, Gonzalez-Sancho JM, Munoz A. Nuclear hormone receptor
antagonism with AP-1 by inhibition of the JNK pathway. Genes Dev
1997; 11: 3351- 3364.
199. Rider LG, Hirasawa N, Santini F, Beaven MA. Activation of the
mitogen activated protein kinase cascade is suppressed by low
concentrations of dexamethasone in mast cells. J Immunol 1996; 157:
2374- 2380.
200. Hirasawa N, Sato Y, Fujita Y, Mue S, Ohuchi K. Inhibition by
dexamethasone of antigen-induced c-Jun N-terminal kinase activation
in rat basophilic leukemia cells. J Immunol 1998; 161: 4939- 4943.
201. Galon J, Franchimont D, Hiroi N, Frey G, Boettner A, Ehrhart-
Bornstein M, et al. Gene profiling reveals unknown enhancing and
suppressive actions of glucocorticoids on immune cells. FASEB J 2002;
16: 61-71.
202. Kino T, Chrousos GP. Tissue-specific glucocorticoid resistance
hypersensitivity syndromes: multifactorial states of clinical importance.J
Allergy Clin Immunol 2002; 109: 609-613.
158
203, Oakley RH, Sar M, Cidlowski JA. The human glucocorticoid receptor
beta-isoform: expression, biochemical properties, and putative function. J
Biol Chem 1996; 271: 9550-9559.
204. Leung DYM, Hamid Q, Vottero A, Szefler SJ, Surs W, Minshall E,
Chrousos GP, KLemm DJ. Association of glucocorticoid insensitivity
with increased expression of glucocorticoid receptor beta. J Exp Med
1997; 186: 1567-1574.
205. Christodoulopoulos P, Leung DY, Elliott MW, Hogg JC, Muro S, Toda
M, Laberge S, Hamid QA. Increased number of glucocorticoid receptor
beta expressing cells in the airways in fatal asthma. J Allergy Clin
Immunol 2000; 106: 479-484.
206. Hamid QA, Wenzel SE, Hauk PJ, Tsicopoulos A, Wallaert B, Lafitte JJ.
Increased glucocorticoid receptor p in airway cells of glucocorticoid
insensitive asthma. Am J Respir Crit Care Med 1999; 159: 1600-1604.
207. Sousa AR, Lane SJ, Cidlowski JA, Staynov DZ, Lee TH. Glucocorticoid
resistance in asthma is associated with elevated in vivo expression of the
glucocorticoid receptor beta-isoform. J Allergy Clin Immunol 2000; 105:
943-950.
208. Gagliardo R, Chanez P, Vignola AM, Bousquet J, Vachier I, Godard P,
Bonsignore G, Demoly P. Mathieu M. Glucocorticoid receptor a and 13 in
glucocorticoid dependent asthma. Am J Respir Crit Care Med 2000; 162:
7-13.
209. Oakley RH, Jewell CM, Yudt MR, Bofetiado DM, Cidlowski JA. The
dominant negative activity of the human glucocorticoid receptor beta-
isoform. J Biol Chem 1999; 274: 27857-27866.
210. Webster JC, Oakley RH, Jewell CM, Cidlowski JA. Pro-inflammatory
cytokines regulate human glucocorticoid receptor gene expression and
lead to the accumulation of the dominant negative 13 isoform: a
mechanism for the generation of glucocorticoid resistance. Proc Natl
Acad Sci USA 2001; 98: 6865 — 6870.
211. Gougat C, Jaffuel D, Gagliardo R, Henriquet C, Bousquet J, Demoly P,
Mathieu M. Over expression of the human glucocorticoid receptor a and
13 isoforms inhibit AP-1 and NF-KB activities independently. J Mol Med
2002; 80: 309-318.
212. Nocturnal asthma is associated with reduced glucocorticoid receptor
binding affinity and decreased steroid responsiveness at night.
J Allergy Clin Immunol 1999; 103: 66-71.
159
213. Barnes PJ, Greening AP, Crompton GK. Glucocorticoid resistance in
asthma. Am J Respir Crit Care Med 1995; 152: S 125-S 140.
214. Adcock IM. Steroid resistance in asthma. Molecular mechanisms. Am J
Respir Crit Care Med 1996; 154: S58-S61.
215. Lane SJ, Lee TH. Glucocorticoid receptor characteristics in monocytes of
patients with Corticosteroid — resistant bronchial asthma. Am Rev Respir
Dis 1991; 143: 1020-1025.
216. Sher ER, Leung DY, Surs W, Kam JC, Zieg G, Kamada AK, Szefler SJ.
Steroid-resistant asthma Cellular mechanisms contributing to inadequate
response to glucocorticoid therapy. J Clin Invest 1994; 93: 33-39.
217. Burnstein Kl, Jewell CM, Cidlowski JA. Human GR receptor cDNA
contains sequences sufficient for receptor down-regulation. J Biol Chem
1990; 265: 7284-7291.
218. Pujols L, Mullol J, Perez M, Roca-Ferrer J, Juan M, Xaubet A, Cidlowski
JA, Picado C. Expression of the human glucocorticoid receptor the a and
(3 isoforms in human respiratory epithelial cells and their regulation by
dexamethasone. Am J Respir Cell Mol Biol 2001; 24: 49-57.
219. Spahn J, Leung DYM, Surs W, Harbeck RJ, Nimmagadda S, Szefler SJ.
Reduced glucocorticoid binding affinity in asthma is related to ongoing
allergic inflammation. Am J Respir Crit Care Med 1995; 151: 1709-1714.
220. Leung DYM, Martin RJ, Szefler JS. The airways of steroid resistant
versus steroid sensitive asthma are associated with different patterns of
cytokine gene expression. J Allergy Clin Immunol 1994; 93: 209A.
221. Spahn JD, Szefler SJ, Surs W, Doherty DE, Nimmagadda Sai R, Leung
DYM . A novel action of IL-13. Induction of diminished monocyte
glucocorticoid receptor-binding affinity. J Immunol 1996, 157: 2654-
2659.
222. Kam JC, Szefler JS, Surs W, Sher ER, Leung DYM. Combination IL-2
and IL-4 reduces glucocorticoid receptor-binding affinity and T cell
response to glucocorticoids. J Immunol 1993; 151: 3460-3466.
223. Nimmagadda SR, Szefler SJ, Spahn JD, Surs W, Leung DY. Allergen
exposure decreases glucocorticoid receptor binding affinity and steroid
responsiveness in atopic asthmatics. Am J Respir Crit Care Med. 1997;
155: 87-93.
160
224. Kraft M, Vianna E , Martin RJ, Leung DYM . Nocturnal asthma is
associated with reduced glucocorticoid receptor binding affinity and
decreased steroid responsiveness at night. J Allergy Clin Immunol
1999; 103: 66-71.
225. Spahn JD, Leung DYM, Surs W, Harbeck RJ, Nimmagadda Sai R,
Szefler SJ. Reduced glucocorticoid binding affinity in asthma is related
to ongoing allergic inflammation. Am J Respir Crit Care Med 1995;
151: 1709-14.
226. Nimmagadda SR, Spahn JD, Nelson HS, Jenkins J, Szefler SJ, Leung
DY. Fluticasone propionate results in improved glucocorticoid receptor
binding affinity and reduced oral glucocorticoid requirements in severe
asthma. Ann Allergy Asthma Immunol. 1998; 81: 35-40.
227. Barnes PJ, Adcock IM .Anti-inflammatory actions of steroids:
molecular mechanisms. Trends Pharmacol Sci 1993 ; 14: 436-41.
228. Berridge MJ. Inositol triphosphate and diacylglycerol: two interacting
second messengers. Annu Rev Biochem 1987; 56: 159-193
229. Condliffe AM, Cadwallader KA, Walker TR, Andrew RC, Cowburn
RS, Chilvers ER. Phosphoinositide 3-kinase: a critical signalling event
in pulmonary cells. Respir Res 2000; 1: 24-29.
230. Hershenson MB, Kelleher MD, Naureckas ET, Abe MK, Rubinstein VJ,
Zimmermann A, Bendele AM, McNulty JA, Panettieri RA, Solway J:
Hyperoxia increases airway cell S-phase traversal in immature rats in
vivo. Am J Respir Cell Mol Biol 1994; 11: 296- 303.
231. Panettieri RA, Murray RK, Eszterhas AJ, Bilgen G, Martin JG:
Repeated allergen inhalations induce DNA synthesis in airway smooth
muscle and epithelial cell in vivo. Am J Physiol 1998; 274: L417—
L424.
232. Scott PH, Belham CM, Al-Hafidh J, Chilvers ER, Peacock AJ: A
regulatory role for cAMP in phosphatidylinositol 3-kinase/p70
ribosomal S6 kinase-mediated DNA synthesis in platelet-derived
growth- factor-stimulated bovine airway smooth-muscle cells. Biochem
J 1996; 318: 965-971.
233. Condliffe AM, Hawkins PT, Stephens LR, Haslett C, Chilvers ER:
Priming of human neutrophil superoxide generation by tumour necrosis
factor is signalled by enhanced phosphatidylinositol 3,4,5-trisphosphate
but not inositol 1,4,5-trisphosphate accumulation. FEBS Lett 1998; 439:
147-151.
161
234. Palframen RT, Collins, PD, Severs, NJ, Rothery S, Williams TJ, Rankin
SM: Mechanisms of acute eosinophil mobilization from bone marrow
by interleukin 5: the role of specific adhesion molecules and
phosphatidylinositol 3-kinase. J Exp Med 1998; 188: 1621-1632.
235. Dunzendorfer S, Meirhofer C, Wiedermann CJ: Signalling in
neuropeptide- induced migration of human eosinophils. J Leukoc Biol
1998; 64: 828-834.
236. Hofmann C, Dichmann S, Zimpfer U, Czech W, Herouy Y, Wagner E,
Norgauer J: Metabolism and function of 3-D-phosphorylated
phosphoinositides in C5a-stimulated eosinophils. Biochem Biophys Res
Commun 2000; 269: 816-821.
237. Pan ZK, Chen LY, Cochrane CG, Zuraw BL: fMet-leu-phe stimulates
proinflammatory cytokine gene expression in human peripheral blood
monocytes: the role of phosphatidylinositol 3-kinase. J Immunol 2000;
164: 404-411.
238. Goekjian PG, Jirousek MR. Protein kinase C inhibitors as novel
anticancer drugs. Expert Opin Investig Drugs 2001; 10: 2117-2140.
239. Evans DJ, Lindsay MA, Webb BL, Kankaanranta H, Giembycz MA,
O'Connor BJ, Barnes PJ. Expression and activation of protein kinase C-
zeta in eosinophils after allergen challenge. Am J Physiol 1999; 277:
L233—L239.
240. Vachier, P. Chanez, T. Radeau, D.C. Le, C. Leger and P. Godard,
Cellular protein kinase C activity in asthma. Am J Respir Crit Care Med
1997; 155: 1211-1216.
241. Page K, Li J, Zhou L, lasvovskaia S, Corbit KC, Soh JW, Weinstein I
B, Brasier AR, Lin A, Hershenson M.B. Regulation of airway epithelial
cell NF-kappa B-dependent gene expression by protein kinase C delta.
J. Immunol 2003.170,5681-5689.
242. Whelchel A, Evans J, Posada J. Inhibition of ERK activation attenuates
endothelin-stimulated airway smooth muscle cell proliferation. Am J
Respir Cell Mol Biol 1997; 16: 589-596.
243. Matsubara M, Ohmori K, Hasegawa K. Histamine H1 Receptor-
Stimulated Interleukin 8 and Granulocyte Macrophage Colony-
Stimulating Factor Production by Bronchial Epithelial Cells Requires
Extracellular Signal-Regulated Kinase Signalling via Protein Kinase C.
Int Arch Allergy Immunol 2006; 139: 279-284.
162
244. Lewis TS, Shapiro PS, Ahn NG, Signal Transduction through MAP
kinase cascades. Adv Cancer Res 1998; 74: 49-139.
245. Brunet A, Pouyssegur J. Mammalian MAP kinase modules: how to
transduce specific signals. Essays Biochem 1997; 32: 1-16.
246. Robinson MJ, Cobb MH. Mitogen activated protein kinase pathways.
Cur Opin Cell Biol 1997; 9: 180-6.
247. Yamaguchi K, Shirakabe K, Shibuya H et al. Identification of a member
of the MAPKKK family as a potential mediator of TGF-beta signal
transduction. Science 1995; 270: 2008-2011.
248. Zhang S, Han J. Sells MA et al. Rho family GTPases regulate p38
MAPK through downstream mediator PAK1. J Biol Chem 1995; 270:
23934-23936.
249. Stein B, Balwin AS, Ballard DW Jr. Greene WC, Angel P, Herrlich P.
Cross coupling of the NFkB p65 and Fos/Jun transcription factors
produces potentiated biological function. EMBO J 1993; 12:3879-3891.
250. Allessi DR, Cuenda A, Cohen P. Dudley DT, Saltiel AR. PD 098059 is
a specific inhibitor of the activation of mitogen-activated protein kinase
kinase in vitro and in vivo. J Biol Chem 1995; 270: 27489-27494.
251. Wang YZ, Bonner JC. Mechanism of extracellular signal-regulated
kinase (ERK)-1 and ERK-2 activation by vanadium pentoxide in rat
pulmonary myofibroblasts. Am J Respir Cell Mol Biol 2000; 22: 590-
597.
252. Laan M, Lotvall J, Chung KF, Linden A.IL-17-induced cytokine release
in human bronchial epithelial cells in vitro: role of mitogen-activated
protein (MAP) kinases. Br J Pharmacol. 2001; 133: 200-206.
253. Lee PJ, Zhang X, Shan P, Ma B, Lee CG, Homer RJ, Zhu
Z, Rincon M, Mossman BT, Elias JA. ERK1/2 mitogen-activated
protein kinase selectively mediates IL-13-induced lung inflammation
and remodelling in vivo. J Clin Invest 2006; 116: 163-173.
254. Blanchet S, Ramgolam K, Baulig A, Marano F, Baeza-Squiban A.
Fine particulate matter induces amphiregulin secretion by bronchial
epithelial cells. Am J Respir Cell Mol Biol 2004; 30: 421-427.
163
255. Tachimoto H, Kikuchi M, Hudson SA, Bickel CA, Hamilton
RG, Bochner BS . Eotaxin-2 Alters Eosinophil Integrin Function via
Mitogen-Activated Protein Kinases. Am J Respir Cell Mol Biol. 2002;
26: 645-649.
256. Lee JC, Laydon JT, McDonnel PC et al. A protein kinase involved in
the regulation of inflammatory cytokine biosynthesis. Nature 1994; 372:
739-46.
257. Tong L, Pay S, White DM, Rogers S, Crane KM, Cywin CL, Brown
ML, Pargellis CA, A highly specific inhibitor of human p38 MAP
kinase binds in the ATP pocket. Nat. Struct. Biol 1997; 4:311- 316.
258. Cohen P. The search for physiological substrates of MAP and SAP
kinases in mammalian cells. Trends Cell Biol 1997; 7: 353-761.
259. Kyriakis JM, Avruch J. Mammalian mitogen-activated protein kinase
signal transduction pathways activated by stress and inflammation.
Physiol Rev 2001; 81, 807-869.
260. J.C. Lee, J.T. Laydon, P.C. McDonnell, T.F. Gallagher, S. Kumar, D.
Green, D. McNulty, M.J. Blumenthal, J.R. Heys, S.W. Landvatter, et
al., A protein kinase involved in the regulation of inflammatory
cytokine biosynthesis. Nature 1994; 372: 739-742.
261. Beyaert R, Cuenda A, Vande Berghe W et al. The p38/RK mitogen-
activated protein kinase pathway regulates interleukin-6 synthesis
response to tumour necrosis factor. EMBO J 1996; 15: 1914-1923.
262. Shapiro L, Dinarello CA. Osmotic regulation of cytokine synthesis in
vitro. Proc Nat Acad Sci USA 1995; 92: 12230-12234.
263. Tashimoto S, Matsumoto K. Gon Y et al. p38 MAP kinase regulates
TNFa, IL-la and PAF-induced RANTES and GM-CSF production by
human bronchial epithelial cells. Clin Exp Allergy 1999; 30: 48-55.
264. Campbell J, Ciesielski CJ, Hunt AE, Horwood NJ, Beech JT, Hayes
LA, Denys A, Feldmann M, Brennan FM, Foxwell BMJ. A novel
mechanism for TNF-a regulation by p38 MAPK: involvement of NF-KB
with implications for therapy in rheumatoid arthritis. J Immunol 2004;
173: 6928— 6937.
265. Chen CC, Wang JK., p38 but not p44/42 mitogen-activated protein
kinase is required for nitric oxide synthase induction mediated by
lipopolysaccharide in RAW 264.7 macrophages. Mol. Pharmacol 1999;
55: 481-488.
164
266. Duan W, Chan JH, McKay K, Crosby JR, Choo HH, Leung BP, Karras
JG, Wong WS. Inhaled p38 {alpha} Mitogen-Activated Protein Kinase
Antisense Oligonucleotide Attenuates Asthma in Mice. Am J Respir
Crit Care Med 2005; 171: 571-578.
267. Crawley JB, Rawlinson L, Lali FV, Page TH, Saklatvala J, Foxwell
BM. T cell proliferation in response to interleukins 2 and 7 requires
p38MAP kinase activation. J Biol Chem1997; 272: 15023-15027.
268. Bergstrand H. Phosphodiesterase inhibition and theophylline. Eur J
Respir Dis 1980; 61: 37- 44.
269. Fredholm BB, Persson CGA. Xanthine derivatives as adenosine
antagonists. Eur J Pharmacol 1982; 81: 673- 6.
270. Dent G, Giembycz MA, Rabe KF, Barnes PJ. Inhibition of eosinophil
cyclic nucleotide PDE activity and opsonized zymosan-stimulated
respiratory burst by type IV-selective PDE inhibitors. Br J Pharmacol
1991; 103: 1339-1346.
271. Cohan VL, Showell HJ, Fisher DA, Pazoles CJ, Watson JW, Turner
CR, Cheng JB. In vitro pharmacology of the novel phosphodiesterase
type 4 inhibitor, CP-80633. J Pharmacol Exp Ther 1996; 278: 1356- 61.
272. Hatzelmann A, Tenor H, Schudt C. Differential effects of non-selective
and selective phosphodiesterase inhibitors on human eosinophil
functions. Br J Pharmacol 1995; 114: 821-31.
273. Walker BAM, Jacobson MA, Knight DA, Salvatore CA, Weir T, Zhou
D, Bai TR. Adenosine A3 receptor expression and function in
eosinophils. Am J Respir Cell Mol Biol 1997; 16: 531-537.
274. Ezeamuzie CI, Philips E. Adenosine A3 receptors on human eosinophils
mediate inhibition of degranulation and superoxide anion release. Br J
Pharmacol 1999; 127: 188-94.
275. Knight K, Zheng X, Rocchini C, Jacobson M, Bai T, Walker B.
Adenosine A3 receptor stimulation inhibits migration of human
eosinophils. J Leukoc Biol 1997; 62: 465-468.
276. Ezeamuzie CI. Involvement of A3 receptors in the potentiation by
adenosine of the inhibitory effect of theophylline on human eosinophil
degranulation: possible novel mechanism of the anti-inflammatory
action of theophylline. Bio Pharmacol 61 (2001) 1551-1559.
165
277. Pauwels RA. New aspects of the therapeutic potential of theophylline in
asthma. J Allergy Clin Immunol 1989;83:548-553.
278. Sullivan PJ, Bekir S, Jaffer Z, Page C, Jeffery P, Costello J. Anti-
inflammatory effects of low-dose oral theophylline in atopic asthma.
Lancet 1994; 343: 1006-1008.
279. Banner KH, Page CP. Anti-inflammatory effects of theophylline and
selective phosphodiesterase inhibitors. Clin Exp Allergy 1996; 26:
(Suppl 2)2-9.
280. Dutoit JI, Salome CM, Woolcock AJ. Inhaled corticosteroids reduce the
severity of bronchial hyper responsiveness in asthma but oral
theophylline does not. Am Rev Respir Dis 1987; 136: 1174--1178.
281. Sullivan P, Bekir S, Jaffar Z, Page C, Jeffery P, Costello J. Anti-
inflammatory effects of low-dose oral theophylline in atopic asthma.
Lancet 1994; 343: 1006-1008.
282. Ward AJ, McKenniff M, Evans JM, Page CP, Costello JF.
Theophylline-an immunomodulatory role in asthma? Am Rev Respir
Dis 1993; 147:518-23.
283. Evans DJ, Taylor DA, Zetterstrom 0, Chung KF, O'Connor BJ, Barnes
PJ. Comparison of low-dose inhaled budesonide plus theophylline and
high-dose inhaled budesonide for moderate asthma. N Engl J Med
1997; 337: 1412-1418.
284. Ukena D, Harnest U, Sakalauskas R, Magyar P, Vetter N, Steffen H,
Leichtl S, Rathgeb F, Keller A, Steinijans VW. Comparison of addition
of theophylline to inhaled steroid with doubling of the dose of inhaled
steroid in asthma. Eur Respir J 1997; 10: 2754-2760.
285. Spatafora M, Chiappara G, Merendino AM, D'Amico D, Bellia V,
Bonsignore G. Theophylline suppresses the release of tumour necrosis
factor-alpha by blood monocytes and alveolar macrophages. Eur Respir
J 1994; 7: 223-228.
286. Ghezzi P, Dinarello CA. IL-1 induces IL-1. Specific inhibition of IL-1
production by IFN-gamma. J Immunol 1988; 140: 4238-4244.
287. Zocchi MR, Pardi R, Gromo G, Ferrero E, Ferrero ME, Besana C,
Rugarli C. Theophylline induced non specific suppressor activity in
human peripheral blood lymphocytes. J Immunopharmacol 1985;7:
217-234.
166
288. Bruserud 0. The effect of theophyllamine on T-lymphocyte activation
in vitro. Clin Immunol Immunopathol 1984; 32: 111-118.
289. Lim S, Tomita K, Carramori G, Jatakanon A, Oliver B, Keller A,
Adcock I, Chung KF, Barnes PJ. Low-dose theophylline reduces
eosinophilic inflammation but not exhaled nitric oxide in mild asthma.
Am J Respir Crit Care Med 2001; 164: 273-276.
290. Sagara H, Makino S, Chibana N, Ota M, Holgate ST, Church MK,
Fukuda T. Theophylline at Therapeutic Concentrations Inhibits NF-
[kappa] B Activation in Human Lung Mast Cells. International
Archives of Allergy and Immunology. 2001; 124: 371-379.
291. Barnes PJ. Cytokine-directed therapies for the treatment of chronic
airway diseases. Cytokine Growth Factor Rev 2003; 14: 511-522.
292. Pretolani M, Goldman M. IL-10: a potential therapy for allergic
inflammation? Immunol Today 1997; 18: 277-280.
293. Moore KW, O'Garra A, de-Waal-Malefyt R, Vieira P, Mosmann
TR.Interleukin-10. Annu Rev Immunol 1993; 11: 165-190.
294. Borish L, Aarons A, Rumbyrt J, Cvietusa P, Negri J, Wenzel S.
Interleukin-10 regulation in normal subjects and patients with asthma. J
Allergy Clin Immunol 1996; 97: 1288-1296.
295. John M, Lim S, Seybold J, Robichaud A, O'Connor B, Barnes PJ, et al.
Inhaled corticosteroids increase IL-10 but reduce MIP- 1 a, GM-CSF
and IFN-y release from alveolar macrophages in asthma. Am J Respir
Crit Care Med 1998; 157: 256-262.
296. Turner DM, Williams DM, Sankaran D, Lazarus M, Sinnott PJ,
Hutchinson IV. An investigation of polymorphism in the interleukin-10
gene promoter. Eur J Immunogenet 1997; 24: 1-8.
297. Kube D, Platzer C, von Knethen A, Straub H, Bohlen Hafner M, Tesch
H. Isolation of the human interleukin 10 promoter. Characterization of
the promoter activity in burkitts's lymphoma cell lines. Cytokine 1996;
7: 1-7.
298. Tomita K, Lim S, Hanazawa T, Usmani 0, Stirling R, Chung KF,
Barnes PJ, Adcock IM. Attenuated production of intracellular IL-10 and
IL-12 in monocytes from patients with severe asthma. Clin Immunol
2002; 102: 258-266.
167
299. Zuany-Amorim C, Haile S, Leduc D, Dumarey C, Huerre M, Vargaftig
BB, Pretolani M. Interleukin-10 inhibits antigen-induced cellular
recruitment into the airways of sensitized mice. J Clin Invest 1995; 95:
2644-2651.
300. Oh JW, Seroogy CM, Meyer EH, Akbari 0, Berry G, Fathman CG, et
al. CD4 T-helper cells engineered to produce IL-10 prevent allergen-
induced airway hyperreactivity and inflammation. J Allergy Clin
Immunol 2002; 110: 460-468.
301. Akdis CA, Blesken T, Akdis M, Wuthrich B, Blaser K. Role of
interleukin 10 in specific immunotherapy. J Clin Invest 1998; 102: 98-
106.
302. Fedorak RN, Gangl A, Elson CO, Rutgeerts P, Schreiber S, Wild G, et
al. Recombinant human interleukin 10 in the treatment of patients with
mild to moderately active Crohn's disease. Gastroenterology 2000; 119:
1473-1482.
303. La Grutta, Gagliardo R, Mirabella F, Pajno GB, Bonsignore
G, Bousquet J, Bellia V, Vignola AM. Clinical and biological
heterogeneity in children with moderate asthma. Am J Resp Crit Care
Med 2003; 167: 1490-1495.
304. Inoue H, Aizawa H, Fukuyama S, Takata S, Matsumoto K, Shigyo
M, Koto H, Hara N. Effect of Inhaled Glucocorticoid on the Cellular
Profile and Cytokine Levels in Induced Sputum from Asthmatic
Patients. Lung 1999; 177: 53- 62.
305. Nagata M, Sedgwick JB, Kita H, Busse WW. Granulocyte macrophage
colony-stimulating factor augments ICAM-1 and VCAM-1 activation of
eosinophil function. Am J Respir Cell Mol Biol 1998; 19: 158-166.
306. Pauwels R, Lofdahl CG, Postma DS, Tattersfield AE, O'Byrne P,
Barnes PJ, Ullman A. Effect of inhaled formoterol and budesonide on
exacerbations of asthma. Formoterol and Corticosteroids Establishing
Therapy (FACET) International Study Group. N Engl J Med 1997; 337:
1405-1411.
307. Shrewsbury S, Pyke S, Britton M. Meta-analysis of increased dose of
inhaled steroid or addition of salmeterol in symptomatic asthma
(MIASMA). BMJ 2000; 320: 1368-1373.
308. Pang L, Knox AJ. Regulation of TNFa-induced eotaxin release from
cultured human airway smooth cells by [32 -agonists and corticosteroids.
FASEB J 2001; 15: 261-269.
168
309. Eickelberg 0, Roth M, Lorx R, Bruce V, Fudiger J, Johnson M, Block
L H. Ligand independent activation of the glucocorticoid receptor by
the [32-adrenergic receptor agonists in primary human lung fibroblasts
and vascular smooth muscle cells. J Biol Chem 1999; 274: 1005-1010.
310. Roth M, Rudiger JJ, Bihl MP, et al. The 132-agonist formoterol activates
the glucocorticoid receptor in vivo. Eur Respir J 2000; 16: 437S.
311. Spoelstra FM, Postma DS, Hovenga H, Noordhoek JA, Kauffman HF.
Additive anti-inflammatory effect of formoterol and budesonide on
human lung fibroblasts. Thorax 2002; 57: 237- 241.
312. Crabtree GR, Smith K, Munck A. Glucocorticoid receptors. In
Methods of Haematology: The Leukaemic Cell. Catovsky D, Chanarin
I, Beutler E, Brown EB, and Jacobs A, eds Churchill Livingstone, New
York 1981; 252 - 269.
313. Price Price DB, Hernandez D, Magyar P, Fiterman J, Beeh KM, James
IG, Konstsantopoulos S, Rojas R, van Noord JA, Pons M, Gilles L, Leff
JA. Randomised controlled trial of montelukast plus inhaled budesonide
versus double dose inhaled budesonide in adult patients with asthma.
Thorax 2003; 58: 211-216
314. Ostrom NK, Decotiis BA, Lincourt WR. Comparative Efficacy and
Safety of Low-dose Fluticasone Propionate and Montelukast in
Children with Persistent Asthma. J Pediatr 2005; 147: 213-220.
315. Irusen EM. The corticosteroid dose-response curve in asthma and how
to identify patients for adjunctive and alternative therapy. SA Fam Pract
2006; 48(2) 34-42.
316. Malmstrom K, Rodriguez- Gomez G, Guerra J. Oral montelukast,
inhaled beclomethasone, and placebo for chronic asthma: a randomized
controlled trial. Ann Intern Med 1999; 130: 487-495.
317. Nelson HS, Busse WW, deBoisblanc BP, Berger WE, Noonan MJ,
Webb DR, Wolford JP, Mahajan PS, Hamedani AG, Shah T, Harding
SM. Fluticasone propionate powder: oral corticosteroid-sparing effect
and improved lung function and quality of life in patients with severe
chronic asthma. J Allergy Clin Immunol 1999; 103; 267-275.
318. Rabe KF, Vermiere PA, Soriano JB, Maier WC. Clinical management
of asthma in 1999: the Asthma Insights and Reality in Europe (AIRE)
study. Eur Respir J 2000; 16: 802-807.
169
319. Larsson S, Lofdahl CG, Linden M. IL-2 and IL-4 counteract budesonide
inhibition of GM-CSF and IL-10, but not of IL-8, IL-12 or TNF-
production by human mononuclear blood cells. Br J Pharmacol 1999;
127: 980-7.
320. Hawrylowicz CH, Richards D, Loke TK, Corrigan C, Lee T. A defect
in corticosteroid- induced IL-10 production in T lymphocytes from
corticosteroid-resistant asthmatic patients. J Allergy Clin Immunol
2002; 109: 369-370.
321. Richards DF, Fernandez M, Caulfield J, Hawrylowicz CM.
Glucorticoids drive human CD8+ T cell differentiation towards a
phenotype with high IL-10 and reduced IL-4, IL-5 and IL- 3 production.
Eur J Immunol 2000; 30: 2344-2354.
322. Matsumoto K, Inoue H, Fukuyama S, Tsuda M, Ikegami T, Kibe A,
Yoshiura Y, Komori M, Hamasaki N, Aizawa H, Nakanishi Y.
Decrease of Interleukin-10-Producing T Cells in the Peripheral Blood of
Severe Unstable Atopic Asthmatics despite similar doses of ICS. hit
Arch Allergy Immunol 2004; 134: 295-302.
323. Mascali JJ, Cvietusa P, Negri J, Borish L. Anti-inflammatory effects of
theophylline: modulation of cytokine production. Ann Allergy Asthma
Immunol 1996; 77: 34-38.
324. Spina D, Page CP. Asthma - a need for a rethink? Trends Pharmacol
Sci. 2002; 23: 311-315.
325. Leckie MJ. Anti-interleukin-5 monoclonal antibodies: preclinical and
clinical evidence in asthma models. Am J Respir Med 2003; 2: 245-259.
326. Bryan SA, Bryan SA, O'Connor BJ, Matti S, Leckie MJ, Kanabar V,
Khan J, Warrington SJ, Renzetti L, Rames A, Bock JA, Boyce MJ,
Hansel TT, Holgate ST, Barnes PJ. Effects of recombinant human
interleukin-12 on eosinophils, airway hyper-responsiveness, and the late
asthmatic response. Lancet 2000; 356: 2149-2153.
327. Howarth PH, Babu KS, Arshad HS, Lau LC, Buckley MG, McConnell
W, Beckett P, Ali MA, Chauhan A, Wilson SJ, Reynolds A, Davies DE,
Holgate ST. Tumour Necrosis Factor (TNF {alpha} ) as a novel
therapeutic target in symptomatic corticosteroid-dependent asthma.
Thorax 2005; 60: 1012- 1018.
328. Berry MA, Hargadon B, Shelley M, Parker D, Shaw DE, Green RH,
Bradding P, Brightling CE, Wardlaw AJ Parvord ID. Evidence of a
Role of Tumor Necrosis Factor [alpha] in Refractory Asthma. . N Engl J
Med 2006; 354:697-710.
170
329. Mori A, Kaminuma 0, Miyazawa K, Ogawa K, Okudaira H, Akiyama,
K.p38-Mitogen-Activated Protein Kinase regulates Human T cell IL-5
synthesis. J Immunol, 1999, 163: 4763-4771.
330. Bodwell JE, Webster JC, Jewell CM, Cidlowski JA, Hu JM, Munck A.
Glucocorticoid receptor phosphorylation: overview, function and cell
cycle-dependence. J Steroid Biochem Mol Biol 1998; 65: 91-99.
331. Caput D, Beutler B, Hartog K, Thayer R, Brown-Shimer S, Cerami A.
Identification of a common nucleotide sequence in the 3' untranslated
region of mRNA molecules specifying inflammatory mediators. Proc
Natl Acad Sci USA 1986; 83: 1670-1674
332. Karin M, Hunter T. Transcriptional control by protein phosphorylation:
signal transmission from the cell surface to the nucleus. Curr Biol 1995;
5: 747-757.
333. Swantek JL, Cobb MH, Geppert TD. Jun N-terminal kinase/stress-
activated protein kinase (JNK/SAPK) is required for lipopolysaccharide
stimulation of tumor necrosis factor alpha (TNF-alpha) translation:
glucocorticoids inhibit TNF-alpha translation by blocking JNK/SAPK.
Mol Cell Biol 1997; 17: 6274-6282.
334. Caelles C, Gonzalez-Sancho JM, Munoz A. Nuclear hormone receptor
antagonism with AP-1 by inhibition of the JNK pathway. Genes Dev
1997; 11: 3351-3364.
335. Rider LG, Hirasawa N, Santini F, Beaven MA. Activation of the
mitogen activated protein kinase cascade is suppressed by low
concentrations of dexamethasone in mast cells. J Immunol 1996; 157:
2374- 2380.
336. Hirasawa N, Sato Y, Fujita Y, Mue S, Ohuchi K. Inhibition by
dexamethasone of antigen-induced c-Jun N-terminal kinase activation
in rat basophilic leukemia cells. J Immunol 1998; 161: 4939-4943.
337. Rogatsky I, Logan SK, Garabedian MJ. Antagonism of glucocorticoid
receptor transcriptional activation by the c-Jun N-terminal kinase. Proc
Natl Acad Sci U SA 1998; 95: 2050-2055.
338. Bamberger CM, Schulte HM, Chrousos GP. Molecular determinants of
glucocorticoid receptor function and tissue sensitivity to
glucocorticoids. Endocr Rev 1996; 17: 245-261.
171
339. Galigniana MD, Piwien-Pilipuk G, Assreuy J. Inhibition of
glucocorticoid receptor binding by nitric oxide. Mol Pharmacol 1999;
55: 317- 323.
340. Lee MS, Silver PA. RNA movement between the nucleus and the
cytoplasm. Curr Opin Genet Dev 1997; 7: 212-219.
341. Almlof T, Wallberg AE, Gustafsson JA, Wright AP. Role of important
hydrophobic amino acids in the interaction between the glucocorticoid
receptor tau 1-core activation domain and target factors. Biochemistry
1998; 37: 9586- 9594.
342. Haddad JJ, Land SC. Redox/ROS regulation of lipopolysaccharide-
induced mitogen-activated protein kinase (MAPK) activation and
MAPK-mediated TNF-alpha biosynthesis. Br J Pharmacol. 2002; 35:
520-536.
343 . Bateman ED, Karpel J, Casale T, Wenzel S, Banerji D. Ciclesonide
reduces the need for oral steroid use in adult patients with severe,
persistent asthma. Chest 2006; 129: 1176-1187.
344. Chapman KR, Cartier A, Hebert J, Mclvor RA, Schellenberg RR. The
role of Omalizumab in the treatment of severe allergic asthma. Can
Respir J 2006; 13 Suppl B: 1B-9B.
345. Irusen EM, Matthews JG, Takahashi A, Barnes P, Chung KF,
Adcock IM. P38MAPkinase-induced glucocorticoid receptor
phosphorylation reduces its activity: role in steroid insensitive asthma. J
Allergy Clin Immunol 2002; 109: 649-657.
346. Adcock IA, Chung KF, Caramori G, Ito K. Kinase inhibitors and airway
inflammation. Eur J Pharmacol 2006; 533: 118-132.
172
